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Approximately half a million individuals suffer from fractures every year and the demand for
bone graft procedures is on a continuous increase. Scaffold based bone tissue engineering (BTE)
has made great progress in regenerating lost bone tissue. Several materials are used for
fabrication of scaffolds for BTE. Biopolymers apart from being a cost effective alternative to
conventional synthetic polymers used for fabrication of scaffolds, offer advantages such as
greater bioactivity and biocompatibility with mammalian tissue. A clinically relevant cell type
proven to improve bone healing is bone marrow derived mesenchymal stem cells (MSCs). The
biomaterial used to deliver these stem cells can induce their differentiation into the osteoblastic
lineage and hasten bone healing.
In this project we used polysaccharide and protein chemistry in a hierarchical scaffold design to
accomplish structural stability and bioactivity. In these scaffolds, a cellulose derivative formed
the micro scale structures, while collagen the most abundant osteogenic extracellular matrix
(ECM) protein of bone, formed the self assembled nanostructures. This dissertation aims at
characterizing these three- dimensional (3D) porous biopolymeric scaffolds of cellulose acetate
(CA) and cellulose acetate coated with Nano-fibrous collagen (CAc), in terms of their ability to
induce bone healing in combination with MSCs.
The CA and CAc scaffolds were compared to similar polyester (Poly-lactic acid co-glycolic
acid) (PLGA) 3D porous scaffolds for their material properties and biological performance. It
was seen that the CA scaffolds had greater hydrophilicity and when functionalized with collagen
led to a more biomimetic self-assembly of collagen nanofibers. During the induced
differentiation of seeded human bone marrow derived mesenchymal stem cells (hMSCs) in vitro,

the cells on polysaccharide scaffolds showed higher levels of osteoblastic progression than the
cells on the polyester scaffolds.
The polysaccharide scaffolds also showed greater biocompatibility at twelve weeks of
subcutaneous implantation in rats. On the other hand, polyester scaffolds started exhibiting
increased foreign body response (FBR) by later time points. Finally, when implanted into critical
sized calvarial defects of mice, the polysaccharide scaffolds seeded with bone marrow stromal
cells showed greater bone formation and greater levels of collagen content, along with a more
even distribution of osteoblastic markers throughout the scaffold structure than the control
polyester scaffolds. Hence these findings demonstrated the potential of cellulose acetate and
collagen, micro- nano structured biopolymeric scaffolds to be used in combination with MSCs as
a biomaterial for bone regeneration.
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1 Chapter 1
1.1

Bone Loss and demand for implants
High impact trauma, pathological conditions such as tumors and infections and conditions
such as osteoporosis can lead to massive defects of the bone(1). About 5- 10% of the total
number of bone fractures result in delayed or non-union and surgical intervention is
needed(2-4). The ease of handling combined with the huge demand renders bone as one of
the most transplanted organs(5). About 0.5 million bone grafts are carried out in the U.S.
alone, while more than two million procedures are performed around the globe (6-8) per
annum(5). Though using bone from the patient itself (autografting) is considered the golden
standard for achieving bone healing, it is restricted by availability and discomfort to the
patient. Allografts on the other hand help overcome these limitations, but carry the threat of
low remodeling due to excessive processing and possibility of disease transmission(9). Hence
bone tissue engineering, where biomaterial scaffolds, biological factors and cells are used
alone or in a combination promises better bone regeneration(9). The demand for bone graft
subsititutes is constantly increasing at a rate of 3.8% every year(10).

1.2

Clinical treatment of critical sized bone defects

1.2.1 Autograft
Autograft is bone harvested from a non- essential site in the host. Hence the donor and the
host are the same in the case of autografts. This grafted bone could be obtained most
commonly from the iliac crest or fibula, chin, ribs, mandibles and parts of the skull from the
patient(11, 12). The outcomes of autografting of bone are seen to be superior to any other
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bone grafting technique. There is regeneration with new bone formation at the defect site,
with complete remodeling of the implanted autograft, with no immune issues(13). Hence
autografts are termed the ‘golden standard’. On the flipside, there are two surgeries needed
on the patient, one for explantation of the autograft and another for implantation of the graft
into the defect site(14). Therefore the procedures are complicated by morbidity at the donor
site. Additionally the availability of non-essential bone is limited in very young and very old
patients, posing another limitation(12, 15).
1.2.2 Allograft
Allograft is bone obtained from another human donor, different from the patient undergoing
the transplantation. This source could be alive as seen with patients who have a total hip
replacement, where the extracted bone could be processed and implanted as a bone graft in a
patient requiring an allograft implantation. The source could be cadaveric and such bone
could be banked, processed and used in patients as an allograft(16). While allografts
overcome limitations of autografts such as no excessive pain to the patient associated with
explantation of the bone to be grafted, and is not limited by availability, they have their set
off limitations. The allografts have been documented to have issues of disease transmission
and immune rejection by host tissue(17, 18). Hence they tend to be treated by extreme
measures to ensure the elimination of biologics that may ensue in disease transmission or
rejection of the allograft. This processing leaves the allograft with poor biological properties
for bone regeneration. Hence unlike autografts, allografts tend to be mildly osteogenic, but
pose a challenge to remodeling and regeneration of lost bone(19).
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1.2.3 Xenograft
Xenograft is a graft obtained from species other than human. Most of these xenografts are
highly processed materials, with high calcium content to favor bone formation. Some popular
products are a coral based xenograft called coral derived granules (CDG)(20), bovine(21)
and porcein processed bone materials. Interpore and Pro-osteon (Interpore International, Inc.,
Irvine, CA) are coral based products available in the market. Bio-Oss (Geistlich
Biomaterials, Geistlich, Switzerland), Osteograf-N (CeraMed Co., Denver, CO), and
Endobon (Merck Co., Darmstadt, Germany) are bovine-based products in the market(22).
While encouraging results have been seen in dentistry with the use of xenografts(23),
orthopaedic outcomes have been limited. There are also concerns of disease transmission and
hence xenografts are not a popular clinical option as bone grafts(24, 25).
1.2.4 Other materials
Other materials used as bone grafts are ceramics, and composites of calcium phosphate such
as HA and tri calcium phosphate (TCP)(25), calcium phosphate cements(26), and calcium
sulphate(27). Since bone contains calcim and phosphate as its mineral component, these
materials are biocompatible and osteoconductive(28). They are however brittle with
mechanical strength far below that of cortical bone. Hence though these ceramic and calcium
phosphate based fillers are used in smaller defects, they are not used in the case of load
bearing long bone defects.
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1.3

Bone Tissue Engineering (BTE)
Though the concept of application of materials to replace lost tissue started, as early in the
17th century when artificial legs were made out of wood and metal(29), the concept of tissue
engineering is relatively young as it has been around for only the past twenty-five years(30).
The term ‘tissue engineering’ was coined in 1987(30, 31). Tissue engineering involves the
integration of engineering, chemistry and biology to achieve tissue regeneration(29). Rather
than the earlier concept of using an inert material that acts as a mechanical replacement for
the lost tissue, the tissue-engineering concept takes advantage of the knowledge gained from
multiple fields and applies it to formulate a platform made of biomaterials, cells, factors and
design considerations to achieve complete healing of lost bone(32).

1.4

Scaffolds in BTE
The scaffold for BTE act as a template for regeneration to occur and the properties of the
biomaterial can dictate the nature of bone regeneration achieved(33). It is well known that
the scaffold’s material properties such as moderate hydrophilicity(34), morphology(35),
porosity(36), chemical functionalities(37, 38) and biomechanical properties(39) can be used
to direct effective bone healing, by influencing the resident osteoblasts and by inducing the
homing, growth and differentiation of progenitor cells. BTE scaffolds act as the delivery
vehicle for stem cells and growth factors, and their design considerations can lead to
controlled delivery of these agents in order to elicit maximum regeneration of lost bone(40).
Therefore the selection of an appropriate material to formulate the scaffold and have a smart
design are important for a biomaterial scaffold for BTE to perform well.
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1.5

Attributes of a successful BTE scaffold
There are three essential attributes for a scaffold for BTE: Osteoconductivity,
osteoinductivity and osteointegrativity.

1.5.1 Osteoconduction
Osteoconduction is the ability of the scaffold to allow the resident cells in bone to grow into
the scaffold(41). Hence osteoconductive materials provide a conducive environment that
allows the bone to grow on the biomaterial’s surface(42). An important consideration in
achieving osteoconduction is vascularization of the biomaterial to maintain live osteoblasts
on the scaffold surface(43). A number of pro-proliferative growth factors like Insulin-like
growth factor (IGF-I, II), fibroblast growth factors (FGFs), transforming growth factor β
(TGF-β), and platelet-derived growth factor (PDGF) are known to be osteoconductive(44).
Collagen and calcium phosphate based materials are known to be osteoconductive(30).
1.5.2 Osteoinduction
Osteoinduction is the ability of the scaffold to facilitate the differentiation of progenitor cell
population into the osteoblastic lineage. This property is important to the scaffold system as
these progenitor cells can further recruit other cell types and secrete factors that hasten the
process of bone healing(45). The first instance of osteoinduction was seen with bone
formation by the implantation of demineralized bone matrix in the muscle, termed extopic
bone formation. Bone morphogenetic proteins (BMPs) were the factors isolated and found to
be responsible for osteoinduction(46). Progenitor cells are found to secrete this growth factor
in response to bone injuries as well(29). Hence most systems utilize BMPs or progenitor cells
to make the systems osteoinductive.
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1.5.3 Osteointegration
Osteointegration is the ability of the scaffold to establish and maintain intimal contact with
the living bone tissue(47, 48). Osteointegration can be seen as an extension of the scaffold’s
ability to be osteoconductive and osteoinductive. A material that allows for progenitor cell
recruitment, differentiation and allows for the proliferation of cells in the bone forms a good
contact with the neighboring bone tissue(49). Rough surfaces and mineral (HA deposited)
scaffold surfaces are known to show greater osteointegration(49). The layer of integration is
about 40- 150 nm thick and hence it is tough to examine by microscopic examination(50).
1.6

Materials used as scaffolds for BTE
Materials of many different properties and origin are used to formulate scaffolds for tissue
engineering. Though initially the idea was to have an inert matrix that allows the lost tissue
to be mechanically replaced, and the expectation from the material was to be immune
acceptable, nowadays smart materials capable of inducing bone regeneration are sought.
Polymers of both natural and synthetic origin have been used for a variety of bone BTE
applications. A way of categorizing these polymers used for BTE is based on their origin- 1.
Synthetic polymers and 2. Natural polymers.

1.6.1 Synthetic polymers in BTE
Most synthetic polymers used in tissue engineering are designed to be degradable, so as to
transfer the load onto the regenerating tissue as they dissolve away. Most of these polymers
have chemical groups that have chemical bonds that are break on the action of water
(hydrolytically degradation) or due to enzymes (enzymatic degradation). Most synthetic
polymers undergo hydrolytic degradation(51). However there are a few engineered polymers
that use amino acid monomers and are engineered to degrade enzymatically. Hydrolytically
degradable polymers are synthesized by condensation (step) polymerization or chain
6

(addition) polymerization reaction(52). The classes of hydrolytically degradable synthetic
polymers used in tissue engineering are:
1. Poly(α-hydroxy acid)s
2. Poly(ortho esters)
3. Polyanhydrides
Though a number of scaffolds have been made with each of these polymers and their
combinations there are a few polymers that have been approved by regulatory authorities for
use in biomedical devices(53). These polymers are:
1.6.1.1 Poly(α-hydroxy acid)s
Poly (α-esters) are polymers that have a labile aliphatic ester linkage in their chemical
backbone. Ring opening and condensation polymerization reactions lead to the synthesis of
poly (α-esters). Poly (α-hydroxy acid)s constitute the most popular and well studied group of
Poly(α-esters). Though polycondensation of monomers could be employes to synthesize
these poly(α-hydroxy acid)s, ring opening polymerization (ROP) reaction offers greater
control over the molecular weight of the product formed. Additionally the reaction conditions
seen with ROP process render it mild in contrast to polycondensation and hence the process
is industrially relevant for scale up of production(54). Poly -lactides, glycolides and
caprolactones are the most widely used poly(α-hydroxy acid)s in BTE applications.
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1.6.1.1.1 Polyglycolides (PGA)
Polyglycolides were some of the earliest degradable polymers employed in tissue
engineering(55). The chemical structure of PGA is given above (Figure 1.1). The high tensile
strength and the solubility of polyglycolides can be attributed to their highly crystalline
nature (45- 55%). Some matrices made of polyglycolide exhibit a modulus of 12.5 GPa. Due
to their great initial mechanical property, BiofixR has been developed as a polyglycolide
based device for bone. Polyglycolides however undergo bulk degradation of the polymer
matrix(56). The end product of degradation is glycine. These degradation products are highly
acidic, but can be shuttled into the tricarboxylic acid metabolic cycle. The buildup of the
acidic pH could be overwhelming for the tissue and hence this polymer is most commonly
used in combination with other polymers to combat the disadvantage(57).

Figure 1.1. Stucture of PGA

1.6.1.1.2 Polylactides (PLA)
Polylactide is a chiral molecule. The L- and D- optically active isoforms are seen in
polylactide as a racemic micture of (D, L)- lactide. The L- lactide isoform is the naturally
occurring one. Poly (L- lactide) (PLLA) is also a crystalline (37% crystallinity) polymer.
The general chemical structure of PLA is shown above (Figure 1.2) PLLA is slow degrading
and has a high modulus of 4.8 GPa. Hence a number of implants and devices for orthopaedic
application have been developed using PLLA. Phantom Soft Thread Soft Tissue Fixation
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Screws, Phantom Suture Anchors (DePuy), Full Thread Bio Interference Screws (Arthrex),
BioScrews, Bio-Anchors, Meniscal Stingers (Linvatec), and
Clearfix Meniscal Darts (Innovasive Devices) are some examples of such orthopaedic
devices(58, 59). Since PLLA is more hydrophobic than polyglycolides, it has a very long
degradation time of more than five years in the body. Hence poly (DL-lactides) (PDLLA) has
also been investigated for tissue engineered device formulation. PDLLA has a lower modulus
than PLLA (1.9 GPa). Mass loss occurs at 12- 16 months in the case of PDLLA(57). All
polylactides exhibit bulk degradation properties(60). Lactic acid is the end product from their
degradation and this can be shuttled into the tricarboxylic acid metabolic cycle for
elimination(57).

Figure 1.2 Structure of PLA
1.6.1.1.3 Poly(lactide-co-glycolide)
The chemical structure of Poly(lactide-co-glycolide) (PLGA), is given above (Figure 1.3).
PLGA is the co-polymer of L / -DL- Lactide and glycolide. Different ratios of lactide and
glydolide have been used to formulate PLGA of various molecular weights and degradation
rates. In the case of PLGA, polymers with an intermediate composition (50/50) were more
susceptible to degradation (1-2 months in vivo) than compositions at the either extreme ends
of the compositional spectrum (75/ 25 PLGA: 4-5 months in vivo, and 85/15 PLGA: 5-6
months in vivo for degradative mass loss)(61). Many studies have used PLGA to create micro
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and nanoscale featured scaffolds for BTE(62). PLGA due to its ease of being engineered to
desired qualities lends itself to be fabricated using a number of scaffold fabrication
techniques such as gas foaming(63), 3D sintered microspheres(64) and electrospun nanofiber
scaffolds(65) . Hence PLGA is a polymer under extensive investigation for BTE and the
United States Food and Drug Administration (U.S.F.D.A) has approved it for several drug
delivery applications. However the degradation kinetics and the degradation products
associated with PLGA continue to pose limitations on achieving controlled release(66) of
factors from the polymer and sometimes pose the threat of loss of activity of factors due to
change in pH.

Figure 1.3 PLGA Structure.
The chemical structure of Poly(lactide-co-glycolide) (PLGA) (Ratio of PGA: PLA is m:n and it
can be modulated to achieve different kinds of PLGA copolymer).

1.6.1.1.4 Polycaprolatone
Polycaprolatone (PCL) is a polymer of ε-caprolactone formed by ring opening
polymerization reaction. It takes around two to three years to degrade in the body. The
chemical strcture of PCL is given above (Figure 1.4). PCL too has good mechanical
properties. It has an excellent elongation coefficient of seven hundred percent its original
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length at break. Composites of PCL with calcium phosphate may be suitable scaffolds for
BTE(67).

Figure 1.4 Structure of PCL
1.6.1.2 Poly (ortho esters)
Poly (ortho ester) (POE) was developed to be a hydrophobic polymer with surface erosion
characteristics by ALZA corporation (Alzamer). The polymer’s hydrophobic nature
combined with its ester linkage that is hydrolytically labile render them slow to degradation
and better at achieving slow and sustained delivery of molecules entrapped into its matrix.
The unique feature of POEs is their ability to be engineered into pH sensitive matrices. Thus
this class of polymer was developed as an ideal platform for drug delivery applications by
tuning the pH of excipients used to control the temporal release of encapsulated drug. There
are four classes of POEs:
POE class I: Diol and diethoxytetrahydrofuran tranesterification yielded POE I. One of their
degradation products acted as an autocatalyst and accelerated the degradation of the polymer.
Hence class II POEs were developed.
POE class II: Diols reacted with diketene acetal led to the synthesis of POE II. Acidic
excipients were needed to accelerated their degradation rate.
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POE class III: Reaction of a triol with an orthoester led to the synthesis of viscous POE III.
However their consistency posed problems with scale-up of production at an industrial levels
and hence the POE class IV polymers were synthesized.
POE class IV: Adding short segments of lactic or glycolic acid to POE II led to the
formulation of POE IV. This gave POE IV the advantage of accelerated degradation without
the addition of pH modulating excipients. These POE IV polymers are being considered for
formulation of BTE scaffolds(68).
1.6.1.3 Polyanhydrides
Polyanhydrides are surface eroding polymers that have aliphatic anhydride bonds in their
backbone that are sensitive to attack by water. However they are highly hydrophobic,
confining the degradation to their surface. Due to their surface eroding property, this class of
polymer is highly suitable for controlled release of drugs. FDA had approved the use of a
Polyanhydride for drug delivery in 1996(69). Many different kinds of polymerization
reactions including melt condensation, ring opening polymerization, interfacial condensation,
and dehydrochlorination can produce polyanhydrides. Polymers such as poly(sebacic
anhydride) (PSA) due to their fast rate of degradation and highly crystalline nature have
limited applications(70). However, poly ((carboxy phenoxy propane)-(sebacic acid)) (PCPPSA) is a well characterized polyanhydride approved by US FDA for drug delivery
applications(71). A 1:1 sebacic acid and erucic acid dimeric copolymer system has been
approved for drug delivery in osteomyeltis(72).
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Table 1.1 Popular synthetic polymers, their properties and applications
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1.6.2

Natural polymers in BTE

Polysaccharides, proteins and polyesters derived from both plant and animal kingdoms
constitute the family of natural polymers. Several of these polymers are part of our diet and
have been used in a variety of human applications in pharmaceutical excipients, prosthetics,
drug delivery and imaging applications. These polymers are known to be recognized by the
biological environment and channeled into metabolic degradation. Due to the similarity that
natural polymers share with the ECM components, these materials may also avoid the
stimulation of chronic immunological reactions and toxicity, often detected with synthetic
polymers(73).
1.6.2.1 Polysaccharides in tissue engineering and drug delivery1
Polysaccharides consist of monosaccharides (sugars) linked together by O-glycosidic
linkages. Differences in the monosaccharide composition, linkage types and patterns, chain
shapes and molecular weight dictates their physical properties, such as solubility, viscosity,
gelling potential and/or surface and interfacial properties. Polysaccharides are derived from
renewable resources, like plants, animals and microorganisms and are therefore widely
distributed in nature. In addition, polysaccharides perform different physiological functions
and hence have great potential applications in the fields of tissue engineering and
regenerative medicine(73)(Figure 1.5).
There are hundreds of known polysaccharides. A list of polysaccharides from varying
sources is listed below:

1

This section was published as a book chapter: Aravamudhan A, Ramos D, Nada AA, Kumbar
SG, Natural Polymers: Polysaccharides and Their Derivatives for Biomedical Applications,
Natural and Synthetic Biomedical Polymers; pg. 67-90, Elsevier Science; 2014.
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Examples of polysaccharides from higher plants include starch, cellulose, exudate gums like
arabinogalactan, gaur gum, and gum arabic.
Examples of algal polysaccharides: Alginates, galactans, and carrageenan.
Examples of polysaccharides from animals: chitin, chitosan, glycosaminoglycans, and
hyaluronic acid
Examples of polysaccharides from microorganisms: dextran, gellan gum, pullulan, xanthan
gum, and bacterial cellulose.
Their monomer composition and biological source provides these polysaccharides with
different sets of physico-chemical properties. Often, polymers of natural origin have
limitations in terms of their solubility and industrially acceptable processability factors such
as high temperature of melting, which are commonly applied to synthetic polymers. For
instance, majority of polysaccharides are water-soluble and oxidize at elevated temperatures
beyond their melting point. These limitations have to be overcome prior to designing any
products using polysaccharides. For instance techniques to crosslink polymer chains have
been developed to stabilize polysaccharide structures in order to give structural stability in
aqueous environments(74, 75). Polysaccharide chitin in its native form cannot be produced
into desired sizes and shapes due to its inability to dissolve in most common industrial
solvents. Thus, chitosan, the deacetylated form of chitin, was produced and applied widely
instead of native chitin itself, as chitosan is water-soluble polymer at low pH. Due to its
properties, chitosan is widely used for biomedical applications(76). The following sections
will summarize these efforts in the context of biomedical applications (as shown in Figure
1.5) of polysaccharides invoking native polysaccharides, semi-synthetic polysaccharide
derivatives and their blends with other synthetic polymers.
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Polymers derived from plants and animal kingdoms have been widely researched as
biomaterials for a variety of biomedical applications including drug delivery and regenerative
medicine. These polymers have biochemical similarity with human ECM components and
hence readily accepted by the body. Additionally, these polymers inherit several advantages
including natural abundance, relative ease of isolation and room for chemical modification to
meet the technological needs. In addition, these polymers undergo enzymatic and/or
hydrolytic degradation in the biologic environment with body friendly degradation
byproducts. Natural polymers include the list of polysaccharides (carbohydrates) and animalderived proteins. Polysaccharides are an important class of biomaterials with significant
research interest for a variety of drug delivery and tissue engineering applications due to their
assured biocompatibility and bioactivity. Polysaccharides are often isolated and purified from
renewable sources including plants, animals and microorganisms. Essentially these polymers
have structural similarities, chemical versatility and their biological performance with the
ECM components; often mitigate issues associated with biomaterial toxicity and host
immune responses. The building blocks of carbohydrate monosaccharide are joined together
by O-glycosidic linkages to form a polysaccharide chain. Polysaccharides offer a diverse set
of physicochemical properties based on the monosaccharide that constitutes the chain, its
composition and source. The popular list of polysaccharides used for a variety of biomedical
applications cellulose, chitin/chitosan, starch, alginates, hyaluronic acids, pullulan, gaur gum,
xanthan gum, and glycosaminoglycans. In spite of many merits as biomaterials these
polysaccharides suffer from various drawbacks including variations in material properties
based on the source, microbial contamination, uncontrolled water uptake, poor mechanical
strength and unpredictable degradation pattern. These inconsistencies have limited their
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usage and biomedical application related technology development. Numerous synthetic
polymers with well-defined mechanical and degradation properties have been developed to
meet the technological needs in the biomedical applications. However, these polymers from
the biologic stand point, lack much-desired bioactivity and biocompatibility and may cause
toxicity and immune response. Polysaccharide structure offers freely available hydroxyl and
amine functionalities that makes it possible to alter its physicochemical properties by
chemically modifying polysaccharide structure. For instance, grafting synthetic monomers on
the polysaccharide chain offers an easy way to control polymer solubility in desired solvents,
water uptake and degradation. These semi-synthetic polymers offer best features of the both
natural and synthetic polymers. Various crosslinking techniques to restrict the polysaccharide
chain movement to control their water uptake, degradation and mechanical properties have
also been developed. Polysaccharide-based porous scaffolds, fiber matrices, hydrogels, micro
and nanoparticles have been developed for a variety of tissue regeneration and drug delivery
applications. In the recent years glycochemistry has gained research momentum for
understanding carbohydrate biological functions and development of carbohydrate-based
drugs and vaccines. Engineered carbohydrate based polymeric structures may serve as an
alternative material platform for a variety of regenerative medicine and drug delivery
applications.
A new non-petroleum based biomaterial platform to meet the versatile needs in biological
science and biomedical engineering could be achieved by collaborative efforts between
academia, government, and industry partnership. The collaborative efforts should include
bringing scientists working in different disciplines of chemistry, biology, polymers, materials
sciences and engineering to work towards these activities. These collaborative efforts could
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lead to the development of a methodology for synthesis of natural polymer based semisynthetic polymers and provide a greater depth of understanding of carbohydrate biological
functions, polymer structure, material properties, degradation and mechanical properties.
Further development of modeling tools to predict structure-property and biological activity of
carbohydrates for biomedical applications. The goal of the new initiatives should focus on
the development of natural polymer based orthopaedic fixation devices, biomedical implants,
drug delivery vehicles, carbohydrate based drugs, hydrogels, surfactants, coagulants and
absorbents for a variety of biomedical applications. The research activities in this area could
generate commercially available technologies and products from the renewable resources and
contribute immensely towards economic development.

19

Figure 1.5 Polysaccharides in biomedical applications
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1.6.2.1.1 Hyaluronic acid
1.6.2.1.1.1 1.6.2.1.1.1 Chemical structure, properties and sources
Chemically HA is a linear polysaccharide made up of: D-glucoronic acid and N-Acetyl-DGlucosamine that are linked to one another by a β-(1->3) linkage. There could be 250-25000
such basic disaccharide units in a polymer chain of hyaluronic acid, connected by β-(1-> 4)
linkage (Figure 1.6). The disaccharide units of hyaluronic acid are extended, forming a rigid
molecule whose many repelling anionic groups bind cations and water molecules. In
solution, hyaluronate occupies a volume approximately 1000 times that in its dry state.
Hyaluronate solutions exhibit clear viscoelastic properties that make them excellent
biological absorbers and lubricants. These properties also attribute to its preferred form of
fabrication into hydrogels. Because of its hydration properties, HA has the ability to bear
compressive loads in vivo, and provide lubrication at the same time. In vitro, HA has been
shown to facilitate cell migration and pericellular matrix formation(77).
Biologically, HA are an important glycosaminoglycan (GAG) component of connective
tissue, synovial fluid (the fluid that lubricates joints) and the vitreous humor of the eye in
mammals(78). The biological roles of HA are widespread and widely appreciated(79-81).
They range from development, angiogenesis, cellular migration and receptor mediated
signaling through receptor CD44 and receptor for HA-mediated motility (RHAMM) in ECM
remodeling and mediation of inflammatory responses(82, 83). HA chain length plays an
essential role in the biological functions elicited in native and hence the engineered tissues.
Therefore the molecular weight of HA is an important consideration for the response elicited.
For instance, while the low molecular HA (less than 3.5X104 Da) is known to be involved in
cytokine activity implicated in inflammatory responses(84), the higher molecular weight HA
(above 2X105 Da) is known to inhibit cell proliferation(85). Similarly, (1-4KDa) smaller
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fragments of HA have a positive effect in promoting vascularization during injury, whereas
the (1-9KDa) large fragment showed no significant effects(85, 86). Not only is the usage of
HA at the correct molecular weight and chain length, but also the hyaluronidas (HAS)
isozyme (Figure 1.7) that is responsible for degradation of HA in the tissue, determines the
chain length of the degradation product. Therefore the enzymes in the tissue where the HA
material is to be implanted is a factor for consideration while using the material in tissue
engineering(87).

Figure 1.6 Structure of Hyaluronic Acid (HA)
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Figure 1.7 Chain length of HA
The 3 HAS isozymes produce distinct chain lengths of HA. HAS1 and HAS3 can produce chains
of 2X105-2X106 Da, while HAS2 produces HA of chain length greater than 2X105 Da (Modified
from Allison et al., 2006(88)).
1.6.2.1.1.2 Attempts made in Tissue Engineering and Drug delivery
1.6.2.1.1.2.1 Hyaluronic acid alone
HA is highly water soluble at room temperature and at acidic pH values, and exhibits high
rates of turnover in vivo (half-life varies from only minutes in the blood to weeks in
cartilage(80, 81, 88-90). These properties pose challenges for the material’s integrity in vivo.
Therefore the usage of HA in its native form in tissue engineering and drug delivery
applications is pretty limited. Several crosslinking methods are used to increase the stability
of HA in such applications. Some of them are as follows: water-soluble carbodiimide
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crosslinking, polyvalent hydrazide crosslinking, divinyl sulfone cross-linking, disulfide
crosslinking,

and

photocrosslinking

hydrogels

through

glycidyl

methacrylate–HA

conjugates(87). Hence these techniques of covalent crosslinking provide the opportunity to
combine HA with more mechanically stronger polymers.
1.6.2.1.1.2.2 HA derivatives and combinations with other polymers
The early usage of HA was in ophthalmic drug delivery systems where it provided an ideal
matrix for covalent attachment of drugs and showed as much as twice the retention in
contrast to free drug (methylprednisolone esters of HA)(91, 92). Different formulations such
as such as gels, solutions and hydrogels with several model drugs such as pilocarpine (Pi)
and tropicamide (Tr) showed that HA ester systems were effective ophthalmic drug delivery
systems(92). HA has also been employed in liposomal dermal drug delivery. HA was
conjugated to the surface of liposomes by carbodiimide crosslinking of its surface carboxyl
residues to the amine residues on the liposome. The epidermal growth factor showed an
encapsulation efficiency of >87% in these HA conjugated liposomes(93). Avid binding of
these HA conjugated liposomes to a cellular monolayer in culture were seen that did not
occur with the unmodified liposomes(93). Sodium butyrate used as an anti proliferative drug
in treatment of cancer has an extremely short half-life of five minutes in vivo. In order to
bypass this constrain butyratic ester derivatives of HA were synthesized by stepwise
chemical treatment of HA. The degree of substitution (DS) varied from 0.1 to 2.24 (1.828.4%). MCF breast cancer cell lines showed maximum anti- proliferative response with DS
of 0.2. It was seen that complete internalization of the HA vehicle occurred in two hours
through CD44 receptors that are frequently over expressed on cancer cells(94). From these
and several other systems where HA and its derivatives have been used to deliver drugs, its
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innate role that facilitates binding of HA to receptors/ specific cell types helps achieve
efficient targeted delivery of intended drug to a tissue while its activity is preserved.
Another major application of modified HA is in formulation of tissue engineering scaffolds.
Radiation mediated crosslinked HA networks have been used as scaffolds for cell growth
with positive outcomes(95). HA modified with methacrylic anhydride (MA) was
photopolymerized to produce HA–MA hydrogels containing porcine chondrocytes(96). The
chondrocytes within the HA scaffolds were viable and were able to produce neo-cartilage
within the porous networks. Photopolymerizable HA–MA hydrogels have also been used in
heart valve applications, in which the HA hydrogels were designed to mimic the cardiac
ECM from which the heart valves develop(97). HA has been combined with other natural/
synthetic polymers to produce scaffolds. For example, HA has been combined with
polypyrrole to create a multifunctional copolymer(98, 99). When implanted into rats, there
was a marked early increase in local vascularization(99). On the other hand it was observed
that polypyrrole–HA polymers were subsequently sulfonated, which was shown to
significantly reduce platelet and cell adhesion(98).
Benzyl derivatives of HA (Hyalograft C and HYAFF-11) are used as polymeric scaffolds for
tissue engineering of cartilage(100). Though the laboratory tests have given mixed results,
the human clinical results show normal cartilage formation when implanted into previously
damaged tissue(101). Hence benzyl esters of HA have a great potential as scaffolds and drug
delivery vehicles for chondrocytes in tissue engineering. Another HA-based scaffold
examined for tissue engineering–based cartilage regeneration is auto-crosslinked
polysaccharide polymer (ACP). While comparing ACP with HYAFF-11, poly (L- lactic acid)
(PLLA) and poly (DL- lactic- glycolic acid) (PLGA) in an osteochondral defect, faster
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degrading scaffolds of ACP, PLGA had greatest regeneration, while it was slower in
HYAFF-11, PLLA that had slower degradation rates. These in vivo data revealed that the
scaffolds degraded within 4 months and were able to repair the osteochondral lesions, again
emphasizing the selection of type of HA and the consideration of hyaluronidase system in the
tissue that would degrade it(102, 103). HYAFF-11 scaffolds have shown very positive effects
as scaffolds for engineering of vascular and hepatic tissue and showed great ability for
maintenance of cell phenotype indicating that it could be used as scaffolds for many tissue
engineering applications(104, 105).
Combining chitosan and high molecular weight HA (2.4X106 Da) in a three-dimensional
(3D) copolymer system promoted chondrocyte adhesion. The production of aggrecan and the
native rounded morphology of seeded chondrocytes increased with the concentration of
added HA and the scaffolds with HA performed better than scaffolds of chitosan alone(106).
Incorporation of chondrocytes and HA into orthopedic implants by crosslinking HA to amine
terminated PLGA–poly (ethylene glycol) (PEG) scaffolds allowed the attachment and
proliferation of donor chondrocytes. It was also observed that collagen II expression, a
marker of healthy cartilage phenotype, and DNA synthesis were significantly increased in
polymers that incorporated HA(107). Combining HA with divinyl sulfone (DVS), and
crosslinking with ultraviolet light, created suitable surfaces for cell adhesion. When a DVScrosslinked HA scaffold was dehydrated before seeding with smooth muscle cells, gels were
more porous and conducive to cell migration and infiltration, but did not lose their nonimmunogenic properties(108-110).

Follow up studies conducted on the same material

showed that smooth muscle cells increased the synthesis of ECM components elastin and
collagen of aortic valve tissues, over cells cultured on tissue culture plastic; this synthesis

26

was controlled by HA fragment size and dose(108, 111). Such studies have shown that HA is
a suitable material for vascular and cardiac tissue engineering. HA was also introduced
directly to engineered structures exogenously. For example, collagen matricides implanted in
rabbits have shown greater numbers of chondrocytes (1.5 times control values) after the
addition of soluble HA. The addition of HA fragments increased the amounts of
proteoglycans, a desirable component of remodeling(112). However, small HA
oligosaccharides (4–16 disaccharides), on the other hand can prevent cell proliferation in
vivo(113). These findings could have implications for improving the potency of implanted
small diameter vascular grafts and preventing stenotic lesions after graft implantation in
cardiovascular tissue engineering.
With the knee osteoarthritis patients increasing to a staggering 19 million in 2010, treatment
by visco-supplimentation has become popular. Visco-supplementation refers to the concept
of synovial fluid replacement with intra-articular injections of hyaluronan mainly for the
relief of pain associated with osteoarthritis(114, 115). Intra-articular injections of hyaluronan
ameliorate pain and increase function, generally for up to 3 months with no serious adverse
events. In the US, the first single-injection hyaluronan for visco-supplementation, SynviscOne®, was approved in early 2009. The global market for dermal fillers is constantly
increasing with 100 different dermal fillers on the market for aesthetic plastic surgery and
about half of them are based on hyaluronan(116). Thus it can be summed up that hyaluronic
acid has already stepped into clinical treatments in tissue engineering and will gain greater
importance in the future.
1.6.2.1.1.3 Promises and challenges with HA
HA has had a profound impact on the field of tissue engineering. The incorporation of HA
into biomaterials and scaffolds has yielded a new class of biocompatible, controllable, and
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readily degradable materials. These new scaffolds have been tested with multiple types of
cells and have been shown to promote beneficial remodeling of engineered tissues, as well as
the gross preservation of cell phenotypes. However harnessing the endogenous activity of the
hyaluronan synthases to stimulate endogenous HA production may be another useful strategy
for the future. Recent research developments regarding HA as a molecular delivery vehicle
for pharmacological and oncological applications, as well as in the orthopedic and
cardiovascular arenas, have the potential to transform the clinical future of tissue
engineering.
1.6.2.1.2 Chondroitin sulfate
1.6.2.1.2.1 Chemical structure, properties and sources
Chemically, Chondroitin sulfate (CS) is a sulphated GAG derivative. Alternating units of Nacetylgalactosamine and glucuronic acid are the monomers that constitute the basic unit of CS
(Figure 1.8). Hundreds of these alternating units could be present together in a CS polymer
chains. CS is a GAG seen associated with proteins in living systems termed proteoglycan. CS is
classified according to the position of sulfation of the monomer unit. The types of CS and their
chemical structure are listed below
Table 1.2 Types of Chondroitin Sulphate (CS)
S.no.

Name (Type)

1.
2.
3.
4.

Chondroitin sulfate A
Chondroitin sulfate C
Chondroitin sulfate D
Chondroitin sulfate E

Synthetic name (Sulphation
of GalNAc)
chondroitin-4-sulfate
chondroitin-6-sulfate
chondroitin-2,6-sulfate
chondroitin-4,6-sulfate

Biologically, CS is a major structural component of the ECM of several tissues of the body,
like cartilage. The biological function and efficacy of CS seems to be highly dependent on
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the chain length of the polymer. For instance, CS extracted from the trachea is usually shorter
Ca. 20-25 kDa, and considered to be of lower quality. On the other hand, CS polymer
extracted from shark is considered more bioactive and of higher quality with longer chain
length Ca. 50-80 kDa. Even CS extracted from a single source could have variable polymer
chain length(117). Hence the type and chain length of CS is likely to determine its biological
functions, such as interaction with growth factors, proteins in GAG complexes of the ECM
and its ability to influence cellular function(118, 119).

CS is also an indispensible

component of tissues for maintaining their mechanical properties. The resistance of cartilage
to compression is attributed to the tightly packed, charged sulphate groups of CS. This leads
to osmotic water retention and swelling of the cartilage and hence endows it with the weightbearing mechanical properties(120). Apart from its structural role, CS has also been an
important player in basic biological processes including cell division and development of
nervous system. Such biological roles are mediated by the binding of CS to growth factors,
cytokines and regulating signaling pathways in neurons(121, 122). Age related changes in
sulphation of the CS chains indicate their fundamental biochemical role in tissues(123)
during age related pathological changes. Loss of CS has been implicated in pathological
conditions. For example, osteo arthritis (OA) in cartilage is seen to occur due to the loss of
CS leading to cartilage degeneration. Many studies on the impact of CS administration in
patients suffering from OA along with in vitro results suggest that CS could improve
pathology of OA through promoting proteoglycans synthesis, usually lost during cartilage
degeneration(124), inhibiting elastase(125-127) and cathepsin G activity(128), and reducing
gene expression for a number of proteolytic enzymes(129).
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The reason for a high variability in the outcomes of treating OA with CS is due to the
variation in the chain length of the polymer used in these studies. While the high quality,
long chain CS is more effective, the low quality, short chain CS have minimal effects on the
pathogenesis of OA. Apart from its effects of improving OA, the anti-inflammatory effects of
CS have led to improvement in conditions such as psoriasis and inflammatory bowel disease.
These effects seem to be related to the inhibition of cytokines such as TNF-α(130), and IL1β induced translocation of NF-κB(131). However most of the effects are dependent on the
type of CS determined by degree and position of sulphation, as well as the chain length of the
polymer(122).

Figure 1.8 Structure of Chondroitin Sulphate (CS)
1.6.2.1.2.2 Attempts made in Tissue engineering and drug delivery
1.6.2.1.2.2.1 Chondroitin sulfate alone
CS is often administered orally as it is seen to improve joint-related pathologies(117). The
intact polymer is often consumed and several studies have examined the levels of the CS in
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blood plasma after consumption(132, 133) in humans, mice and horses. The degree of
sulphation and chain length of the polymer were seen to determine the rate of uptake,
retention and clearance from these biological systems. For instance, tracheal CS with lower
molecular weight is absorbed quickly within 1-5 hours and reached a peak plasma
concentration at around 10 hours. On the other hand shark CS of high molecular weight is
seen to be have a slower rate of uptake at around 8.7 hours and was retained in the system for
as long as 16 hours(133). It was also observed that desulphated chondroitin had quick uptake
rate (15 minutes) and was also cleared within 3 hours(134). Further, in vitro experiments
showed that there was a direct correlation between the polymer size and the rate at which it
crossed the gut wall(135). This in turn reflected as the rate of uptake and retention of the
polymer in the biological system. Therefore smaller CS polymer is taken up and cleared
quickly, while the larger CS polymer takes longer time to be absorbed and cleared from a
system.
1.6.2.1.2.2.2 Chondroitin sulfate derivatives and combination with other polymers
CS is a water-soluble polymer. Early attempts of using CS as a vehicle for colonic drug
delivery, crosslinked the polymer to different degrees to achieve a biodegradable system for
controlled release of model drugs, indomethacin. A linear correlation between degree of
crosslinking and rate of drug release emerged, indicating that the level of crosslinking of CS
can be used to regulate the kinetics of drug delivery(136, 137). Still, crosslinking of CS is
used as a strategy to decrease the dissolution of CS in water. For example, treatment of
water-soluble CS polymer with different proportions of trisodium trimetaphosphate (TMFS)
achieved crosslinking of CS and reduced solubility for the usage of the polymer in drug
delivery applications(138).
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Mostly due to its highly water-soluble nature and lack of mechanical stability, CS has been
modified with or used along with other polymers for drug delivery and tissue engineering
applications. Porous sponge of CS-chitosan was used for the delivery of Platelet Derived
Growth Factor (PDGF), aimed at achieving greater bone regeneration. Aqueous CS-Chitosan
solution was subjected to freeze drying followed by crosslinking to form a porous sponge
with 100-150µm pore size. PDGF-BB was incorporated into the CS–chitosan sponge by
soaking CS–chitosan sponge into the PDGF-BB solution. Amount of CS could act a factor to
control the release of PDGF-BB from the sponge(139). It was also seen that presence of CS
increased the osteoconductive characteristics of the material. Hence, the bioactive CS could
be used in combination with other polymers in the formulation of materials for delivery of
growth factors.
As CS has biological roles that are advantageous and is a water-soluble and enzymatically
biodegradable polysaccharide, it has been used in combination with materials such as
collagen in preparation of scaffold matrices. Addition of CS to collagen type I matrix was
achieved by using 1-ethyl-3- (3-dimethyl aminopropyl) carbodiimide (EDC) as a crosslinking
agent. The CS bound matrix had increased water-binding capacity, with decreased tensile
strength and temperature of denaturation(139).

Apart from imparting advantageous

biological properties to the scaffold, CS also presented the opportunity to control the
scaffold’s mechanical and degradation characteristics.
As explained in the previous section, CS is an important component of joint ECM and known
to play crucial roles in development and amelioration of joint/cartilage pathologies. Hence, it
is used extensively in osteochondral tissue engineering. Here again a number of CS variants
such as modified CS or CS in combination with other natural and/or synthetic polymers have
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been utilized for the formulation of scaffolds. Scaffolds of different formats were utilized.
Both fibrous spongy scaffolds and hydrogel scaffolds have been formulated utilizing CS.
While employing CS in combination with Collagen type I in the form of fibrous sponge
matrix, a clear advantage in chondrocyte proliferation and phenotype maintenance were
seen(140). Similarly sponges with a pore diameter of 180µm were synthesized using natural
polymers gelatin, CS and HA together. When these scaffolds were seeded with chondrocytes,
they maintained their morphology for up to 5 weeks and showed higher levels of aggrecan
production than scaffolds that did not contain CS and HA components. These in vitro studies
clearly point to the potential of scaffolds incorporating CS for cartilage tissue
engineering(141, 142).
A number of hydrogel scaffolds have also been formulated using CS for cartilage.
Chondrocytes have a rounded morphology and this is seen to be best preserved in hydrogels,
and therefore hydrogel scaffolds are an ideal option for cartilage regeneration. Polymers such
as poly ethylene glycol (PEG), poly vinyl alcohol (PVA), and poly (3-hydroxybutyrate)
(PHB) have been used with CS to formulate hydrogels. While PVA hydrogels alone could
not support cell adhesion, the addition of CS lowered the extreme hydrophilicity of the
hydrogel and facilitated greater cell attachment in the scaffold(143). When CS containing
Collagen hydrogel was conjugated to a fabric of PHB, it showed greater osteogenic potential
than the parent fabric, on the seeded osteoblasts(144). The presence of CS in PEG hydrogels,
promoted the chondrogenic differentiation of seeded bone marrow derived mesenchymal
stem cells (MSCs), but did not allow them to proceed onto a hypertrophic state. This was an
optimal

outcome

suitable

for

chondrocyte

differentiation,

to

achieve

cartilage

regeneration(145). In a recent study, the polysaccharide backbone was modified with
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methacrylate and aldehyde groups to form an adhesive gel. This modification led to better
integration of the hydrogel with the implanted tissue in vivo, as seen in a rat model. This was
due to greater scaffold-protein interaction brought about by the addition of modified
CS(146). Efforts have been made to deliver CS using scaffolding principles to joints affected
by OA. For instance, a scaffold with 40% chitosan and 60% CS was designed to serve as a
carrier of CS proved effective(147). Hence CS by itself after certain modifications and in
combination with other synthetic and natural polymers has a great potential in scaffolding
and drug delivery for osteochondral regeneration.
1.6.2.1.2.3 Promises and challenges with Chondroitin sulfate
There have been many promising outcomes with CS as a drug and as a matrix for tissue
engineering, both in vitro and in vivo. However clinical outcomes have been inconsistent and
have variable results. Better experimental design and ways to determine the polymer length
and level of sulphation would be crucial to determining to the fate of exogenously
administered CS. Better experimental design and greater understanding of the biological role
of CS are important factors for determining the polymer’s role and most suitable type of CS
polymer that lend the desirable biological outcomes.
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1.6.2.1.3 Chitin and chitosan
1.6.2.1.3.1 Chemical structure, properties and sources
Chitin is a structural polysaccharide found in nature. Chemically, chitin is made monomer
units of 2-acetamido-2-deoxy-b-D-glucose connected through β (1->4) linkages (Figure 1.9).
The C-2 position in the glucose ring in the monomers has an acetamido group. The Ndeacetylation of this chitin leads to the formation of chitosan. The degree of conversion of
the acetamido group to amine group is never really complete. This is given by the degree of
deacetylation (DD) of the chitosan. The DD of chitosan can vary from 30- 95%. This
conversion of chitin to chitosan renders the material more readily soluble and processable for
various applications (Figure 1.10). Though crystalline chitosan is insoluble in aqueous
solution at a pH> 7.0, in dilute acid where pH <6.0, the positively charged amino group
facilitates its solubility(148, 149). There are three reactive functional groups in chitosan- the
amino group at C-2, a primary and secondary –OH group at C-3 and C-6 positions
respectively. These reactive groups allow for chemical modification of chitosan such as
covalent and ionic modifications.
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Figure 1.9 Structure of Chitin and Chitosan
Chitosan is one of the highly studied and utilized polysaccharide for tissue engineering. A
process called “internal bubbling process (IBP)” can be used to form porous structures from
chitosan by freezing and lyophilizing a solution of chitosan. The addition of CaCO3 to
chitosan is used in this process to create porous chitosan gels(150). This processability of
chitosan is attributed to its cationic nature. The cationic property also leads to interaction of
the material with negatively charged small molecules and proteins in biological systems. This
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is structurally very similar to native GAGs and hence plays crucial role in stimulating
favorable responses in biological systems. Chitosan’s mechanical properties are determined
by the pore sizes, the molecular weight and crystallinity of the polymer. High porosity, lower
molecular weight and less crystalline polymers are mechanically less competent and vice
versa. Apart from these properties, chitosan is biodegradable. The acetylated residues of
chitosan are targeted by lysozyme in vivo and this seems to be the major mechanism of
chitosan degradation. Therefore DD, and crystallinity of the polymer are inversely related to
degradation. Thus the higher DD (>85%), the more crystalline the chitosan polymer and the
slower its degradation in the body(151-153).
Chitosan is known to have antibacterial properties that(154) are attributed to the attack of
negatively charged groups on the cell wall by the positively charged chitosan polymer. This
leads to lysis of bacterial cell wall, and hence its bactericidal activity. Inhibition of bacterial
growth by chitosan is also attributed to its binding of bacterial DNA and interference of
bacterial transcription(155). Chitosan is also seen to have minimal immune rejection. Chitin
is the major source for chitosan (Figure 1.10). It is the most abundant polymer to undergo
biosynthesis, next to cellulose. It is a constituent of the exoskeleton in animals, like
crustaceans, molluscs and insects. It is also a polymer found in the cell wall of certain fungi.
Most of the polymer used for commercial source comes as a byproduct of the fishery
industry(156).
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Figure 1.10 Nanofibers of Citin and Chitosan
Chitin (on left) and Chitosan after deacetylation (on right) Nanofibers(157).
1.6.2.1.3.2 Attempts made in Tissue engineering and drug delivery
1.6.2.1.3.2.1 Chitosan alone
The various biological properties of chitosan have been discussed above. Chitosan has also
been used as a dietary supplement. It is seen to lower low-density cholesterol and is helpful
in weight loss(158). Apart from its direct consumption, chitosan is used in drug formulations
of different types such as microparticles, liposomes, granules, gels for oral and parenteral
drug delivery. In most of these applications chitosan is physically or chemically crosslinked
to obtain stability. The degree of crosslinking and drug loading are parameters used to
control drug delivery(159, 160). In tissue engineering, chitosan alone was used initially.
Since the mechanical and dissolution properties of the polymer make it tough to work with
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and formulate scaffolds, chemical modifications and their combinations with other natural
and synthetic polymers is at present the more popular strategy. Common strategies are
discussed in the following section.
1.6.2.1.3.2.2 Chitosan derivatives and combination with other polymers
Some of the limitations chitosan suffers from are those of insolubility at neutral pH and high
water absorption by the polymer at a rapid rate. These factors pose problems of
processability and also lead to rapid drug release from chitosan. Hence chitosan is modified
to overcome these limitations. Most modifications are brought about by reactions with the
amine or hydroxyl groups of the glucoseamine unit in chitosan. Using the reactive amine
group a number of modifying reactions are carried out. A simple example is a reaction in
which an aldehyde functional group reacts with –NH2 group of chitosan by reductive
amination(161). The introduction of N-cyanoethyl groups into the side chain of glucosamine
in chitosan is a good example of this process. This reaction produced some crosslinking
through a reaction between the nitrile group and the amine group of chitosan(162). Examples
of covalent modifications of chitosan include acylation and quarternization. When two
oppositely charged polymers (a polycation and a polyanion) in a solution phase, separate out
in a solution, a dense polymer phase called coacervate and a supernatant with low polymer
content separate out. This process is termed polyelectrolyte complex formation.
Polyelectrolyte complex formation has been used in a number of chitosan drug delivery
systems(163, 164) where controlled release of the loaded drug was desired. Modified
chitosan and its blends with other polymers have been used in different formats.
Nanoparticles and microparticles of chitosan and its derivatives have been formulated using
techniques such as emulsification/solvent evaporation(157), spray drying(165), ionotropic
gelation and coacervation(166), emulsion crosslinking(167) and sieving(168). Thin films
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have been produced using solution casting, while crosslinking and gelation processes have
been applied to produce hydrogels of chitosan for drug delivery(169). Chitosan drug delivery
vehicles in the form of tablets and gels are applied in dental, buccal, gastrointestinal, colonspecific, and gene delivery applications due to their favorable biological properties(169). In
tissue engineering, chitosan had been used mostly in minimally modified forms. The focus
presently has shifted to improving the properties by introducing chemical modifications to
form derivatives of chitosan for specific tissue regeneration purposes. Some of them are
listed below:
Introduction of sugars
Synthesis of chitosan bound to sugar has many applications in drug delivery and tissue
engineering. This is due to the fact that cells, viruses and bacteria recognize these sugar
moieties and hence render these polymers good agents for targeting several target
components in tissue engineering. For example, galactosylated chitosan (GC), worked as a
good ECM for hepatocytes(170). Specific antigen presenting B cells were recognized by
mannosylated chitosan (MC)(171).
Graft polymerization
Chemical grafting of chitosan can be used to functionalize chitosan and obtain important
derivatives. Ceric ion, fenton’s reagent, gamma-irradiation, various radicals, and ring
opening reactions are the various routes used to achieve graft polymerization of
chitosan(172). Cell morphology and function were controlled by chitosan graft-polymerized
onto poly (L-lactide) (PLA) by plasma coupling reaction(173). Further cooperative
complementation through graft copolymerization or blend with poly (α- hydroxy acids) using
a photosensitive crosslinking agent led to attachment of chitosan onto PLA films. These films
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showed improved cell attachment(174). On the other hand copolymerization of chitosan with
heparin inhibited platelet adhesion(175). Therefore graft polymerization can help modulate
chitosan’s properties to elicit a desired cellular response.
Immobilization of specific sequences
Specific amino acid sequences promote cell adhesion. The most commonly used sequence is
the arginine-glycine-aspartic acid (RGD) from adhesion proteins, such as collagen and
fibronectin that bind cells through cellular integrin receptors. Photo crosslinking RGD
peptides to chitosan improved the adhesion of human endothelial cells, compared to
unmodified chitosan scaffolds(176). In another approach the –COOH group of amino acids
such as lysine, arginine, aspartate, phenylalanine react to the –NH2 group of chitosan. These
functionalized chitosan polymers were entrapped onto the surface of PLA to improve cellular
responses(177).
Production of nanofibers
Nanofibers mimic the structure of natural ECM closely. Hence enhanced cellular responses
are achieved on electrospun nanofiber scaffolds. Chitosan nanofibers ranging from several
down to a few nanometers have been produced by electrospinning technique(178, 179)
Thermal gelation
Thermal gelling is a technique of injecting a polymeric aqueous solution, while keeping the
temperature above the polymer’s sol-gel transition temperature and allow the polymer to
form a gel as it reaches the body temperature. A thermal gelling chitosan polymer was
formed by neutralizing highly deacetylated chitosan solution with glycerol phosphate (GP).
Chitosan remained in solution at physiological pH. Chitosan/GP solution gelled at body
temperature and hence was an attractive, injectable hydrogel drug delivery system local
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delivery of antineoplastic drugs like pachlitaxal(180). Derivatives of chitosan have been used
in skin, bone, cartilage, liver tissue engineering. A detailed description of chitosan is given
elsewhere in this book.
1.6.2.1.3.3 Promises and challenges with Chitosan in tissue engineering
Chitin and its derivatives have a number of applications in drug delivery and tissue
engineering. While being an abundantly available polymer, chitosan is also biodegradable
inside the body, mostly by the enzymatic activity of lysozyme. However chitosan/chitin by
itself lacks good mechanical properties required in certain structural applications. Chemical
modifications of chitosan and blending the polymer with other natural and synthetic
polymers are done to overcome this limitation. On the whole, chitosan has a huge potential in
tissue engineering and drug delivery applications.
1.6.2.1.4 Alginic acid
1.6.2.1.4.1 Chemical structure, properties and sources
Alginic acid is an anionic, strictly linear (unbranched) copolymer of mannuronic acid (M
block) and guluronic acid (G block) units arranged in an irregular pattern of varying
proportions of GG, MG, and MM blocks (Matsumoto, Kawai, & Masuda, 1992) (Figure
1.11). C5 epimerization and flipping of sugar ring to 1C4 position (Christensena, 2011) is seen
to occur for steric stability in the polymer. The M residues are linked at 4C1 (diequatorial
links). The G residues are the C-5 epimers of M. These G residues are linked at 1C4 with
diaxial links(181). The G and M blocks are present as similar or strictly alternating (GG,
MM, or GM). Due to the diaxial linkage, G blocks (GG) are stiffer than alternating blocks
(GM), and hence more soluble at lower pH. The content of G in alginates varies from 40-70
% depending on the source and determines the quality of the alginate polymer. The
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molecular weight of alginate can vary widely between 50-100,000 kDa. It is generally seen
that alginates with high G block content are highly suitable for biomedical application due to
the ease of processiblity, and low immunogenicity in the body. Hence the content of G and M
blocks is a crucial factor that determines the properties and applications of the resultant
alginate(182). Alginates are polysaccharides produced by a wide variety of brown seaweeds
(Laminaria sp., Macrocystis sp., Lessonia sp., etc.). Additionally bacteria also synthesize
alginates and these can be used as tools to tailor alginate production, by understanding the
biosynthesis of the polymer in these bacteria. A family of enzymes termed mannuronan-C5epimerases that convert M into G at the polymer level. By genetically selecting and
engineering Pseudomonas strains that contain only a single epimerase for the production of
high G containing alginates has been possible. Using such strategies, alginates with up to
90%

G

content

and

extremely

long

G-blocks

have

Figure 1.11 Gellation of Alginic Acid
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been

produced(183-185).

Mechanism of gellation of alginic acid in the presence of Ca2+. Possible junctions: (a) GG/GG
junctions, (b) MG/MG junctions, and (c)mixed GG/MG, with Ca2+.
Though such strategies are useful to engineer alginates, most of the alginates extracted for largescale applications originate from natural sources such as seaweeds. The quality is determined by
the species and even the seasonal variations. The alginate could contain from 10-70% G.
Techniques of separation such as fractionation and precipitation in calcium can help separate the
G-block and M-block rich alginates. The molecular weight of alginate is a critical factor to
influence its viscosity in solution, besides the concentration of the polymer. The most important
property of alginate is its ability to gel in the presence of cations (like Ca2+, and Ba2+) (Figure
1.12). The carboxylic acid groups of sugars in G blocks of adjacent polymer chains crosslink
with multivalent cations to form a gel. Factors that influence the stiffness of the gel are
molecular weight distribution of the alginate polymer (dependent on M/G ratio), and the
stoichiometry of alginate with the chelating cation(186, 187).
1.6.2.1.4.2 Attempts made in Tissue engineering and drug delivery
1.6.2.1.4.2.1 Alginate alone
The usage of polymers in biomedical applications such as drug delivery and tissue
engineering are highly dependent on its ability to degrade in the body(188). There are
enzymes that can degrade alginate in the human body. The mechanism of degradation of
alginate in the body happens in multiple ways as described below:
Disintegration of the alginate material occurs by exchange of gelling calcium ion with
sodium. Acid hydrolysis and alkali hydrolysis are two possible processes that can lead to
disintegration. At a physiological pH of 7.4, β-elimination by alkali hydrolysis is the
predominant mechanism of alginate polymer length reduction. Oxidation of the gels, by
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agents such as peroxides(189) help hasten the process, but also weaken the gel, in a ring
opening reaction of the polymer.
Degradation by reactive oxygen species (ROS). Most polymers including alginates undergo
‘free radical de-polymerization’ or ‘oxidative-reductive de-polymerization’. Water molecules
or molecular oxygen generates free radicals in living systems. Exposure of polymer to
gamma irradiation hastens this process and can be used to enhance the rate of
degradation(190).
Thus the major disadvantages of alginate are the lack of enzymatic degradation and its inert
nature that makes it non-adherent for cells. To overcome these limitations, alginate is widely
used as its derivative in combination with other polymers in drug delivery and tissue
engineering applications. Alginate by itself is used widely in many industries. It is used as a
stabilizer and emulsifier in food industry, as it interacts with proteins, fats and fibers.
Alginate-pectin mixtures are used as gelling agents independent of sugar content in foods.
Hence, alginate is used in many low calorie substitute foods. The high hydrophilicity of
alginates renders the material biocompatible and non-immunogenic. Therefore it is used
widely in pharmaceutical industry as drug excipient(181), dental impression material(191),
and as a material for wound dressing(192).
1.6.2.1.4.2.2 Alginate Derivatives and combinations with other polymers
In general alginates are formed into gels either by using multivalent cations or by covalent
crosslinking. These modifications will be discussed further, here. The major purpose in
subjecting algnates to chemical and physical modifications is to tailor their physical
properties such as degradation, mechanical strength, and biological properties such as
enhanced interaction with cells. Mechanical properties like stiffness and strength of alginate
gels can be controlled by physical factors. Concentration of polymer(193) and its molecular
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weight(186) can be used to determine the density of polymer solution for formulation of gels.
Increase of both these factors leads to higher viscosity of the polymer solution and hence a
stiffer and mechanically strong gel. Cationicpoly- (ethyleneimine) (PEI)(194) addition leads
to improvement of alginate gel’s mechanical properties. High molecular weight PEI increases
the resistance of the gel to de- crosslinking agents and thus improves the gel’s stiffness.
Gelling conditions such as temperature, type and concentration of crosslinker also affect the
mechanical properties of alginate gels. Low temperature cross-linking(195) leads to slow
crosslinking, due to reduced rate of calcium ion diffusion. This results in the formation of
gels with enhanced mechanical properties. Apart from these factors, the presence of cells in
the gels is also shown to improve its mechanical strength(196).
As discussed above in the previous section there are many methods used to control the
degradation of alginates. Gamma irradiation(197) and partial oxidation(198) can be used to
reduce the molecular weight of polymer and accelerate degradation rates. These techniques
also affect the mechanical strength of alginate gels. Gels with bimodal molecular weight
distribution have been formulated with one molecular weight polymer being oxidized, and
the other left untreated. This approach also accelerated gel degradation rate. In gels that are
covalently crosslinked, the linker density(199) determines the rate of degradation as well as
the strength of the gel.

As alginates are not conducive to cell adhesion, covalent

modification of the polymer, coupling whole (like fibronectin and collagen)(200, 201) or
parts of cell adhesion molecules (like RGD peptides) is a popular strategy used to increase
cellular responses. Here the concentration(202) of these adhesion molecules and the
composition of the gel (M/G ratio) determine the effectiveness of the gel in inducing cell
adhesion.
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Alginate based hydrogels have been used as drug delivery vehicles for low molecular weight
(small) molecule drugs as well as proteins such as growth factors. Drug-alginate interactions
play a crucial role in determining the rate of drug release from alginate gel matrices. Drug
release rate can be completely controlled by charge polarity (hydrophilic molecules will be
released quickly and hydrophobic ones more slowly), when there is no chemical interaction
between the drug and the alginate matrix. Carbodiimide chemistry is used to link hydrophilic
drugs(203) to alginate matrices to delay their release. In such a scenario the rate of drug
release is determined by polymer degradation. Here a linker such as AAD could be used to
attach the drug to alginate and the rate of release would be controlled by the concentration of
the spacer. Ionic complexes can also be used to attach drugs to alginate(204). Proteins such
as growth factors have been successfully delivered by alginate gel systems. It was seen that
such deliver systems preserved the bioactivity of the factors. Hence angiognic growth factors
like β- Fibroblast Growth Factor (FGF-β)(205), and Vascular Endothelial Growth Factor
(VEGF) loaded into alginate beads were successful in inducing angiogenesis to a greater
extent than free administration of the growth factors. Ionic complexes were used to link
VEGF(206, 207) to alginate matrix and the dissolution of this complex along with diffusion
acted to control the release of active VEGF from the gels over several weeks in vivo.
In most tissue engineering applications alginates with modified physical, chemical and
biological properties are desirable. These characteristics can be achieved by chemically
modifying alginate to form its derivatives and blends with other polymers. Alginate has a
number of hydroxyl and carboxyl groups along its polymer backbone and these are ideal
candidates for its chemical modification. Chemical modifications that can be carried out
using the hydroxyl group are as follows:
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Oxidation: Oxidation of alginate polymer chain produced a decrease in the stiffness of the
polymer by breaking C2–C3 bond. Here sodium alginate is usually the substrate to be reacted
with sodium periodate. This leads to oxidation on the –OH group at C-2 and C-3 position of
the uronic acid on sodium alginate. Two aldehyde groups result in each oxidized monomeric
units. The resultant oxidized alginate has reactive groups on its backbone and large rotational
freedom of the molecule. This renders the polymer more amenable to further chemical
modifications and greater biodegradation(208, 209).
Reductive amination of oxidized alginate: Oxidized alginate can be used as a substrate for
chemical reactions such as reductive amination. Reductive amination is performed with alkyl
amine by using NaCNBH3 as reducing agent. This reaction is favorable at a pH of 6-7 and
byproducts such as aldehyde/ ketone are negligible under the reaction conditions(210).
Sulfation: On sulfation, alginate structurally resembles heparin and attains anti coagulant
properties, alongside high blood compatibility(211). Reacting sodium alginate with
formamide and chlorosulfuric acid (ClSO3H) at 60°C can sulfate it.
Copolymerization: Microwave irradiation of sodium alginate and acrylamide led to synthesis
of various grades of grafted polymers(212). Alginate-g-vinyl sulfonic acid prepared by
employing potassium peroxydiphosphate/thiourea redox system has also been reported(213).
These synthesized graft copolymer exhibit better results for swelling, metal ion uptake, and
resistance to biodegradability in comparison to parent alginates themselves.
Linking Cyclodextrins: α-cyclodextrin (α-CD) can be covalently linked to alginate. This
reaction can be targeted to the hydroxyl groups of the alginate by cyanogen bromide (CNBr)
method to prevent reaction at the carboxyl group. This specificity was necessary to form the
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calcium–alginate beads that have great potential in encapsulating bacteria for environmental
remediation(214).
Chemical modifications that can be carried out using the carboxyl group are as follows:
Esterification: Alkyl group is attached to a molecule during esterification. Addition of alkyl
group to the backbone of alginate results in increasing the hydrophobicity of alginate.
Alginate can be modified by direct esterification using several alcohols in the presence of
catalyst. The alcohol is present in excess to ensure that the equilibrium is in favour of product
formation. Propene glycol ester of alginate (PGA) was obtained by esterification of alginate
with propyleneoxide. This is a commercially useful derivative of alginate(215).
Ugi Reaction: Hydrophobically modified alginate can be prepared by the Ugi
multicomponent condensation reaction. The Ugi reaction is amulti-component reaction in
organic chemistry involving a ketone or aldehyde, an amine, an isocyanide and a carboxylic
acid to form a bis-amide(216).
Amidation: In amidation reaction, a coupling agent, 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (EDC-HCl) is reacted with alginate to form amide linkages
between amine-containing molecules and the carboxylate moieties on the alginate polymer
backbone. This results in hydrophobic modification of the alginate(217).
A general outline of reactions used to modify alginate for biomedical applications was
summed up above. Though mostly hydrogel of alginate is the most popular form of
application of the polymer, other formats have also been formulated. Alginate foams(218),
fibers(219, 220) and nanofibers(221) are other forms in which alginates are fabricated(182).
Bioartificial pancreas, bone(222), vasculature and liver(223) are some of the tissueengineered organs where alginate materials have been used successfully.
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1.6.2.1.4.3 Promises and challenges with Alginates in tissue engineering
Alginates are a versatile class of polysaccharides that present a great tool as materials for
tissue engineering. They have been formulated as gels, microspheres, foams and fibers in
tissue engineering and for delivery of drugs and biological factors. Some constraints posed
by the material are its non- enzymatic degradation in the human body and its extremely
hydrophilic nature that discourage cell anchorage. However, these limitations have been
overcome by subjecting its –OH and –COOH functionalities to chemical modifications.
Understanding of the biosynthetic pathways leading to alginate biosynthesis in bacterial
systems has been very useful in tailoring their polymer chain composition and the molecular
weight of the polymer. Yet, more work needs to be done in improving these systems.
Alginate hence serves as a low cost biopolymer that is a good tool in biomedical engineering.
1.6.2.1.5 Cellulose
1.6.2.1.5.1 Chemical structure, properties and sources
Cellulose, the “sugar of plant cell wall” is the most abundant biopolymer in the biosphere.
The basic monomer unit of cellulose is β-D-anhydroglucopyranose. These units are joined
together covalently by acetal functions between the equatorial group of the C4 carbon atom and
the C1 carbon atom (β-1,4-glycosidic bonds). These β-1,4-glycosidic linkages bestow cellulose
with its resistance to chemical/ enzymatic attack(224) (Figure 1.13). Therefore cellulose is a
linear-chain polymer with a large number of hydroxyl groups (three -OH groups per anhydrous
AGU unit). This linear structure can be extended to molecules containing 1000–1500 β-Dglucose monomer units, in a cellulose polymer chain. This chain length of cellulose is expressed
in terms of number of constituent AGUs, termed degree of polymerization (DP). The degree of
linearity and the presence of extensive –OH groups throughout the cellulose chain are
responsible for formation of inter and intra molecular hydrogen bonds throughout the polymer
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chain. This causes cellulose chains to organize in parallel arrangements into crystallities and
crystallite strands, the basic elements of the supramolecular structure of the cellulose fibrils and
the cellulose fibers. This arrangement of fibers in the polymer is termed its supramolecular
structure and it in turn influences its physical and chemical properties. Cellulose is known to
exist in at least five allomorphic forms. Cellulose I is the form found in nature. Cellulose may
occur in other crystal structures denoted cellulose II, III and IV. Cellulose II is the most stable
structure of technical relevance. This structure can be formed from cellulose I by treatment with
an aqueous solution of sodium hydroxide. This leads to regeneration of native cellulose from
solutions of semi-stable derivatives. This crystalline structure is modified from cellulose I. A
parallel chain arrangement of cellulose in cellulose I form undergoes a change to form cellulose
II. This renders the cellulose II more accessible to chemical treatments and hence more reactive.
A fringe fibrillar model is used to describe the microfibrillar structure of cellulose polymer. It
describes the structure to be made of crystalline regions of varying dimensions called crystallites
and noncrystalline regions. This structure explained the partial crystallinity and reactivity of
cellulose in relation to its microfibrillar structure(225).
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Figure 1.12 Structure of Cellulose

Figure 1.13 Anhydroglucose unit of Cellulose
Numbering of carbon atoms in anhydroglucose unit of cellulose
Cellulose behaves an active chemical due to the three-hydroxyl groups in each glucose
residue. The hydroxyl groups at the second and third positions behave as secondary alcohols,
while the hydroxyl group at the sixth position acts as a primary alcohol (Numbering as
shown in Figure 1.14). These –OH groups are the responsible for the reactivity of cellulose.
Degree of substitution (DS) is the term used to indicate the average number of –OH groups
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substituted in an anhydroglucose unit of a cellulose molecule. That is, a DS of 3 indicates
that all the 3 –OH groups have been substituted in the anhydroglucose units of the cellulose
derivative. In general, the relative reactivity of the hydroxyl groups can be expressed as OH–
C6 >> OH–C2 > OH–C3(226).
Cellulose, like the polysaccharides above, has certain drawbacks. These include poor
solubility in common solvents, poor crease resistance, poor dimensional stability, lack of
thermoplasticity, high hydrophilicity and lack of antimicrobial properties. To overcome such
drawbacks, the controlled physical and/or chemical modification of the cellulose structure is
essential(226). Introduction of functional groups into cellulose can alleviate these problems,
while maintaining the desirable intrinsic properties of cellulose. Apart from the conventional
plant source, cellulose is also obtained from bacteria, termed bacterial cellulose.
Understanding and engineering these biological systems has opened further doors for
bringing in desired modifications into cellulose.
1.6.2.1.5.2 Attempts made in Tissue engineering and drug delivery
1.6.2.1.5.2.1 Cellulose alone
As cellulose in its native form has extensive hydrogen bonds, it is not very processible. Most
of the early attempts resorted to viscose process of regenerating (restoring cellulose structure
back) cellulose from its derivatives. Regenerated cellulose has been used as a matrix for
wound dressing. Early results indicated that implanted viscose cellulose sponges led to
increased granulation tissue formation over a period of time and that the pore structure of the
scaffold could influence cell infiltration within a certain limit(227). On the other hand it was
seen that a lower content of cellulose and lower pore diameter induced greater tissue invasion
of the implant and later on it also proved to be a matrix conducive for bone formation in a rat
model(228). However, cellulose sponges were seen to be slow degrading matrices taking up to
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sixty weeks for them to be degraded(229). Cellulose also was used successfully as an enzyme
carrier by dissolving cellulose in ionic liquid and regenerating it. Usage of a hydrophobic
ionic liquid preserved the enzymatic activity to a greater extent(230). While biodegradation
remains a challenge for the absorption of cellulose, it was seen that treatments that markedly
reduced crystallinity led to degradation as well as high biocompatibility of regenerated
cellulose(231). In recent years, microbial cellulose (MC) produced by bacterial species such
as Acetobacter xylinum has gained much attention as a material for use in biomedical
appliances. Though chemically similar to plant cellulose, MC has a microfibrillar and
nanostructured arrangement that enables higher water retention by the material. This property
is conducive in its application in wound dressing, production of vascular conduits etc(232).
This cellulose was also seen to have a high degree of biocompatibility(233).
1.6.2.1.5.2.2 Cellulose derivatives and combination with other polymers
The supramolecular structure of cellulose and the extensive hydrogen bonded chemical
structure of cellulose render it insoluble in water and organic compounds. Therefore most of
the reactions involving cellulose are carried out in solid or swollen state as heterogeneous
reactions. Here, the limiting factors for the hetrogenous reaction are the breakage of hydrogen
bonds (by alkaline treatment) and degree of interaction with the reaction media (by swelling).
Therefore, specific solvents that disrupt the hydrogen bonds in cellulose such as N, Ndimethylacetamide

and

lithium

chloride

(DMA/LiCl),

Dimethyl

Sulfoxide/Tetrabutylammonium Fluoride (DMSO/ TBAF)(234) are used widely for the
purpose. Hence, even though using such strategies, cellulose alone has been employed for
different purposes as a material, its derivatives are easier to work with as they overcome the
limitations posed by cellulose. The following section gives an overview of derivatives of
cellulose and its combination with other polymers:
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Cellulose Esters:
Esters of cellulose with interesting properties such as bioactivity, thermal and dissolution
behavior can be obtained by esterification of cellulose with nitric acid in the presence of
sulfuric acid, phosphoric acid or acetic acid. Commercially important cellulose esters are
cellulose acetate, cellulose acetate propionate and cellulose acetate butyrate. Cellulose esters
of aliphatic, aromatic, bulky, and functionalized carboxylic acidscan be synthesized through
the activation of free acids in situ with tosyl chloride, N, N’-carbonyldiimidazole, and
iminium chloride under homogeneous acylation with DMA/LiCl or DMSO/ TBAF. A wide
range of cellulose esters that vary in their degree of substitution, various substituent
distributions and several desirable properties can be obtained through these reactions.
Recently a number of enzymes that degrade cellulose esters have been reported. Some of them
are acetyl esterases, carbohydrate esterase (CE) family 1, and Esterases of the CE 5(235-238)
family.
Cellulose esters have been put to use in many biomedical applications. Hemodialysis
membranes used in purification of blood, for patients with renal failure have employed meltspun cellulose diacetate membrane. These membranes have been produced by Altin
(company) and used successfully. They were advantageous and had less toxicity than
synthetic polymer based membranes(239). Cellulose acetate is seen as a preferred material for
the fabrication of blood filration devices that are used to separate a fraction of the blood such
as red blood cells and leukocytes(240, 241). Cellulose acetate and regenerated cellulose
fibrous matrices have been successful in supporting the growth of cardiac myocytes and
present a potential scaffold platform for cardiac regeneration(242) (Entcheva et al., 2004).
Cellulose Ethers:
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Carboxymethyl cellulose (CMC) is the major cellulose ether. By activating the non-crystalline
regions of cellulose, selective regions of alkylating reagents can attack the cellulose. This is
termed the concept of reactive structure fractions and is used widely for the production of
CMC. Another route for carrying out the same reaction is by derivatization of cellulose in
reactive microstructures, formed by induced phase separation. This process involves the usage
of NaOH in anhydrous state in combination with solvents like DMA/LiCl. These CMC
products have a distribution of substituents that deviate significantly from statistical prediction
of the product theoretically.
CMC is used in several drug delivery and tissue engineering purposes. The release of
apomorphine, a drug used to regulate motor responses in Parkinson’s disease was successfully
incorporated into CMC powder formulation exhibited a sustained nasal release, and it
performed better than starch based delivery vehicle(243). Sodium CMC has been used
successfully in gastrointestinal drug delivery(244). Hence CMC is seen as a successful drug
delivery system for mucosal tissue(245). Apart from drug delivery, CMC is useful as a
scaffold in tissue engineering too. pH dependent swelling of CMC hydrogels, were capable of
releasing drugs at the right pH present in the tissue of interest and showed potential as a
wound dressing material(246). CMC hydrogels could be used for encapsulating cells of
nucleus pulposis and hence are a potential replacement for intervertebral disc
degeneration(247). CMC has been combined with chitosan(248) and hydroxyapatite(249) for
bone and dental regeneration purposes too.
Silyl Cellulose:
Silyl ethers of cellulose are characterized by a remarkable increase in thermal stability,
lipophilic behavior and a lack of hydrogen bonds. They can be used as selective protecting
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groups in organic synthesis, due the simple cleavage of the silyl ethers under acidic conditions
or through nucleophilic attack. Therefore, the silyl ethers of cellulose are very attractive for
engineering polysaccharide chemistry(250). The silylation of polar protic -OH groups of
cellulose with chlorosilanes and silazanes leads to these silyl ethers. The degree of
substitution (DS) and position of silyl substitution is determined by the reaction condition. All
the three –OH groups will be substituted when trimethyl silylation with hexamethyldisilazane
(HMDS) in liquid ammonia, is used in the reaction. Dissolution of cellulose in DMA/LiCl
(homogeneous reaction) makes the –OH groups more accessible. Following this, if the
synthesis takes place in the presence of imidazole, the bulky silylation reagent
thexyldimethylchlorosilane (TDSCl) leads to complete silylation at O6 and O2 (DS value=2.0).
Here, the primary and the most reactive secondary -OH groups are converted. If silyl ether
formation starts with the same reagent in cellulose suspension in aprotic dipolar media like Nmethylpyrrolidone (NMP), which contain gaseous ammonia, silylation of all primary C6-OH
groups takes place. This state does not permit any further reaction of the secondary hydroxy
groups(251).
Cellulose Sulfonates:
The most frequently synthesized and used cellulose sulfonates are the p-toluenesulfonates
(tosylates), methanesulfonates (mesylates), p-bromobenzenesulfonates (brosylates), and
trifluoromethanesulfonates (triflates). The synthesis of sulfonates is through simple
esterification of the -OH groups of cellulose with the corresponding sulfonic acid chlorides or
anhydride is a way to attach nucleofuge groups to cellulose(252). By varying the solvent and
reaction conditions, the DS of the polymer can be controlled. For instance, at temperatures of
7°C, cellulose tosylate with a maximum DS of 2.3 can be formed with tosyl chloride in the
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presence of triethylamine. The DS of sulfonated cellulose can also be controlled by the molar
ratio of tosyl chloride to glucose units of the cellulose.
Aminocellulose:
Aminocellulose are aminodeoxy derivatives bearing the nitrogen function directly on the
cellulose skeleton. These are useful in immobilization of enzymes and other proteins. By
having a specific structural design based on cellulose tosylates. Aminodeoxycellulose are
synthesized with corresponding halogen derivatives and sulfonates as starting materials. PDA
cellulose is a material used successfully for immobilization of enzymes like oxidoreductases,
glucose oxidases, peroxidases using gluteraldehyde. Diazo coupling and redox coupling have
also been utilized to link ascorbates, and dyes. Here too, the solvent composition and reaction
conditions can determine the reaction chemistry (SN2) and hence the DS of the product
formed(253).
Resinification of cellulose:
Resinification of cellulose can impart crease-resistance termed ‘‘durable press’’ properties to
cellulose. The reaction of cellulose with bi- or poly-functional compounds leads to formation
of crosslinked cellulose matrix, called resinified cellulose(224).
Graft polymerization of cellulose:
A new approach to modification of cellulose is by graft polymerization. A graft copolymer
generally consists of a long sequence of one monomer, referred to as the backbone polymer
(main chain) (cellulose in this case) with one or more branches (grafts) of long sequences of a
different monomer(254). Graft copolymerization permits the combination of the best
properties of two or more polymers in one physical unit(226). The aim with cellulose graft
polymerization is to retain the inherent properties of cellulose and incorporate qualities from

58

the polymer grafted onto it. Depending on the nature of the grafted polymer, properties such
as dimensional-stability, resistance to abrasion and wear, wrinkle recovery, oil and water
repellence, elasticity, sorbancy, ion exchange capabilities, temperature responsiveness,
thermal resistance and resistance to microbiological attack can be incorporated into
cellulose(255-259).
The methods for graft polymerization of cellulose can be generally classified into three major
groups such as (i) free radical polymerization, (ii) ionic and ring opening polymerization and
(iii) living radical polymerization.
Strategies used in cellulose graft polymerization can be divided into three categories:
The ‘grafting to’ approach- here the functional pre-formed polymer with its reactive endgroup is coupled with the functional groups located on the backbone of cellulose, the major
polymer. The inherent weakness of this approach is a hindrance to diffusion caused by
crowding of polymer chains on the surface (Odian, 2004).
The ‘grafting-from’ approach- here the growth of polymer chains occurs from initiating sites
on the cellulose backbone. This is the most commonly used approach. Easy access of the
reactive groups to the chain end of the growing polymer is achieved in ‘grafting-from’
approach. This makes it possible to attain high graft density(260).
The ‘grafting through’ approach- in this approach, a vinyl macromonomer of cellulose, is
copolymerised with a low molecular weight co-monomer. Though this approach is more
convenient, a cellulose-derived macromonomer has to be synthesized. This poses a limitation
to this technique (Odian, 2004).
1.6.2.1.5.3 Promises and challenges with cellulose
Cellulose and other polysaccharides discussed above have been gaining importance as
polymeric materials. Increasing the knowledge of organic, polymer chemistry and the
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chemistry of low-molecular weight polysaccharides can greatly help us understand more
about the chemistry of cellulose and control the different processing techniques for cellulose
to a greater extent. Having a multidisciplinary approach will further help us utilize the
polymer more in biomedical applications. The development of derivatives and grafted
polymers of cellulose have been important steps towards the utilization of cellulose, which is
considered as a renewable resource. Processes such as lyocell processing of cellulose are
environment friendly techniques and promise a safer polymer processing technology. New
insights are still being obtained on the process of wood pulping and biosynthetic pathways in
cellulose synthesis. By using this knowledge, engineering cellulose and utilizing bacteria for
production of the polymer are the advances we could expect in the future.
1.6.2.2 Proteins in tissue engineering
Proteins are the building blocks of life and their sophisticated chemistry makes them excellent
scaffolding materials for BTE. Some common proteins used in BTE are:
1. Collagen
2. Fibronectin
3. Fibrin
4. Vitronectin
5. Keratin
6. Silk
1.6.2.2.1 Collagen
About 20- 30% of mammalian protein is collagen and therefore it is the most abundant animal
protein biopolymer(261). There are around 28 types of collagen found in various tissues(262).
All of the collagen shares a structural similarity. Their basic unit is termed tropocollagen and
consists of 3 parallel polypeptide chains- GXY, where G is glycine, X is usually proline, and
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Y is usually 4-hydroxyproline, arranged to form a triple helical structure. This tropocollagen
further forms the fibrous collagen structure seen in different tissues(263). The natural source
of collagen is animal tissue like skin, tail and tendon. Collagen can be formulated into
hydrogels, fibers and microspheres. These matrices have been used for drug delivery(264) and
in BTE applications(265). In the case of bone 60% of its weight is attributed to the mineral
content. The remaining 40% of bone weight comes from the proteins and water. Of the
proteins found in bone, collagen constitutes 90%. Hence many BTE scaffolds use collagen as
a biomaterial by itself or in combination with other materials. Collagen acts as a ligand to the
cellular integrin that act as their receptors like α2β1 and α1β1 integrin. This binding of
collagen to integrin elicits a signaling cascade that is conducive to cell survival, adhesion,
proliferation and osteoblastic differentiation(266). Though collagen has excellent tissue
compatibility and osteoconductive properties, collagen matrices lack mechanical strength to
be used for BTE. Therefore, oftentimes collagen is combined with other natural/ synthetic
polymers for BTE applications(267).
1.6.2.2.2 Fibronectin
Fibronectin too is an ECM protein. It provides structural support, and also acts as ligand to
certain integrin receptors, apart from recruiting other biological factors(268). These
functionalities of fibronectin offer it the ability to induce cell adhesion, proliferation and
differentiation. There are two forms of Fibronectin- the secreted, soluble form produced by
hepatocytes in the liver and the insoluble form secreted by cells such as fibroblasts. The
soluble form of fibronectin is a major component of blood plasma. The secreted fibronectin
from cells is composed of two non- identical polypeptide chais linked by a disulfide bond at
the carboxy terminal end of the peptides.

There are three modules in each subunit of

fibronectin. Each subunit is about 230- 270 KDa in molecular weight. The three modules
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forming each of these subunits are: type I, type II and type III(269). Owing to its
biocompatibility and cell adhesion properties, fibronectin and the adhesion subunits of
fibronectin have been coated onto many BTE implants(268, 270).
1.6.2.2.3 Fibrin
Fibrin is an ECM protein formed during blood clot. The polymerization of soluble fibrinogen
turns to insoluble fibrin by the action of thrombin(271). Fibrinogen is made of three pairs of
polypeptides Aα, Bβ and γ, bridged by disulfide bonds(272). When thrombin cleaves Aα and
Bβ chains at their N- termini, the polymerization of fibrinogen to fibrin ensues(273). The
fibrin fibrils aggregate to form a clot. The FDA has approved fibrin sealants for use as
medical adhesives. Fibrin biomaterials are used as drug delivery and wound healing
scaffolds(274).
1.6.2.2.4 Vitronectin
Glycoprotein vitronectin is also a ligand for integrin receptors on cells(275). Vitronectin is
found both in circulation and in different tissues. It is also seen that vitronectin plays a role in
linking cell adhesion, humoral immunity and cell invasion into tissues. Vitronectin mediates
cell adhesion and spread and hence coating scaffolds with fibronectin induced cell adhesion
and spreading(276).
1.6.2.2.5 Keratin
Keratin is a protein found in animal tissues such as nail, hair, and horns. It presents a
filamentous structure made of hierarchically arranged structures. Cell adhesion domains
termed LDV domains were found in keratin(277). It was seen that keratin biomaterials led to
growth and differentiation of MC3T3-E1 preosteoblasts. Hence keratin is seen as a potential
scaffolding platform for BTE(278).
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1.6.2.2.6 Silk
Silk is a protein produced by insects like worms and spiders. It is also a hierarchically
structured filamentous protein(279). A glycoprotein matrix called sericin embeds the two
microfilaments of silk and this constitutes the basic structure of silk. The sericin protein in silk
fibroi is shown to have immunogenic effects. Therefor, this protein is removed from silk
while using the material for biomedical applications. Silk is a 370 kDa fibroin protein, with a
lighter chain fibroin of 25 kDa and a P25 protein of 325 kDa form the microfilament
structure(280). The presence of α-helix and β-turns in the protein structure of silk renders the
material mechanically strong. The silk produced by silk worm B. mori is the most polular
source of the protein. Silk based materials are being developed as various tissue engineered
scaffolds including materials for bone(281).
1.7 Design of Scaffolds for BTE
There are several processing techniques used in BTE for the formulation of 3D porous
scaffold structures. These processing techniques facilitate the inclusion of more than one
material into a desired shape and form with pore sizes that are needed for the particular tissue
engineered application. Some of the most common techniques are as follows(282).
1.7.1

Processes used for fabrication of macro and microporous BTE scaffolds

1.7.1.1 Thermally induced phase separation (TIPS)
In this technique, a homogenous solution of the polymer used for scaffolding is dissolved in
dimethylcarbonate overnight. Ceramics are added to the polymer solution and dispersed into
the polymer phase by sonication. This mixture is then maintained at -196°C for two hours
after quenching in liquid nitrogen. This mixture is transferred into a cooling bath at -10°C
with the application of vacuum. The solvent evaporates after the mixture is subjected to 48
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hours of -10°C, followed by 48 hours of exposure to 0°C. Finally it is transferred to an oven at
room temperature for the material to reach its equilibrium mass(283).
The TIPS technique can produce scaffolds with macro and microstructures, with a high degree
of porosity for various tissue engineering applications(284, 285). It is possible to gain control
over the porosity of the scaffold formulated by modulating the parameters like concentration
of the polymer and ceramic used, the solvent used for the system and the temperature of
quenching(284). PDLLA/ Bioglass scaffolds prepared by TIPS have shown to support MG-63
osteosarcoma cell line viability and proliferation and hence can be seen as potential scaffolds
for BTE(286). Scaffolds of PDLLA or PLGA/ 45S5 Bioglass with high porosity hold promise
as a scaffold for BTE(286, 287). Scaffolds formulated using TIPS have shown to have
nanotopographical features and hence greater bioactivity(288, 289).
1.7.1.2 Solvent casting and particle leaching
The solvent casting technique involves casting of a well-dissolved polymer or a polymer/
seramic composit solution to allow the solvent to evaporate. The casting mould can be used to
design the 3D shape of the resulting scaffold material. While the technique is very simple to
carry out, there are some disadvantages to it as well. Only a few shapes can be formulated and
the process could lead to entrapment of solvent in the matrix. The entrapped solvents could
attribute to the scaffold’s toxicity as well as denaturation of bioactive molecules in a
composite scaffold system(290).
Polymer microsphere constructs made by water oil/water emulsions can further be sovent
sintered with the inclusion of salt or sugar during the sintering step. These porogens can be
leached once the sintering is achieved. This technique gives tissue engineers the scope of
engineering matrices with controlled porosity(288). However particle leaching has
disadvantages such as limitations of dimensionality achieved in the scaffold, solvent retention,
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and loss of bioactivity of encapsulated biomolecules. BTE scaffolds that incorporate calcium
phosphate with graded porosity have been formulated using this technique(291). Optimally
porous salt leached PLGA microsphere 3D sintered matrices have been used to improve the
oxygen transfer in an otherwise less porous 3D porous sintered microsphere matrix(36).
1.7.1.3 Solid freeform fabrication techniques (SFFT)
Scaffolds with controlled macro and micro porous architecture are created by conventional
foam fabrication procedures such as phase separation, porogen leaching and emulsion-solvent
diffusion(292, 293). Computer aided imaging by micro CT and magnetic resonance (MR) has
aided with production of scaffolds with programmed porosities, using SFFT(293). A PLLA/
TCP composite scaffold with about 90% porosity was successfully developed using
SFFT(285). Its porosity was programed to be 400 µm in between the multiple layers of the
scaffold along with micropores of 10 µm diameter. Similarly PLA scaffolds developed by
SFFT combined computer aided programed macropore size of 500–800 µm, with solvent
derived 50–100 µm void size(292). Though SFFT gives better control over the scaffold
architecture, it may be a time consuming technique.
1.7.1.4 Microsphere sintering
Applying thermal(294) or solvent sintering(295) can sinter polymeric microspheres formed by
emulsion solvent evaporation technique. This leads to the formation of 3D porous matrices
with a porosity of 30- 40%, with pore diameter around 90 µm(294), as reported in literature.
The polymer solutions could be made to incorporate bioactive molecules like ceramics and
growth factors(296). The mechanical properties of these matrices can be constructed so that it
is close to cancellous bone. The microsphere platform also offers scope for other
modifications such as incorporation of nanofibers to be used in BTE(297).
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1.7.1.5 Coated scaffolds
Porous scaffolds prepared by any of the above techniques can be coated by dipping in a slurry
of polymer or by electrophoretic deposition (EPD). The slurry could contain ceramics or
growth factors. The slurry dipping technique performs better than EPD technique of
coating(298). Deposition of biomineral by SBF solution using the slurry dipping technique
has been used successfully in many BTE scaffolds to make them more osteoconductive(299).
1.7.1.6 3D Printing
3D Printing is an extension of SFF technology, where complex free structures can be created
using a computer-aided design (CAD). Unlike many other machining processes that are
subtractive in nature to create a desired scaffold structure, the 3D Printing technique uses an
additive manufacturing approach (AM). The rapid prototyping (RP) system used in 3D
printing combines liquids, powders and sheets to form the parts of the scaffold(300).
Depending on the polymer used, the process can be tailored and performed at high or room
temperature. This flexibility allows for incorporation of factors, hydroxyapatite and cells into
the scaffold structure(301). In fused deposition molding (FDM) a CAD design is created using
the information from CT and MR imaging data(302). The CAD data is input into the printer’s
software that slices the data to form instructive printable layers. This information is sent to the
polymer extrusion head and it prints the entire design one layer after another. Many polymers
such as PCL(303), PDLLA and PLLA(304) have been used and in a combination with TCP
and AH for producing BTE scaffolds using 3D printing(305). Some constraints of polymer
processing parameters still exist with 3D printing, but progress is being made at a rapid pace
with 3D printing technology.

66

1.7.2 Processes used for fabrication of nanoscale BTE scaffolds
TIPS (described above), self-assembly of polymers, and electrospinning can be used to
fabricate BTE scaffolds with nanoscale features.
1.7.2.1 Self assembly
Using the principles of protein folding can be applied towards the formation of an orderly
nanofibrillar network. As few as two to three peptides can self assemble through their
hydrophobic end groups to form nanofibers(306-308). Hydrogels(309) formulated by peptide
molecule self assembly and nanofibers incorporated into scaffolds are examples of BTE
scaffolds where the self assembly of proteins and peptides has been employed(310).
1.7.2.2 Electrospinning
Electrospinning is a popular technique for formulating polymeric nanofibrillar scaffolds for
BTE. When an electric field is applied to a polymer solution, to over come the forces of
surface tension, a continuous jet of polymer solution is obtained. This jet of polymer is
allowed to collect at a grounded collector plate and the solvent evaporates leaving back the
polymeric nanofibers at the collector plate(311). Electrospinning is a versatile technique that
is simple and can be used to produce nanofibers of different fiber diameter(312),
alignment(312) and could be fabricated to incorporate minerals(313). However nanofibers
suffer from a few constraints. The electrospun nanofiber matrices have a surface to volume
ratio that leads to burst release of encapsulated factors. Another issue is that the fibers form a
2D mat rather than a 3D scaffold. Hence electrospinning alone cannot be used to formulate
scaffolds for BTE as these matrices are not 3 dimensional and have no mechanical
compatibility with bone(289).

67

1.8 Cells used in BTE
Though scaffolds can act as the support structures, including cells and factors into tissue
engineered constructs is essential for complete bone regeneration. While the incorporation of
growth factors has proved to be beneficial, there are challenges of non-targeted bone
formation and problems of maintaining the bioactivity of the factors while delivering them.
Hence using cells is a clinically relevant and a simpler option in BTE. There are two cell types
that could be used in tissue engineering. These two types of cells are somatic cells and stem
cells.
1.8.1

Somatic cells in BTE

1.8.1.1 Cells used in analysis of BTE scaffolds
Transfected cells that are immortalized are used to test a number of BTE scaffolds in culture.
They can replicate osteoblastic proliferation and differentiation in the body. Studies with these
cell types have indicated the potential of the BTE scaffold to perform in the body. Examples
of such cell types are the murine MC3T3-E1 cells that are preostoblats derived from mouse
calvaria(314) and the MG-63, Saos-2 and U-2 OS human osteosarcoma cell lines(315). They
however have limited use with scaffolds implanted into the body, as these cells are capable of
causing cancers due to the presence of transfected genes in them.
1.8.1.2 Cells used in vivo
Primary calvarial osteoblasts from rats(316), mice and humans(317) are used to determine the
osteoconductive potential of BTE scaffolds. These are more reflective of the environment in
the body and the responses may be more clinically relevant when examining the response of
bone to a biomaterial being tested(316). They can also be transplanted into the body of
animals of the same species. However their availability may be a limiting factor for their
usage in vivo.
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1.8.2 Stem cells in BTE
While somatic cells like osteoblasts and periosteal cells can be used in BTE constructs, they
have limited potential for expansion and avoiding de-differentiation. Hence stem cells hold
great potential in BTE. The scaffolds can include features like nanoscaled dimensions and
chemical functionalities that can direct the differentiation of stem cells. Stem cells could be of
two types based on their source:
1. Embryo derived and
2. Adult derived
1.8.2.1 Embryo derived stem cells
1.8.2.1.1 Embryonic stem cells
Embryonic stem cells (ESCs) are totipotent stem cells with the ability to differentiate into
multiple lineages. They also have the ability to maintain this potential while proliferating
greatly. They have shown great potential towards osteoblastic differentiation. ESCs offer a
great differentiation potential, but also have the ability to form tumors when implanted in
vivo. This is termed teratogenicity. Apart from this, obtaining ESCs would involve their
harvest from unborn embryos. Therefore using them in humans is challenging due to ethical,
clinical and regulatory concerns associated with ESCs.
1.8.2.1.2 Amniotic fluid derived stem cells (AFSCs)
Amniotic fluid derived stem cells (AFSCs), are partly embryonic in origin and have are a little
less multipotent than ESCs. They can maintain their potential while dividing upto 250 times.
They can differentiate well in the osteoblastic lineage. Studies have used AFSCs to
characterize the performance of BTE scaffolds in vitro.
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1.8.2.2 Adult stem cells
1.8.2.2.1 Induced pluripotent stem cells (iPSCs)
Induced pluripotent stem cells (iPSCs) were formulated to overcome the limitations of ESCs.
By the transfection of the reprogramming factor genes (Oct4, Sox2, cMyc and Klf4) into
somatic cells, the cells are reprogrammed to stem cells (iPSCs). These cells are being
investigated for use in BTE(318).
1.8.2.2.2 Bone marrow derived mesenchymal stem cells (BM-MSCs)
The bone marrow has multipotent stem cells that can differentiate into cells of the
mesodermal lineage including bone, cartilage, adipose, and skeletal muscle(319). These BMMSCs, are used widely both in research and in clinical procedures(320). The ease of
accessibility, their large potential for self renewal, and minimal ethical and regulatory issues
concerning BM-MSCs, makes these cells an attractive option for application in BTE(321).
MSCs are found in the bone marrow and thought to play an essential role in bone
healing(322). Their participation could be direct (they can differentiate into cells of the
osteochondral lineage) and indirectly too by secretion of cytokines that allow for progenitor
cells to home into the site of injury and help with processes like angiogenesis(323). BMMSCs are also known to have immunomodulatory effect when implanted into an osseous
defect(324, 325).
1.8.2.2.3 Adipose derived stem cells (ADSCs)
The fat tissue in the body contains a population of multipotent stem cells called Adipose
derived stem cells (ADSCs)(326, 327). These cells have a great proliferative and multilineage
differentiation potential. Several experiments have shown the potential of ADSCs to
differentiate in the osteogenic lineage when given the right media in vitro(328).
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ADSCs have shown to be osteogenic when implanted into animals along with biodegradable
BTE scaffold. Ectopic ossification by ADSCs that turned into osteoblasts under subcutaneous
implantation(329) in mice and the capability of ADSCs to heal cranial defects by
intramembranous ossification demonstrated their potential to be used in BTE(330). Hence the
first phases of clinical trials combining ADSCs with autologous materials to induce bone
formation were successful(331). Hence BM-MSCs and ADSCs are the most clinically
relevant stem cell sources, presently.
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2 Chapter 2 Preliminary Studies
Cellulose and Collagen Derived Micro-Nano Structured Scaffolds for Bone Tissue
Engineering2
2.1

Introduction

Scaffold based tissue engineering strategy has emerged as an alternative to autografts and
allografts to regenerate damaged or lost tissue(332, 333). Bone graft substitutes or scaffolds
are routinely used as viable alternatives to biological grafts due to ease of fabrication,
handling and storage. Scaffolds often utilize a biodegradable three-dimensional (3D)
architecture to serve as a temporary ECM to support tissue ingrowth. In particular, scaffolds
for BTE are desired to have osteoconductive (promote osteoblast proliferation),
osteoinductive (promote osteoblastic differentiation of progenitor cells) and osteointegrative
(form an intimate contact and anchor into the surrounding bone) properties to promote bone
regeneration(334). In the repair of a bone defect, the scaffold is designed to maintain the
structure of the defect and restore the functions of the lost bone. Ideally the scaffold should
satisfy a number of design criteria to achieve comparable properties present in autologous
grafts: The scaffold should be (1) biocompatible so that it is integrated with the host tissue
without any adverse immune response, (2) mechanically competent in order to tolerate the
local forces. This is most critical for protecting the tissues and transmitting the compressive,
tensile forces and mechanical cues across the defect to the regenerating cells, (3)
biodegradable with non-toxic degradation products that can be metabolized and excreted by
2

This study was published as a research article: Aravamudhan A, Ramos DM, Nip J, Harmon
M, James R, Deng M, Laurencin CT, Yu X, Kumbar SG. Cellulose and Collagen Derived MicroNano Structured Scaffolds for Bone Tissue Engineering. J. Biomed. Nanotechnology, 9 (4), 719731, 2013
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the body, and with controllable degradation kinetics to match the rate of bone formation so
that the newly produced tissue compensates the mechanical and mass loss of the degraded
matrix, (4) osteoconductive with porous structures to allow cell infiltration, proliferation,
neovascularization, and nutrient transport. It is desirable for BTE scaffolds to have highly
interconnected pores with a minimum pore size of >100 µm to promote ingrowth of tissue and
vasculature(335). The interconnected pore spaces enable the transport of oxygen and
nutrients. Surface roughness of the scaffold promotes cellular adhesion, proliferation, and
differentiation of anchorage-dependent cells(336, 337). (5) Lastly, scaffolds should be able to
integrate with the surrounding osseous tissue through the formation of bonds with the bone.
Scaffold chemical composition and topographical properties play an important role in guiding
cell behavior and tissue regeneration in vivo. For instance, scaffolds presenting acrylate
groups have been reported to maintain multipotency of progenitors(338) while functional
groups such as amine, hydroxyl and carboxyl, lead to greater differentiation in the
osteochondral lineage(38, 339), both in the absence and presence of inductive media. Recent
studies have demonstrated the importance of topographical features in regulating cell
behavior, including preferential adhesion, migration, proliferation and expression of cellspecific phenotype(340). Several studies have reported the role of nano, micro and
combination of micro-nano dimensional patterns in regulating stem cell differentiation into
osteogenic lineage even in the absence of inductive media(64, 341, 342). In our previous
studies we have reported enhanced cell migration and mature osteoblast phenotype
development on the hierarchical structures comprised of micro-nano dimensions for BTE
applications(297).
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Biomaterials of both synthetic and natural biodegradable polymers have shown great promise
in tissue engineering. Though synthetic polymers such as polyesters can be synthesized with
desired molecular weight and elasticity, their degradation pattern often is reported to have a
negative impact on tissue healing due to acidic degradation products(343). Different buffering
systems made of polymer–polymer or polymer-calcium phosphates have been developed to
neutralize acidic degradation products(344). On the other hand, polymers of natural origin due
to their compositional similarity with native ECM components offer greater biocompatibility
in tissue healing(335, 345). It is often a challenge to produce load-bearing scaffolds using
natural polymers due their limited solubility and processability. For example, collagen(346,
347), chitosan(345), polysaccharide(348) and protein based scaffolds are often presented in
the form of porous sponges, fiber matrix or hydrogels. These scaffolds lack the mechanical
stability and require chemical crosslinking to produce stable scaffolds. During scaffold
fabrication, extensive processing and crosslinking compromises the biological functionality of
these scaffolds(349-351). In this work we report the fabrication and characterization of
mechanically stable micro-nano structured scaffolds based on a derivative of cellulose and
type I collagen for bone tissue engineering. Sintered microspheres of cellulose acetate
microstructure contribute towards ideal mechanical and pore property of the scaffolds for
BTE. Scaffold surface functionalization with collagen nanofibers combines the nano fiber
structures with the microsphere based scaffold framework to enhance the surface area as well
as bioactivity. In this work we report the fabrication, optimization and characterization of
cellulose acetate, and collagen functionalized scaffolds for BTE application.
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2.2
2.2.1

Materials and Methods
Materials

Cellulose acetate (Mn 30 K) (CA), ethyl cellulose (Mn 30 K) (EC), and poly(vinyl alcohol)
(30,000–70,000) (PVA) were procured from Sigma-Aldrich (St. Louis, MO, USA).
Poly(lactic-co-glycolic acid) 85:15 (PLGA) was purchased from Alkermes (Wilmington, OH).
Acetone, dichloromethane, cyclohexane, 10% formalin in PBS and gluteraldehyde were
purchased from Fisher Scientific (Fair Lawn, NJ, USA). Promega MTS reagent kit
(Madison, WI, USA), Bio-Rad Alkaline phosphatase (ALP) substrate kit (Hercules, CA,
USA) and Invitrogen quantity PicoGreen dsDNA assay kit (Eugene, Oregon, USA) were used
in this study. Alizarin Red and cetylpyridinium chloride were procured from Acros Organics
(New Jersey, USA). Cell culture media was prepared by mixing 1:1 ratio of F-12 Nutrient
Mixture (Invitrogen, Greens Island, NJ) and DMEM (Invitrogen, Greens Island, NJ, USA).
Basal media was prepared by adding 10% FBS (Invitrogen, Greens Island, NJ, USA) and 1%
Penicillin-Streptomycin (Invitrogen, Greens Island, NJ, USA) to 1:1 mixture of F-12 and
DMEM. Osteogenic media was prepared by adding 0.05 mM L-ascorbic acid (Sigma, St.
Louis, MO, USA) and 3.15 mM glycerol 2-phosphate disodium salt (Sigma, St. Louis, MO,
USA) to basal media. RNAse and DNAse free water and 7.4 pH PBS buffer used were
purchased from Invitrogen (Greens Island, NJ, USA). Human osteoblasts used in this study
were purchased from PromoCell (Heidelberg, Germany).
2.2.2

Polysaccharide Microsphere Fabrication

Microspheres of CA and EC were fabricated via an oil-inwater solvent-evaporation technique.
In brief, 20% EC or 13% (w/v) CA solutions in methylene chloride and acetone at a ratio 9:1
were emulsified into an aqueous phase containing 1% (w/v) PVA. Emulsion was stirred at a
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constant stirring rate of 250 rpm overnight and hardened microspheres were collected
following solvent evaporation. Microspheres were washed repeatedly with deionized (DI)
water and segregated into different sizes namely: 300–425, 600–710 and 710–800 m using
sieves. Control PLGA microspheres were also prepared using a similar protocol.
2.2.3

3D Porous Scaffold Fabrication

Polysaccharide microspheres were sintered together into 3D porous scaffolds at the room
temperature using a mixture of solvent and non-solvent(352, 353). In brief, a Teflon mould
was filled with CA or EC microspheres to which 200 µL of an optimized solvent/non-solvent
composition was added to cover the microspheres to achieve sintering. The solvent/nonsolvent composition of acetone: cyclohexane ratio was varied from 1:0, 2:1, 3:1, 4:1 and 5:1
to achive microsphere sitering. The solvent and non-solvent mixture was allowed to evaporate
in a fume hood for 30 minutes followed by vacuum drying for an additional 24 hours.
Cylindrical scaffolds measuring 10 mm by 5 mm were fabricated to characterize compressive
mechanical properties and porosity while 8 mm by 2 mm tablet type cylindrical scaffolds
were made for evaluating in vitro osteocompatibility studies. Control PLGA microsphere
scaffolds were fabricated by heating the stainless steel mold at 95°C for 2 h to achieve
sintering.
2.2.4

Functionalization of 3D Scaffolds: Micro-Nano Structured Scaffolds

Sintered microsphere scaffolds were surface functionalized with collagen type I nanofibers
using principles of molecular self-assembly(354). Optimization studies used different aqueous
collagen concentrations, solution pH and incubation time. These studies were aimed to
achieve uniform collagen functionalization without compromising the pores in the sintered
microsphere scaffolds. In a typical study scaffolds were incubated in a 0.1% (w/v) solution of
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collagen type I with a pH adjusted to 5.2 at 37°C for 24 h(355). These nanofiber-functionalize
scaffolds were washed with DI water and stored in a desiccator until further use.
2.2.5

Collagen Content in Micro-Nano Structured Scaffolds

The amount of collagen present on each scaffold was quantified with a calorimetric
bicinchoninic acid (BCA) Protein Assay Reagent kit (Pierce). Proteins form a purple colored
chelation complex with BCA via reduction of cupric ions to cuprous ions. The purple color of
this complex is directly proportional to the protein concentration and the absorbance was read
at 562 nm using a BioTek plate reader. In brief, collagen coated micro-nano structured
scaffolds were transferred to a new 48 well plate and incubated with 1 mL of aqueous 1%
acetic acid for 1 hour followed by mixing with the aid of a pipette to extract all collagen from
the scaffold. Similarly collagen remaining on the TCPS surface during coating experiment
was also extracted for the estimation of collagen content. A 25 µL of the collagen extract was
mixed with 200 µL of BCA reagent followed by 30 min incubation at 37°C and analyzed at
562 nm using a plate reader. A sample size of n = 6 was used for all these estimations. The
absorbance of six known collagen concentrations: 62.5, 125, 250, 500, 1000 and 2000 µg/mL
were used to construct a standard curve to convert absorbance readings to collagen
concentrations.
2.2.6

Scanning Electron Microscopy (SEM)

Surface morphology of the scaffolds was characterized by using SEM and field emission
SEM (FESEM). Scaffold surfaces were sputter coated with Au/Pd using a Hummer V
sputtering system (Technics Inc., Baltimore, MD) prior to imaging. The samples were viewed
using JSM 6400 scanning electron microscope (JEOL, Boston, MA, USA) operated at an
accelerating voltage of 20 kV at various magnifications. Uncoated micro-nano structured
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scaffolds were imaged using a tabletop TM-1000 (Hitachi, Closter, New Jersey) at various
magnifications. Nanofiber diameter was measured using Image J, NIH software. For each
fiber diameter measurement 3 different samples at 3 different locations were considered
(average of 100 fibers).
2.2.7

Micro-Nano Structured Scaffolds: Collagen Nanofiber Stability in Solution

Collagen nanofiber stability on the micro-nano structured scaffolds, in culture media up to 28
days, was qualitatively determined by using SEM. In brief, micro-nano structured scaffolds
were incubated in 1.8 mL of basal media up to 28 days and media was changed every other
day. At predetermined time points of 1, 3, 7, 14, 21 and 28 days scaffolds (n = 3) were taken
out and gently washed with DI water and dried. Scaffolds were imaged at various
magnifications to qualitatively estimate nanofiber stability.
2.2.8

Compressive Mechanical Properties

Cylindrical scaffolds (10×5 mm) of CA, both in dry and wet (n = 12) conditions were tested
under compression until failure using an Instron® tester (model 5544; Instron, Canton, MA).
Dry scaffolds were incubated in PBS overnight and held at a temeprature of 37°C in the water
bath to produce scaffolds for testing under wet conditions. Prior to testing, excess of PBS
from the sacffolds was wiped using a Kimwipes TM. Both dry and wet samples were subjected
to compression testing at a rate of 1 mm/min at ambient conditions until failure.
From the load and displacement values a stress–strain curve was constructed. For each
scaffold the following parameters were calculated:
(1) Compressive modulus = slope of the linear region of the stress versus strain curve,
(2) Compressive strength = maximum force/the original cross-sectional area,
(3) Maximum compressive load = maximum force applied, and
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(4) Energy absorbed at failure = area under the stress–strain curve at the point of failure.
2.2.9

Porosimetry

Both simple polysaccharide microsphere scaffolds and micro-nano structured scaffolds were
characterized for median pore diameter and porosity. Micromeritics Autopore III porosimeter
(Norcross, GA) was employed to measure the volume of mercury intrusion at specific
pressures for the scaffolds (n = 6). The scaffold pore volume and the pore size were calculated
by substituting this information into the Washburn equation. A set of 6 scaffolds (10×5 mm)
in a 5 mL penetrometer was used for each measurement.
2.2.10 Cell Culture
HOB were plated in tissue culture flasks (125 cm2) and cultured in basal media as specified in
the materials section. The media was replaced every other day, and culture was maintained in
a tissue culture incubator at 37°C and 5% carbon dioxide. Cells were trypsinized at 90%
confluency and cells at passage 6 were used for scaffold seeding. Both CA and EC scaffolds
were autoclave sterilized at 121°C for 30 min. Control PLGA scaffolds were sterilized by
incubation in 70% ethanol for 15 min and 30 min UV light exposure on both sides. Optimized
collagen concentration and pH conditions were used for collagen nanofiber functionalization
of scaffold. Functionalization experiments were carried out using sterile microsphere scaffolds
and collagen solution in the cell culture hood and maintained in a tissue culture incubator at
37 °C for 24 hours. Scaffolds were placed in 24-well plates and incubated with 2 mL of basal
medium for 30 min prior to cell seeding. Each scaffold was seeded with 50,000 cells and
allowed to stand for 2 h in the incubator prior to adding 1.8 mL of basal media to allow HOB
adhesion onto scaffolds. Following 24 hours of incubation, the medium was changed from
basal to osteogenic. Cultures were maintained for 28 days and media was changed every other
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day. One set of scaffolds was cultured in basal media up to 28 days to establish HOB viability
using MTS assay. For all these experiments a sample size of n=5 was used.
2.2.11 Cell Viability Assay
The cell viability on these scaffolds was measured using MTS assay at culture times of 1, 3, 7,
14, 21 and 28 days. The metabolically active cells react with the tetrazolium salt in the MTS
reagent to produce a formazan dye that can be observed at 490 nm. At each time point the
cellular constructs were washed twice with PBS to removenon-adherent cells and then
transferred to a new 24-well plate. These constructs were incubated with 200 µL of MTS
reagent with 1 mL of basal medium for 2 hours. Aliquots were taken and their absorbance was
read on a plate reader (BioTek Synergy HT, USA). The absorbance of six known cell numbers
10,000, 30,000, 50,000, 75,000,100,000, and 150,000, were used to construct a standard curve
to convert absorbance readings to cell numbers. The absorbance values of the samples were
fitted with the standard curve to determine the cell number on the scaffolds.
2.2.12 Cell Proliferation (Picogreends DNA Assay)
HOB proliferation after changing to osteogenic media was quantified by measuring the
amount of cellular DNA content at various culture points using a PicoGreen®
dsDNAassay(297, 356). In brief, at different culture times of 1, 3, 7, 14, 21 and 28 days the
cellular constructs were washed twice with PBS, transferred to new well plates and 1mL of
1% Triton X-100 solution was added to lyse the cells. The well plates underwent three freezethaw cycles, between −70°C and room temperature. The contents were mixed individually
with the aid of a pipette to extract cell lysate from the 3D scaffolds prior to analysis. 125 µL
of sample DNA was transferred into a new well plate to which 375 µL (component B) and
500 µL (Component A) kit reagents were added. Well plates were covered with aluminum foil
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to prevent light exposure and incubated for 5 min. A BioTek plate reader was used to measure
fluorescence (485 nm/535 nm). Optical readings were converted in DNA concentration using
a standard curve(352).
2.2.13 Alkaline Phosphatase Activity
ALP expression by HOB cultured scaffolds at various time points was evaluated as an early
marker of the retention of osteoblast phenotype using an ALP substrate kit(357). A 100 µL of
cell lysate was transferred into a well plate to which a 400 µL of P-NPP (para-nitro phenol
phosphate) substrate and buffer solution were added and incubated at 37 °C for 30 min. After
30 minutes, adding a 500 µL of 0.4 N of sodium hydroxide stopped the reaction. The intensity
of the color produced though the reaction is proportional to ALP activity. The optical density
of the solution was measured at 405 nm using a BioTek plate reader. The results for ALP
activity optical density were normalized to DNA content determined in a companion DNA
assay(352).
2.2.14 Mineralized Matrix Deposition Assay
Mineralized matrix deposition on the scaffolds by HOB was evaluated using an Alizarin Red
staining method for calcium deposition(358). This colorimetric analysis is based on
solubilizing the red matrix precipitate with cetylpyridinium chloride (CPC) to yield a purple
solution. In brief, at 7, 14, 21 and 28 days of cell culture, cellular constructs were fixed in
10% formalin at 4 °C for 1 h and then stained with 40 mM alizarin red solution for 10 min at
room temperature. After washing 5–10 times with distilled water to remove the
adsorbed/absorbed dye, chemically bound red matrix precipitate was solubilized in 1 mL of
10% CPC until color was stable. The optical density of the solution was read at 562 nm using
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BioTek plate reader. The results for calcium deposition were also normalized with DNA
content determined in a companion DNA assay(297).
2.2.15 Live/Dead Cell Viability
Cell viability on scaffolds was performed using a live/dead cell viability kit and then imaged.
In brief, calcein AM enters live cells and reacts with intracellular esterase to produce a bright
green fluorescence, while ethidium homodimer-1 enters only dead cells with damaged
membranes and produces a bright red fluorescence upon binding to nucleic acids. Scaffolds
were imaged at 3 days using a BioRad Radiance 2100 Multiphoton/Laser Scanning Confocal
Microscope (LSCM) at magnifications of 10× and 20× with and without transmitted light to
view cells independently and alongside the scaffold.
2.2.16 Statistical Analysis
All results were first evaluated using one-way analysis of variation (ANOVA) followed by
Tukey’s (HSD) analysis of the differences between groups with a confidence range of
95.00%.
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2.3
2.3.1

Results
Fabrication of Sintered Microsphere Scaffold and Effect of Solvent Composition on
Sintering Morphology

In general cellulose microspheres had a rough morphology as opposed to control PLGA
microspheres as evidenced by SEM images. These microspheres were segregated into
different sizes using sieves(295). Figure 1 illustrates the morphology of the microsphere
scaffolds at different sintering conditions. For instance, scaffolds sintered with higher solvent
content in the solvent/non-solvent composition lead to greater bonding between adjacent
microspheres (Figures 2.1(A)–(H)). Increasing the solvent content resulted in distorted
microsphere structure with compromised pore properties. Based on the morphology and pore
property measurement studies, scaffolds sintered at a ratio of 3:1 acetone: cyclohexane was
found to be optimal for further characterization (Figures 2.1(C) and (D)).
2.3.2

Morphology of Functionalized Microsphere Scaffolds with Collagen to Form MicroNano Structures

Figure 2.2 and 2.3 indicate the morphology of the CA and EC cellulose collagen micro-nano
structured scaffolds respectively, at various magnifications and scaffold depths. Collagen
nanofiber assembly was found to be uniform throughout the scaffold architecture. These fibers
were in the diameter range of 140±40 nm for CA scaffolds and 120±34 nm for EC
scaffolds(355). We also characterized the quantity of collagen present in each scaffold using a
calorimetric BCA protein assay. The average collagen content on each polysaccharide
scaffold and the encapsulation efficiency are presented in Table 2.1.
The porous microsphere scaffold could retain only 42% of the collagen on the scaffold and
rest was deposited on the TCPS. Functionalizing scaffolds of different materials with collagen
nanofibers may present different morphologies and material properties. Uniform collagen
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nanofiber functionalization around the cellulose microsphere surfaces without compromising
in the pore properties was evident in the images (Figures 2.2 and 2.3).
2.3.3

Temporal Stability of Nanofibers on the Scaffold Surface Under Culture Condition

Collagen nanofiber functionalized scaffolds were incubated in culture media for three weeks, and
imaged at different time points (Figure 2.4) using SEM at 50 and 500× magnifications in order
to determine the stability of collagen nanofibers. These scaffolds were imaged on Day 1
(Figures 2.4(A), (B)), Day 3 (Figsures 2.4(C), (D)), Day 7 (Figures 4(E), (F)), Day 14 and
(Figures 4(G), (H)), Day 21 (Figures 2.4(I), (J)). It is apparent from the images that collagen
nanofibers not only remained stable but supported passive mineralization with time.
2.3.4

Mechanical Property and Porosity of Scaffolds Under Dry and Wet Conditions

Dry CA scaffolds under compression testing showed an average maximum compressive
modulus of 266.75 ± 33.22 MPa, strength 12.15 ± 2.23, load 225.14 ± 42.09 and energy at
failure 0.34±0.13 J. The same scaffolds under wet conditions showed an average maximum
compressive modulus of 130.53±13.97 MPa, strength 7.15 ± 1.24 MPa, load 144.76 ± 24.43 N
and energy at failure 0.36±0.12 J (Table 2.2). Under wet conditions, the compressive
mechanical properties of the scaffolds reduced to almost half that of the scaffold under dry
condition. Nanofiber functionalized scaffold porosity was found to be 33.9±5.2% with an
average pore diameter 185.4± 8.6 µm.
2.3.5

Cell Survival and Proliferation

Figure 2.5 showed osteoblast survival measured up to 28 days on micro-nano structured
scaffolds, control PLAGA scaffolds and TCPS. At all time points TCPS showed significantly
higher cell number based on metabolic activity compared to test scaffolds and control PLGA
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(Figure 2.5) in basal media. However, cell numbers on test and PLAGA control scaffolds
were comparable. The observed differences in cell metabolic activity may be due to the
difference in number of cells that initially adhered to the scaffold and the change in scaffold
environment (2D and 3D). For instance, a fraction of the seeded cells may attach to the 3D
porous scaffold while the rest will attach to the TCPS container. Higher metabolic activity on
2D TCPS compared to 3D scaffold environment may reflect the inverse relationship between
cellular proliferation and phenotypic differentiation. HOB proliferation in osteogenic media
showed significantly higher DNA content on the micro-nano structured scaffolds than TCPS
(Figure 2.6).
2.3.6

Differentiation Measured by Alkaline Phosphatase Content and Mineral Deposition

Osteoblasts cultured on micro-nano structured scaffolds resulted in the higher levels of ALP
expression as compared to TCPS controls (Figure 2.7). Expression of ALP on polysaccharide
micro-nano structures was either higher or comparable to PLAGA micro-nano structures.
Scaffold mineralization also followed a similar ALP expression trends where significantly
higher amounts of calcium were deposited on the micronano structured scaffolds as compared
to TCPS control (Figure 2.8). In general, calcium deposition on polysaccharide structures was
either higher or comparable to PLAGA micro-nano structures. osteoblasts seeded on EC
scaffolds start showing very early expression of phenotypic markers (ALP and Calcium
deposition) while CA scaffolds make up towards the later time points (Figures 2.7 and 2.8).
2.3.7

Cell viability and morphology

In Figure 2.9, the cell viability at different planes and locations of the scaffold can be seen. For
instance, for similar cell seeding densities micro-nano structured scaffolds showed significantly
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higher number of viable cells distributed uniformly throughout scaffold architecture (Figures
2.9(C), (D)) while the viable cells were only at the microsphere junctions on the microsphere
scaffolds (Figures 2.9(A), (B)).

Table 2.1 Quantification of Collagen on Scaffold and Coating Efficiency
Total
Collagen
Concentration used for
coating
2000 µg/mL

Collagen per
scaffold
AVG
847.5

STD
171.7

Collagen on
TCPS
AVG
1146.7

STD
166.8

Scaffold
coating
Efficiency
42.3%

Table 2.2 Sacffold Compressive mechanical properties in dry and hydrated state
Dry Scaffold

Wet Scaffold

Compressive Modulus (Mpa)
266.75±33.22

130.53±13.97

Maximum Compressive Load (N)
225.14±42.09

144.76±24.43

Compressive Strength (MPa)
12.15±2.23

7.15±1.24

Energy at Failure (J)
0.34±0.13

0.36±0.12
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Figure 2.1 Optimization of Sintering solution
Effect of solvent/non-solvent composition on the morphology of the resulting sintered
microsphere scaffolds. Anetone is a solvent for CA while cyclohexane is a non-solovent.
Acetone:cyclohexane ratio was varied from 1:0, 2:1, 3:1, 4:1 and 5:1. The 30× and 100× SEM
images of CA scaffolds with varying acetone/cyclohexane sintering solution concentrations: A.
2:1 30×, B. 2:1 100× C. 3:1 30×, D. 3:1 100×, E. 4:1 30×, F. 4:1 100×, G. 5:1 30×, H. 5:1
100×. Higher solvent compositions led to greater bonding between adjcent microspheres.
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Figure 2.2 Morphology of CA-collagen scaffolds
SEM micrographs (B and C) illustrate the top view of CA-composite scaffold surface
morphology where A is a control CA scaffold without collagen. Micrographs A-D were recorded
on an environmental SEM without applying Au-Pd coating. Representative micrographs D-F
illustrates the deep interior surface morphology of the composite scaffolds taken on several
randomly broken pieces of the different scaffolds. Micrographs E and F at higher magnifications
were imaged after coating with Au-Pd using a FESEM. Preferred Collagen nanofiber (140 ±
40nm) assembly on the microsphere surface may be attributed to polysaccharide hydrophilic
nature as well as slower water evaporation during scaffold drying process. Collagen coating was
uniform throughout the scaffold 3D architecture with enhanced surface area as compared to neat
CA scaffolds.
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Figure 2.3 Morphology of EC-collagen scaffolds
SEM micrographs (B and C) illustrate the top view of EC-composite scaffold surface
morphology where A is a control EC scaffold without collagen. Micrographs A-C, E and F were
recorded on an environmental SEM without applying Au-Pd coating. Representative
micrographs D-F illustrates the deep interior surface morphology of the composite scaffolds
taken on several randomly broken pieces of the different scaffolds. Micrograph D was imaged
after coating with Au-Pd using a FESEM. Collagen nanofibers (120 ± 34 nm) coating was
uniform throughout the scaffold 3-D architecture. Composite scaffolds in general present
enhanced surface area as compared to EC scaffolds.
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Figure 2.4 Collagen Nanofiber stability in vitro
Stability of collagen nanofibers in composite scaffolds following incubation in culture media.
Representative SEM micrographs (A B) Day 1, (C,D) Day 3, (E,F) Day 7, (G,H) Day 14 and (I,
J) Day 21 illustrates the deep interior surface morphology of the composite scaffolds taken on
several randomly broken pieces of the different scaffolds at two different magnifications of 50
and 500 X. Culture media was replaced every other day just to mimic cell culture conditions.
Scaffolds were imaged after coating with Au-Pd using a FESEM. Collagen nanofibers act like a
nucleating agent and favored salt deposition from the culture media which seemed to increase
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with culture time. It was difficult to image samples with increasing culture time due to increased
amount of salt deposition that lead to charging and destroyed the image quality.
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Figure 2.5 Metabolic activity of seeded HOBs
Proliferation of HOB seeded on polysaccharide composite scaffolds in basal media measured
using MTS assay. At each time point quintuplicate samples were measured and comparisons
were made within the group. (*) indicates the statistical significance within the group at p<0.05.
These studies were designed to establish composite cellulose material compatibility with HOB.
In general HOB proliferation on cellulose composite scaffolds was comparable to PLAGA
composite scaffolds and attained confluency by day14. TCPS control showed significantly
higher cell number beyond 7days as compared to composite scaffolds.
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Figure 2.6 Prolifeartion of seeded HOBs
Proliferation of HOB seeded on polysaccharide composite scaffolds in osteogenic media
following day 1 culture in basal media. At each time point quintuplicate samples were
measured and comparisons were made within the group. (*) indicates the statistical
significance within the group at p<0.05. Cell proliferation was significantly higher on
composite scaffolds up to day 14 as compared to TCPS 2D control. CA composite scaffolds
showed significantly higher amount of DNA at day 7 and the composite scaffolds achieved
confluency by day 14. Higher amount of DNA content on composite scaffolds can be
attributed to material bioactivity, 3D environment and higher surface area offered by
nanofiber structures.
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Figure 2.7 ALP activity of Seeded HOBs
Normalized alkaline phosphatase activity expressed by HOB cultured on polysaccharide
composite scaffolds in osteogenic media following day 1 culture in basal media. At each time
point quintuplicate samples were measured and comparisons were made within the group. (*)
indicates the statistical significance within the group at p<0.05. In general significantly higher
levels of ALP activity were observed on composite scaffolds as compared to TCPS controls.
ALP activity was polysaccharide composites was either higher are comparable to PLAGA
composites.
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Figure 2.8 Mineralization by seeded HOBs
Relative mineralized matrix deposited on scaffolds at various culture points normalized with
DNA content. Significantly higher amount of Calcium was deposited on the composite scaffolds
as compared to TCPS control. Calcium deposition on polysaccharide composites was either
higher are comparable to PLAGA composites. At each time point quintuplicate samples were
measured and comparisons were made within the group. (*) indicates the statistical significance
within the group at p<0.05.
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Figure 2.9 Viability of seeded HOBs
Representative confocal micrographs showing survival and morphology of HOB cultured on
polysaccharide CA (A), (B) and micro-nano structured scaffolds (C), (D) without (A), (C) and
with (B), (D) transmitted light at 3 days after cell seeding. Confocal images clearly indicated the
higher cell number on composite scaffolds as compared to neat scaffolds. Majority of the cells
were viable had a well-spread morphology and distributed uniformly throughout the microsphere
surface and microsphere junctions. Cell survival was determined by viability assay where live
cells appear as fluorescent green color and dead cells as fluorescent red.
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2.4

Discussion

Scaffolds are designed to serve as a temporary ECM and hence are required to provide structural
support and a physical environment for cells to attach, grow, migrate and respond to signals(332,
333). Additionally scaffolds for BTE should provide mechanical properties similar to bone(359).
A variety of scaffolds in various forms and pore properties have been fabricated and
characterized for bone tissue engineering applications using polymers of both natural and
synthetic origin(346, 360). In particular, biodegradable polyesters including PLA, PGA, and their
copolymer (PLAGA) based scaffolds and orthopedic fixation devices in the form of screws and
plates have been widely researched(361). Reproducible mechanical and degradation properties
obtained by the precise control over molecular weight and crystallinity during polyester synthesis
makes them attractive for scaffolding applications(353, 362, 363). However, acidic degradation
products may cause inflammation depending on the anatomical compartment and their clearance
from those locations(364). A comprehensive 9-year clinical study reported several inflammatory
foreign body reactions and severe osteoarthritis in the joints near α-hydroxyester implants(365).
To achieve mechanical and degradation properties ideal for implant performance, high molecular
weight and crystalline polymers were used(362) with degradation varying from 2–6 years based
on the molecular weight and crystallinity(362). However, a six-year evaluation of ankle fractures
stabilized with PLA screws showed the absence of osseous replacement(366). Faster degrading
implants show delayed tissue replacement with evidence of an osteolytic lesion during
the final stages of degradation. Polyester blends with other class of polymers and ceramics have
been reported to neutralize acidic degradation products and support tissue healing(344, 367,
368). Scaffolds derived from polymers of natural origin, namely polysaccharides and proteins,
are known to be bioactive and highly biocompatible(369). Further these scaffolds support cell
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attachment, proliferation and differentiation in vitro and during in vivo implantation(370).
In our earlier publications we have demonstrated the benefits of sintered microsphere scaffold
platform in terms of controlling mechanical and pore properties as well as cell and tissue
infiltration using both in vitro and in vivo experiments(64, 363). Sintered microsphere scaffolds
are designed as a negative template of trabecular bone. For instance, trabecular bone is 70%
porous with 30% material content while sintered microsphere scaffolds present about 30%
porosity with 70% material content(371). We have also demonstrated that scaffolds fabricated
using microspheres in the size range of 600–710 µm present optimal pore volume and
mechanical strength to support bone repair and promote tissue ingrowth(353). In our previous
study we have reported the feasibility of fabricating mechanically strong sintered microsphere
scaffolds using cellulose derivatives and evaluated their ability to support HOB growth and
mineralized matrix production(352). Collagen is the most abundant protein within the ECM.
The most abundant type-I collagen readily forms fibrils in a self-assembly process. Hence
collagen has been popularly used to coat non-biological surfaces to simulate native ECM fibrous
structures. Numerous pre-clinical and human clinical studies have utilized ECM scaffolds of
both allogeneic and xenogeneic origin for the repair and regeneration of different tissue types
with a huge success. These scaffolds promote angiogenesis, recruitment of circulating progenitor
cells and complete scaffold degradation coupled with damaged tissue remodeling. This study
evaluates micro-nano structured biomimetic scaffolds with correct combination of mechanical
properties and ECM mimicry obtained by surface functionalization of cellulose based sintered
microsphere scaffolds with collagen nanofiber for BTE applications.
Sintered microsphere scaffold platforms have been shown to offer several advantages over
conventional salt leaching andelectrospun nanofiber scaffolds scaffolds for load bearing bone
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healing applications(295, 371). This technique creates 100% interconnected porous structures
with a great control over mechanical and pore properties(363). Scaffold mechanical properties
greatly depend on the number of bonds and extent of bonding between adjacent
microspheres(295). For instance, use of larger microspheres creates larger pores with lesser
number of bonds with adjacent microspheres in the scaffold and hence results in reduced
mechanical properties. Two cellulose derivatives, namely cellulose acetate and ethyl cellulose,
were used to fabricate microspheres using an oil-in-water-emulsion-solvent evaporation
method(352).
In general cellulose microspheres had a rough morphology as opposed to control PLAGA
microspheres as evidenced by SEM images. Scaffold mechanical and pore properties are
inversely proportional and therefore a balance between these two important parameters needs to
be optimized for BTE application(371). Hence, we chose microspheres in the diameter range of
300–425, 600–710 and 710–800 µm for fabricating 3D porous structures via a solvent/non
solvent sintering technique and characterized their mechanical properties(295). This study
concluded that scaffolds fabricated from 600–710 µm sized microspheres resulted in optimal
mechanical and pore properties as well as osteoblast response(352). In this study we wanted to
optimize the combination of solvent/non-solvent composition and sintering conditions to
fabricate scaffolds using 600– 710 µm sized microspheres of both CA and EC. For these
polymeric systems acetone was used as a solvent and cyclohexane as a non-solvent. Solvent/non
solvent assisted polymeric microsphere sintering based on Flory-Huggins solution theory is
published elsewhere(295). According to this theory a greater affinity between the solvent and
polymer allows the solvent to dissolve progressively longer chains causing the surface of the
microspheres to swell and intertwine with each other(295). Hence at an optimal solvent/non-
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solvent composition microsphere surfaces turn sticky, bond with adjacent microspheres and
harden as the solvent evaporates(295). Very few attempts have been made to create natural
polymer based sintered microsphere scaffolds for BTE applications. One of these studies
combined chitosan with PLAGA and produced the heat sintered microsphere scaffolds and
evaluated its cellar response in vitro(372) and the response when implaned into the body(373).
These scaffolds showed superior osteoblast phenotype expression as compared to PLAGA
control scaffolds but clearly failed to have significant effect in vivo bone healing(373). Such an
oberved effect may be due to crosslinking of chitosan to produce Schiff base at elevated
temperature during sintering(161, 349). Often crossliked natural polymers tend to loose their
bioactivity due to utilization of available functional groups to produce crosslinked bonds(161). In
general hydrogels, sponges or fiber matrices created using natural polymers were reported to be
bioactive, but clearly lacked mechanical competence(346). As such cellulose and chosen
cellulose derivatives are practically isoluble in water in spite of being hydrophillic, which makes
them attractive for creating microspheres and their scaffolds without crosslinking(253).
Type I collagen is the major organic ECM component of bone offering bioactivity and
strength(369). On the other hand, the role of topographic features including pores, fibers, ridges,
grooves and their combinations in the nanometer scale have been shown to influence cell
function and consequent regenerative capacity(374). Therefore, presentation of this bioactive
collagen in nanofibrillar form is intended to endow the greatest biomimetic properties possible to
the scaffold(375).

Collagen nanofiber functionalization was carried out to improve the

bioactivity(297, 355) of the 3D porous scaffolds fabricated as above.. The collagen nanofibers
presented a uniform coating of the cellulose (CA and EC) microspheres (Figures 2.2, and 2.3).
Functionalizing scaffolds of different materials with collagen nanofibers may present different
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morphologies and material properties. For instance, water contact angles for CA, EC and
PLAGA are roughly 55, 35 and 80°, which makes cellulose scaffolds relatively hydrophilic than
the control PLAGA(375-377). This lead to uniform collagen nanofiber functionalization around
the microsphere surfaces without compromising the pores (Figures 2.2, 2.3). Such a difference
in hydrophilicity of the scaffold material may reflect in different levels of cell adhesion,
proliferation and differentiation in spite of both the test and control scaffolds being coated with
collagen nanofibers compromising the pores(378, 379). In our earlier communication we have
reported micronano structured scaffolds using two synthetic polymers on the sintered
microsphere scaffold platform(297). The PLLA nanofibers were created in the open pores of the
poly

phosphazene

technique(297).

microsphere

scaffold

using

thermally

induced

phase

separation

These scaffolds were successful in promoting the osteoblast phenotype

development but compromised scaffold pore properties to some extent. The hydrophilic nature of
polysaccharide microspheres promote uniform deposition of collagen nanofiber adhesion on the
microsphere surface without affecting the pore properties of the scaffold, a factor that is critical
for tissue ingrowth while increasing the surface area for cell adhesion and biomimetics at the
same time(297).

In a similar approach polysaccharide microfibers functionalized with

collagennanofibers acted as an ECM equivalent and promoted osteogenesis and angiogenesis in
vitro(380) . Several studies reported the use of collagen in the form of hydrogel to deliver cells
and tissue void filler where they clearly lacked the mechanical properties(355). Micro-nano
structured scaffolds effectively combine the benefits two natural polymers without
compromising pore and mechanical properties. Sustainment of the functionalized collagen
nanofibers in culture as well as in vivo implantation can predict the scaffold bioactivity and
performance. It is apparent from the images that collagen nanofibers not only remained stable
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but increased passive mineralization with time(335). This form of biomineralization is a
prerequisite for proper osteoinduction in vivo by a biomaterial(381), and points to the possible
bioactivity of the material towards directing osteogenesis in vivo(335).
Mechanical properties of degradable polymers significantly vary under physiological conditions
as opposed to dry samples(382). Hence we observed that the mechanical properties of the
cellulose based scaffolds halved. These values were superior to several polysaccharidebased
tissue-engineering scaffolds and PLAGA-based heat sintered microsphere scaffolds of similar
pore properties earlier reported in literature(353, 363). These polysaccharide scaffolds showed
compressive mechanical properties are comparable to those in the mid range of human trabecular
bone and ideally suited for bone tissue engineering applications(359). This mechanical property
is
highly desirable to serve the functional role of replacing lost bone tissue and the biological role
of directing progenitor cell differentiation into osteoblastic lineage(383). Nanofiber
functionalized scaffold porosity was found to be with an average pore diameter 185.4°+/_8.6 µm.
Nanofiber functionalization neither compromised the mechanical property nor the porosity of the
microsphere scaffolds. These micro-nano structures made of natural polymers may significantly
improve the scaffold performance both as a supporting material as well as a bioactive platform
for bone regeneration(371).
Osteoconductivity, the ability of a material to support the survival of osteoblasts, is an important
basic characteristic of a scaffold in bone tissue engineering. Figure 2.5 shows osteoblast survival
measured up to 28 days on micro-nano structured scaffolds, control PLAGA scaffolds and
TCPS. At all time points TCPS showed significantly higher cell number based on metabolic
activity compared to test scaffolds and control PLAGA in basal media. However, cell numbers
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on test and PLAGA control scaffolds were comparable. Such observed differences in cell
metabolic activity may be due to the differences in number of cells that initially adhered to the
scaffold and the difference in scaffold environment (2.2D and 2.3D). For instance, a fraction of
the seeded cells may attach to the 3D porous scaffold while the rest will attach to the TCPS
container. Higher metabolic activity on 2D TCPS as compared to 3D scaffold environment may
reflect the inverse relationship between cellular proliferation and phenotypic differentiation.
HOB proliferation in osteogenic media showed significantly higher DNA content on the micronano structured scaffolds than TCPS (Figure 2.6). Higher DNA content observed on the micro
nano structured scaffolds presumably due to increased surface area and bioactivity provided by
collagen nanofiber. Type-I collagen is known to enhance osteoblast viability and proliferation.
Hence collagen coated implants supported the osteoblast spreading through rapid formation of
focal adhesions and their associated stress fibers(347). Often 2D surfaces such as TCPS could
induce greater number of focal adhesions but clearly fails to mimic the desired 3D environment.
Collagen functionalized scaffolds present a 3D environment and brings about a desirable cellular
response(384). In general higher DNA content is an indication of higher levels of mitotic
(proliferative) cellular activity. Higher DNA content was observed on the TCPS as compared to
test scaffolds (CA, and EC). This may represent a scenario where cells are at different stages of
maturity on scaffolds than on TCPS. For instance, as osteoblasts progress towards mature
osteocyte lineage, they are seen to be in the interphase state of cell cycle(385-387). Hence DNA
content may not be a true indicator of cell division during an interphase stage wherein DNA
content is likely to be more than cell number. Such an observation was made on the scaffolds
using MTS assay (metabolic activity) and pico green DNA assay in the current study. In this
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situation, it may translate into a greater level of cellular activity towards the differentiation
program than cell division on test scaffolds.
Osteogenic differentiation is characterized by the robust ALP expression at early stages while
mineralization occurs at later stages(388, 389). It is clear from the literature that a robust ALP
expression inevitably leads to mineralization of the regenerated tissue(388). Osteoblasts cultured
on
micro-nano structured scaffolds resulted in the higher levels of ALP expression as compared to
TCPS controls (Figure 2.7). Expression of ALP on polysaccharide micro-nano structures was
either higher or comparable to PLAGA micro-nano structures. Scaffold mineralization also
followed a similar ALP expression trend where significantly higher amounts of calcium were
deposited on the micronano structured scaffolds as compared to TCPS control (Figure 2.8). In
general calcium deposition on polysaccharide structures was either higher or comparable to
PLAGA micro-nano structures. Similar observations were also made on the polymeric scaffolds
coated with cell matrix derived proteins where these scaffolds lead to higher levels of ALP
expression as well as calcium deposition in vitro. The two cellulose derivatives EC and CA by
virtue of their structure present different physical, mechanical and chemical properties. For
instance, osteoblasts seeded on EC scaffolds start showing very early expression of phenotypic
markers (ALP and Calcium deposition) while CA scaffolds make up towards the later time
points (Figures. 2.7 and 2.8). Such an observed phenomenon may be due to the differences in
relative hydrophilicity of the two materials. It has been reported that hydrophilic functionalities
such as hydroxyl and methyl groups (as seen in EC) favor osteoinduction(37) compared to the
more neutral acetate groups, which translates into early osteoblast maturation on EC scaffolds in
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contrast to CA scaffolds. Often in addition to material chemistry and surface topography,
mechanical properties of the scaffolds contribute towards cell differentiation(390).

2.5 Conclusions
In this work we report fabrication and characterization of cellulose and collagen based micronano structured scaffolds for BTE applications. This natural polymer based scaffolds show
compressive mechanical properties in the mid range of human trabecular bone and may be
ideally suited for bone tissue engineering applications. Collagen nanofiber functionalization did
not compromise mechanical and pore properties of the microsphere scaffolds. Better human
osteoblast adhesion, proliferation, alkaline phosphatase expression and mineralized matrix
synthesis on these scaffolds as compared to that on control tissue culture plastic and PLAGA
scaffolds confirm the potential for use in bone tissue engineering.
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2.6

SPECIFIC AIMS

Tissue engineering seeks to design functional substitutes to achieve regeneration of lost tissue.
Biodegradable three-dimensional (3D) porous structures called scaffolds are an important
component of engineered tissue. Scaffolds derived from polymers of natural origin, like
polysaccharides and proteins have improved biocompatibility over synthetic scaffolds due to
their biochemical similarity to the native ECM. However, due to limitations of solubility and
processing, polysaccharide and protein scaffolds have been fabricated as porous sponges or fiber
matrices that do not have mechanical properties essential for bone tissue-engineering (BTE)
applications. Polysaccharide, cellulose that forms the primary structural component of plant cell
walls is analogous to the structural protein, collagen in the ECM of bone. Extensive hydrogen
bonding between hydroxyl functionalities gives cellulose strength that makes it suitable for load
bearing applications. This bonding also makes the polymer difficult to process due to its limited
solubility in common solvents and instability at higher temperature. This limitation can be
overcome by the use of derivatives of cellulose for scaffold fabrication. Previously we have
reported fabrication of mechanically strong cellulose acetate (CA) and their collagen nanofiber
functionalized scaffolds for BTE applications. These scaffolds have shown to have
osteocoductive (support growth of osteoblast) abilities. The present project aims to characterize
the response of seeded mesenchymal stem cells (MSCs) on these scaffolds and to examine the
regenerative potential of polysaccharide and collagen based micro- nano structured scaffolds.
We hypothesize that polysaccharide chemistry and collagen nanofibers offer bioactivity to
induce the osteogenic differentiation of (MSCs in vitro, would be biocompatible and
mediate effective bone regeneration in vivo. This project will be conducted by performing the
following three specific aims:
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2.6.1

Specific Aim 1: To characterize and contrast the unmodified and collagen
functionalized CA scaffolds for their material properties

The CA and CA-collagen scaffolds will be contrasted with PLGA and PLGA-collagen scaffolds
for the efficiency of collagen nanofiber functionalization. Further, the change in material
crystallinity and surface morphology will be determined, in order to understand the difference in
physical properties of the test and control scaffolds after being functionalized with collagen
nanofibers. The hydration property of all the materials subjected to different treatments will be
studied.
2.6.2

Specific Aim2: To test the performance of CA-collagen, micro-nano structured
scaffolds in vitro using bone marrow derived MSCs.

The CA and CA-collagen scaffolds will be tested for their ability to support adhesion,
proliferation and differentiation of MSCs in the presence of basal and osteogenic media in vitro
and contrasted with PLGA and PLGA-collagen scaffolds. We will assess cell viability,
proliferation, expression of osteogenic genes, proteins, ALP activity (early osteogenic
differentiation marker) and mineralization (later stage marker).
2.6.3

Specific Aim3: To test the performance of CA-collagen, micro-nano structured
scaffolds in vivo

2.6.3.1 Specific Aim3a: To test the biocompatibility of CA-collagen, micro-nano structured
scaffolds in vivo in a subcutaneous implantation.
The scaffolds would be tested for their biocompatibility in vivo. The scaffolds would be
implanted subcutaneously in rats. Results will be compared with control scaffolds. At 4, 8, and
12-week time points, animals will be sacrificed and implant will be evaluated for
cytocompatibility, and cellularization by histological examination.
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2.6.3.2 Specific Aim3b: To test the performance of CA-collagen, micro-nano structured
scaffolds in vivo in a bone defect in mouse calvarium.
The CA, CA-collagen and PLGA scaffolds will be tested for their functional performance in
vivo. At 8-week time point, the animals will be sacrificed and new bone formation will be
evaluated by X-ray radiography and histological analyses.
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3 Chapter 3
Characterize of the Material Properties of Unmodified and Collagen Functionalized CA
Scaffolds
3.1

Introduction

Several scaffold fabrication techniques and materials are used in constructing the scaffolds for
BTE. It is crucial to achieve a mechanically strong, porous, three dimensional scaffold that
allows cells of the organ to infiltrate into the materials as well as induce the stem cells to
differentiate and heal a defect, once the material is implanted. A sintered microsphere
microsphere scaffold serves the needs of mechanical strength and material transfer (33(391)40%(392) porosity is usually observed), in a 3D environment. However, most bodily ECM
components are presented as nanofibers(393). A number of studies have shown the biological
efficacy of nanofiber matrices in inducing favorable tissue healing response(289, 310). Hence
taking this factor into consideration, we formulated a two-component system made of a base 3D
porous sintered CA scaffold further functionalized with collagen nanofibers(391). The principle
of protein self-assembly was employed to achieve the formation of collagen nanofibers on these
3D porous structures of CA(355). Synthetic polymer PLGA was used as the control material due
to its widespread application in BTE(394-396). PLGA has also been approved for several
applications like drug delivery and suture formulations(397). The PLGA materials were
formulated into 3D porous sintered microspheres with similar dimensions as CA and
functionalized with collagen nanofibers similarly. It has been shown in literature that protein
assembly on hydrophilic and polar surfaces may be more biomimetic than on hydrophobic,
nonpolar surfaces(398). We hypothesized that the CA material due to its hydrophilic and polar
nature may lead to more effective collagen nanofiber presentation, with nanofibers decorating
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the microspheres(391) rather than significantly occupying the pores in contrast to PLGA which
is known to be a much more hydrophobic material. In this study CA and PLGA microspheres
were subjected to incubation in the functionalizing buffer (without collagen) and the
functionalizing solution (with collagen). The changes in the scaffold’s wettability, chemical
nature, and crystallinity with treatment were examined. Additionally quantification of total
amount of collagen functionalizing the materials and the presentation of these fibers were
examined. As the material characteristics of a scaffold dictate its biological performance, it is
important to examine the change in the phiso- chemical nature of a matrix when subjecting it to a
modification such as collagen nanofiber functionalization of scaffolds by self-assembly.

3.2
3.2.1

Materials and Methods
Materials

Cellulose acetate (Mw: 30K) (CA), and Polyvinyl Alcohol (30,000-70,000) (PVA) were
procured from Sigma -Aldrich (St. Louis, MO, USA). Poly (lactic-co-glycolic acid) 85:15
(PLGA) was purchased from lakeshore biomaterials (Birmingham, USA).

Acetone,

Dichloromethane, Cyclohaxane, Paraformaldehyde and Gluteraldehyde were purchased from
Fisher Scientific (Fair Lawn, NJ, USA).
3.2.2

Preparation of microspheres

Oil in water solvent- evaporation, followed by sintering of formed microspheres using a
solvent/non-solvent mixture was used for producing microsphere of i) Cellulose acetate (CA), ii)
poly (lactic-co-glycolic acid) 85:15 (PLGA). In brief, 13 (w/v) % of CA polymer was dissolved
in a solvent mixture containing methylene chloride and acetone at a ratio of 9:1 to produce
microspheres. A 20 (w/v) % solution in methylene chloride was used in the case of PLGA
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polymer to produce the microspheres. The polymer solutions were then poured in a thin stream
into an aqueous media containing 1.25(w/v) % PVA as a surfactant, with constant stirring at
250rpm to form an oil-in-water emulsion. These suspensions were stirred overnight to evaporate
the solvent to obtain hardened microspheres. Isolated microspheres were washed repeatedly with
deionized (DI) water, dried, and sieved into different microsphere sizes. Microspheres in the size
range of 600-710 and 710-800µm were mixed at a weight ratio of 1:1 and sintered into micro
porous scaffolds using either solvent-non-solvent or heat sintering based on the polymer(352,
391).
3.2.3

Preparation of micro-porous sintered microsphere scaffolds

Teflon molds of different dimensions were filled with CA microspheres to which a 200µL
volume of an optimized solvent/non-solvent composition, acetone: cyclohexane in the ratio of
3:1 (v/v), was added to cover the microspheres. Solvent was allowed to evaporate at room
temperature to obtain sintered microsphere scaffolds. Cylindrical scaffolds measuring 5mm
diameter X 10mm height were used for the characterization of hydration properties. The control
PLGA micro porous scaffolds with identical micro-particle sizes were produced by heat sintering
at 95oC for 45 minutes using Teflon molds(352).
3.2.4

Preparation of micro-nano structured scaffolds

A modified biomimetic approach was used to functionalize micro porous scaffolds with type I
collagen. In brief, both control and test scaffolds were incubated in a 0.1 (w/v) % collagen type I
solution with a pH adjusted to 4.2 at 37°C for 7 days to promote molecular collagen selfassembly. The dried scaffolds were treated with UV light for 30 min each side to achieve
collagen nanofiber stability and washed repeatedly with DI water to remove buffer salts.
Microspheres in the size range of 300-425µm diameters were functionalized with collagen and
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used for material characterizations presented in this study. The effect of coating buffer pH was
studied by incubating scaffolds in the buffer alone without collagen (391).
3.2.5

Quantification of Scaffold collagen Content

Amount of collagen present on each scaffold was estimated with a calorimetry using a
bicinchoninic acid (BCA) Protein Assay Reagent kit (Pierce). Proteins form a purple colored
chelation complex with BCA via reducing the cupric ions to cuprous ions. The purple color of
this complex is directly proportional to the protein concentration and the absorbance was read at
562 nm using a BioTek plate reader. In brief, collagen coated composite scaffolds were
transferred to a new 48 well plate and incubated with 500µL of aqueous 1% acetic acid overnight
with agitation followed by mixing with the aid of a pipette to extract all collagen from the
scaffold. Similarly collagen remaining on the TCPS surface during the coating experiment was
also extracted and quantified. A volume of 25µL of the collagen extract was mixed with 200µL
of BCA reagent followed by 30 min incubation at 37oC and analyzed at 562 nm using a plate
reader. A sample size of n=4 was used for all estimations. The absorbance of six known collagen
concentrations 0, 62.5, 125, 250, 500, and 1000 µg/mL were used to construct a standard curve
to convert absorbance readings to collagen concentrations. The content of collagen on the
scaffolds and the plates used for incubation were measured and the percentage of collagen on the
scaffold against that on the plate was calculated to obtain the collagen coating efficiency on each
scaffold.
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3.2.6

Morphology of collagen by two- photon microscopy

Micro-nano structured scaffolds namely PLGAc and CAc were imaged at an excitation
wavelength of 890nm and the collagen second harmonic generation (SHG) signal along with
autofluorescent signal from the scaffold material were acquired with bandpass filters of 435–
485nm

(SHG),

500–550nm

(scaffold

autofluorescence),

and

570–620nm

(scaffold

autofluorescence). The SHG signal is generated from the triple helical structure of collagen.
3.2.7

Characterization internal structure of scaffolds by SEM

Scanning electron microscopy (SEM) was used to characterize scaffold morphology and evaluate
collagen fiber diameter and distribution. Scaffolds were sputter coated with Au/Pd using a
Polaron E5100 sputtering system (Quorum Technologies, East Sussex, UK) to achieve an
eighteen nanometer thick coating before viewing under SEM. The samples were viewed using
FEI Nova NanoSEM 450 scanning electron microscope (FEI, Hillsboro, OR, USA) operated at
an accelerating voltage of 2kV at various magnifications. Collagen fibers at different locations
were selected randomly on the functionalized samples and these images were used for measuring
the fiber diameter using FIJI, NIH software and averaged (an average of 100 fibers).
3.2.8

Scaffold water uptake by gravimetric analysis

Scaffolds of 10mm X 5mm size were used for analysis of weight and volume changes on
hydration over 72hours. Scaffolds dry weight and dimensions were noted prior to testing for
hydration studies (0h). All groups namely CA and PLGA (treated with DI water), CA- buffer/
PLGA-buffer (treated with buffer without collagen) and CAc/PLGAc (treated with collagen
solution) were individually placed in microcentrifuge tubes with 1mL of PBS (pH 7.4)
(n=6/group) and incubated at 37°C. At the end of 24h, 48h and 72h, the scaffolds were isolated
and the changes in weight were noted with a Mettler Toledo® (XP56C-Mass Comparator)
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balance with an accuracy of 0.01mg and dimensional changes were measured with a digital
calipers (at six different points on the scaffold).

The volume changes in the individual

cylindrical scaffolds were calculated using the relation=π X (diameter/2)2 X height.
3.2.9

Microsphere surface chemistry by ATR-FTIR analysis

Fourier Transform Infrared Spectroscope (FTIR), Nicolet Magna 560, using ZnSe and Ge
crystal (Nicolet Instrument Corporation, Madison, WI, USA) was used to measure the
Attenuated Total Reflection (ATR)-infrared red (IR) spectra of the CA, CA-buffer, CAc and
PLGA, PLGA-buffer, PLGAc treated microsphere surfaces. The Nicolet OMNICR software was
used to blank the runs every time before samples were placed on the pedestal for measurement of
their spectra. Sample scans were run at 320 scans per specimen to extract the spectra in the range
400-4000cm-1.
3.2.10 Microsphere surface crystallinity by XRD analysis
A Bruker D2 Phaser powder diffractometer (Bruker axs, Inc., Madison, WI, USA), was used to
measure the wide angle x-ray diffraction of CA, CA-buffer, CAc and PLGA, PLGA-buffer,
PLGAc microspheres. A 2θ between 10-60° with an increment of 0.02° was captured, for all the
polymers.
3.2.11 Polymer molecular weight by GPC analysis
A Waters GPC system with Jordi Gel fluorinated DVB columns (1-100K, 2-10K & 1-500Å) was
used for running the PLGA, PLGA-buffer and PLGAc microparticles. Tetrahydrofuran (THF)
was used as a mobile phase along with Varian 380-LC Evaporative Light Scattering Detector
(ELSD) detector. In brief, 0.1 (w/w) % polymer solutions in THF were filtered through 0.2µm
nylon filter prior to testing. A flow rate of 1.25mL/min with an injection volume of 100µl was
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used for the analysis. The molecular weight distributions were compared with polystyrene
standards with molecular weight ranges 450- 200,000 Da. For CA based samples, a Waters GPC
system with two mixed bed Jordi Gel DVB columns were used with dimethylacetamide
(DMAC) as the mobile phase. For this analysis 0.2 (w/w) % CA in DMAC was used with at an
injection volume 200µL and a flow rate of 1.25mL/min. Samples were analyzed using a Waters
2414 refractive index detector (RI) detector. The molecular weight distributions were compared
with poly (methyl methacrylate) (PMMA) standards with molecular weight ranges 20001100,000Da.
3.2.12 Statistical analysis
All data are reported as the mean ± standard deviation (SD) of results from at least three
independent runs. In case of experiments with two groups a student t- test was performed. In the
case of experiments with multiple groups and multiple time points a 2- way- ANOVA with
Bonferroni posttest was performed. In the case of experiments that focused on one time point and
several groups, a one- way- ANOVA with Tukey posttest was performed. 95% Confidence
interval was employed to arrive at the p values. The denotation of significances given by p
values are- *p<0.001 (extremely significant), #p<0.01 (very significant),

@

p<0.05 (significant).

Analyses were performed using GraphPad Prism Software (GraphPad Software, San Diego, CA).
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3.3
3.3.1

Results
Characterization of collagen nanofibers

Scanning electron microscopic (SEM) images showed a smoother microsphere surface for PLGA
while CA scaffolds presented a rougher surface with many features (Figure 3.1a). Similar
quantity of collagen content was observed on both PLGA and CA scaffolds as determined by
protein assay (Figure 3.1b). However, major differences were observed in terms of collagen
assembly, fibril diameter and collagen distribution on PLGA and CA micro-nano structures.
Collagen fibers on PLGA showed a wider range of fiber diameter distribution with a mean fiber
diameter of 150nm, while the collagen fibers on CA showed a narrow range of distribution with
a mean fiber diameter of 80nm (Figure 3.1c). ). At 50,000X magnification, the collagen fibers of
CAc presented a D-band like pattern of triple helical collagen. Such banding patterns were very
sparse in the case of the collagen fibers on PLGA (Figure 1d). On subjecting the PLGAc and the
CAc scaffolds to two-photon excitation, the second harmonic signal derived from the collagen
fibers on CAc was stronger than that of PLGAc (Figure 1e). In addition, the CAc group typically
had collagen fibers arranged in co-operative sheets while the collagen fibers in the PLGAc group
were more dispersed.
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3.3.2

Analysis of hydration property

The volumetric changes on hydration between PLGA and CA groups also showed a significant
volume gain by all the CA groups in contrast to PLGA (Figure 2d). The volume changes on the
PLGA groups occurred in the first 24h of hydration (Figure 2e), are also in agreement with
weight gain profiles (Figure 2b). Volumetric changes for both PLGA and CA based scaffolds
were stabilized by 24 hours. However at 72 hours, only PLGAc and PLGA-buffer groups
showed volumetric changes (Figure 2e), which remained unaltered for all CA groups (Figure
2f).
3.3.3

Characterization of Materials properties

To investigate the changes in material properties due to treatment with the collagen solution, the
ATR-FTIR spectra of both PLGA and CA were probed after incubation in water (PLGA, CA),
aqueous buffer without collagen (PLGA-buffer, CA-buffer) and with collagen (PLGAc, CAc).
The characteristic alkyl groups (2800-2900cm-1), C-O ester group (1050- 1450cm-1) and C=O
stretch (1750cm-1) of PLGA remained unaffected. However, major differences in absorbance
frequencies were noted around 1600cm-1 and 3300cm-1 following treatment with acidic collagen
solution (Figure 3.3a). The XRD spectra of the PLGA groups treated with buffer and collagen
showed a steeper peak at around a 2θ angle of 20°, in contrast to the non- treated PLGA (Figure
3.3b). In the case of CA groups, all treatments showed characteristic bands of ether (1040cm-1),
acetyl ester (1220cm-1) and carbonyl (1740cm-1) groups that were unaffected following acidic
collagen solution treatment(399). However, the treatments lead to an additional band around
1600cm-1 (Figure 3.4a). Following treatment CA showed a steeper peak at around a 2θ angle of
20° in its XRD pattern (Figure 3.4b).
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Scaffolds derived from PLGA showed significant decline in weight average molecular weight
(Mw) and Z-average molecular weight (Mz) with no change in polydispersity index (PI) (Figure
3.5 a, b, c, d). On the other hand in the case of CA the buffer and the collagen treatments
resulted in a decrease in number average molecular weight (Mn) that affected the PI ((Figure 3.5
e, f, g, h).
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Figure 3.1 Characterization of collagen nanofibers
SEM images of a) PLGA, PLGA- buffer treated and PLGAc, CA, CA-buffer treated and CAc
scaffold interiors. Scale bar on top = 1mm, middle =50µm, and bottom = 5µm b) Percentage of
total collagen on scaffolds after coating (coating efficiency), n=4, Unpaired t-test done and no
statistical significance was seen. c) Diameter of collagen fibers on PLGAc and CAc at
magnifications of 50,000X, n=10, Unpaired t-test done and a *P<0.001 was obtained. d) SEM
images of collagen nanofibers on PLGAc and CAc at 50,000X (D- band-like patterns indicated
by arrows on CAc), scalebar = 2 µm and e) Second harmonic signals from collagen fibers on
PLGAc and CAc at 10X (blue color indicated by arrows), scalebar = 100 µm.
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Figure 3.2 Hydration properies
Effect of hydration on the scaffold weight and volume changes over 72 hours of incubation in
PBS at 37°C. Changes in scaffold weight a) PLGA and CA groups, b) PLGA, PLGA- Buffer
treated and PLGAc, c) CA, CA- Buffer treated and CAc. Changes in scaffold volume d) PLGA
and CA groups e) PLGA, PLGA- Buffer treated and PLGAc, f) CA, CA- Buffer treated and
CAc. Two- way ANOVA with Bonferroni post- test, with 95% confidence intervals, *P<0.001,
#
P<0.01, @P<0.05.
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Figure 3.3 Changes in PLGA chemistry on collagen treatment
a) ATR- FTIR (from 400- 4000 cm-1) and b) XRD spectra (2θ= 10-60Ο) of PLGA, PLGAbuffer treated and PLGAc (Red- PLGA, blue- PLGA buffer treated, pink- PLGAc, greenlyophilized collagen).

120

Figure 3.4 Changes in CA chemistry on collagen treatment
a) ATR- FTIR (from 400- 4000 cm-1) and b) XRD spectra (2θ= 10-60Ο) of CA,CA- buffer
treated and CAc. (Red- CA, blue- CA buffer treated, pink- CAc, green- lyophilized collagen)
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Figure 3.5 Molecular weight changes on collagen treatment
Molecular weights determined by Gel permeation chromatographic analysis of a), b), c), d) PLGA
and e), f), g), h) CA polymers after treatments: a), e) Mn- Number average molecular weight, b),
f) Mw- weight average molecular weight, c), g) Mz- z average molecular weight, d), h) PIPolydispersity index= Mw/Mn). One – way ANOVA with Tukey post test, with 95% confidence
intervals, *P<0.001, #P<0.01, @P<0.05.
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3.4

Discussion

In our scaffold system, the 3D porous sintered CA and PLGA matrices are exposed to a mildly
acidic buffer solution (pH 4.2) dissolving the collagen, for a prolonged period of time to allow
the solution to evaporate and to allow the nanofibers to self assemble. The effect of this
treatment on the material may be important as there could be certain physical and chemical
changes happening to the parent polymer during the treatment.
A smoother microsphere surface was observed for PLGA while CA scaffolds presented a
rougher surface with many features (Figure 3.1a). The surface topography of materials could
play an important instructive role in directing cellular responses. For instance osteoblasts were
seen to maintain their phenotype(400) and respond more towards signaling factors like BMP2(401), and vitamin D3(402, 403) when cultured on microscale and nanoscale(404) rough
surfaces. Hence the CA materials may be more osteoconductive in nature than the PLGA
materials due to the rougher topography presented by them.
The total collagen content was not very different when the CA and the PLGA 3D porous sintered
microsphere scaffolds were functionalized with collagen nanofibers (Figure 3.1b). However the
morphology of the fibers was very different between the PLGAc and CAc groups (Figure 3.1c,
d, e). The D- banding patterns (Figure 3.1d) and the greater levels of second harmonic signal
generated by the collagen on CAc than PLGAc (Figure 3.1e) may indicate a more native
presentation of the functionalizing collagen nanofibers on the CA surface than on the PLGA
surface. It has also been shown that collagen nanofiber in its native form is far more inductive
towards bone formation than collagen that is denatured(405, 406). Hence we hypothesize that
CAc matrices may be more osteoinductive than the PLGAc scaffolds.
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The water uptake by all the CA groups was significantly higher than PLGA groups (Figure
3.2.a, d). All CA structures gained significant weight in the first 24 hours and achieved
equilibrium weight by 72 hours. The CA-buffer and CAc groups showed progressive weight gain
at all time points between 24-72h. The addition of collagen in CAc (Figure 3.2c) and the
presence of additional carboxylic acid groups in CA-buffer samples (Figure 3.4a) increased
exposure to acidic pH resulting in greater hydrophilicity and weight gain than CA structures.
Exposure of CA to highly acidic or alkaline environment may lead to deacetylation(399), by
showing changes at ether (1040cm-1), acetyl ester (1220cm-1) and carbonyl (1740cm-1) groups. In
the case of CA groups, all treatments showed characteristic bands of ether (1040cm-1), acetyl
ester (1220cm-1) and carbonyl (1740cm-1) groups that were identical and thus these chemical
groups were unaffected following acidic collagen solution treatment(399). However, treatment
lead to an additional band around 1600cm-1 on CA microsphere surface due to the presence of
carboxylic acid salts. Hence the mild acidic environment did not have a degradative effect on
CA due to its more robust chemistry (Figure 3.4a, b).
However, PLGA-buffer groups appear to be more hydrophobic as the acidic pH treatment may
lead to degradation on the surface (Figure 3.3a). The intensity of absorbance around 1600cm-1
increased due to the cleavage of ester bond resulting in carboxylic acid salts (O=C-ONa) of
PLGA following treatment. Likewise the increase in absorbance around 3300cm-1 in PLGA was
attributed to an increase in hydroxyl content from alcohol groups (Figure 3.3a, b), probably due
to a mild degradative change on the surface of the polymer(407, 408). Lee et al also observed
such changes with the degradation of PLGA when it was exposed to irradiation(407).
The wettability of surfaces also plays an important role in determining cellular responses like cell
adhesion(409). Cells adhere to materials through adhesion mediating proteins that adsorb onto
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biomaterial surface. While highly hydrophobic surfaces favor high level of protein adsorption,
they also mediate more material- protein and protein-protein interactions, but minimal proteincell interaction due to masking of the active protein domains responsible for cell adhesion(410).
This is explained by the rigid conformation of proteins achieved on hydrophobic non- polar
surfaces against a more flexible protein conformation achieved on hydrophilic non- polar
surfaces(398), which may quantitatively adsorb less protein(410). On the other hand highly
hydrophilic surfaces may not allow for protein adhesion on their surface at all and hence such
surfaces too are not good for cell adhesion on materials(411, 412). Hence the hydration behavior
of material would dictate protein adsorption and self- assembly on it.
The chemical functional groups on a material can influence cellular responses immensely. For
instance Curran et al. cultured bone marrow derived mesenchymal stem cells (MSCs) on glass
substrates modified to contain the functional groups: like -CH3, -SH, –COOH, –OH, and –NH2,
under basal and octeogenic and chondrogenic conditions. They found that the -CH3 functional
groups helped maintain the multipotency of MSCs, while the –OH and –NH2 groups were
conducive for osteogenic differentiation, and the –COOH and –SH groups on the substrate
supported chondrogenic differentiation. These differences were observed both under basal and
stimulated conditions(413). Many other studies have used materials that varied only by the
chemical functional groups on the biomaterial’s surface and all of them have shown that the
chemical functionalities on the material surface can have a profound influence on stem cell
behavior(37, 340). These changes can be attributed to the resulting material surface energy and
hydration characteristic that determine the conformation of adsorbed proteins and in turn cellular
adhesion(414).
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From these observations in literature that state the importance of chemical functionalities,
hydrophilic characteristics and their relationship to the conformation of adsorbed proteins, we
conclude that the hydrophilic characteristics of CA scaffolds presumably induced the adsorbed
collagen nanofibers to be presented in a more native conformation than on PLGA. We
hypothesize that these may translate into better cell adhesion and differentiation responses in
vitro and in vivo.

3.5

Conclusions

We conclude that the process of collagen nanofiber functionalization on CA and PLGA scaffolds
had very different outcomes. While the quantity of collagen present in both the scaffolds was
similar the native structure of collagen nanofibers was apparent on CA scaffolds than on PLGA.
On examining the water uptake behavior of these matrices, it was seen that the PLGA matrices
did not have significant improvement in their hydrophilic nature, while the CA matrices showed
greater water uptake on treatment with the collagen solution. The stable nature of CA against the
more readily degradative nature of PLGA led to preserving the chemistry of CA, while inducing
a mild degradation on the surface of PLGA microspheres that nullified the effect of collagen that
usually

renders

the

material

more
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hydrophilic

upon

its

incorporation.

4 Chapter 4
Characterization of Human Bone Marrow Derived Mesenchymal Stem Cell (hMSC)
Response to CA-Collagen, Micro-Nano Structured Scaffolds in vitro
4.1

Introduction

In BTE the scaffold plays an important role. But in order to achieve complete bone healing, the
delivery of cells and/ or growth factors(397) and/ or small molecules is necessary(415). While
growth factors like BMP-2(416), VEGF(417), FGF-2(418) have been very effective in inducing
tissue responses like bone formation, angiogenesis and homing and proliferation of stem/
progenitor cells, a number of constrains still exist in the delivery of these factors(415). For
instance BMP-2 is very effective in inducing bone formation, but ectopic bone formation has
also shown to occur at non-target sites that can lead to pathological outcomes(419). Yet another
constraint in delivering proteins such as growth factors is the challenge of retaining their
biological activity during the process of their targeted delivery. On the other hand small
molecules that are easier to handle and pose less threat of denaturation or loss of function during
processing, but induce many different cellular signaling pathways and targeting a specific
therapeutic outcome without side effects is a challenge(420). However delivering the patient’s
autologous bone marrow derived stem cells is a simple and clinically relevant strategy to
improve the outcomes of bone healing. It has been demonstrated that bone marrow derives
mesenchymal stem cells (MSCs) are capable of differentiating in the osteochondral lineage.
Additionally, the phisio- chemical nature of the biomaterial has dictated the differentiation of
stem cells in the specific lineage. A detailed description of the mechanisms by which materials
dictate protein adsorption and in turn cell adhesion is given in the Discussion section of chapter
3. Briefly, the various factors influencing the differentiation of MSCs(421) are the mechanical
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property of the matrix(422), chemical functionalities(37) on the surface of the scaffold, the
hydration properties(410) and the surface topography of the biomaterial(379, 400). Many studies
have used these mechanical and phisio- chemical properties alone and in combination with
inductive media to differentiate stem cells in the osteochondral lineage. In Chapter 3, the higher
hydrophilicity of all the CA materials over PLGA was established. The collagen nanofibers on
the CAc 3D- porous scaffolds presented a more native triple helical presentation than on PLGAc.
We hypothesized that these differences in material charecteristics between the PLGA and CA
(uncoated and collagen coated) scaffolds may positively influence MSC differentiation in the
osteo-chondral lineage in vitro. Hence, here in this chapter high density cultures of MSCs were
seeded onto PLGA, CA, PLGAc and CAc 3D- porous scaffolds and their viability,
proliferateion, osteo-chondral gene expression and the osteoblastic protein presentation were
tested. These studies are meant to establish the osteoinductive behavior of the materials towards
stem cells.

4.2
4.2.1

Materials and Methods
Materials

Cellulose acetate (Mw: 30K) (CA), and Polyvinyl Alcohol (30,000-70,000) (PVA) were
procured from Sigma -Aldrich (St. Louis, MO, USA). Poly (lactic-co-glycolic acid) 85:15
(PLGA) was purchased from lakeshore biomaterials (Birmingham, USA).

Acetone,

Dichloromethane, Cyclohaxane, Paraformaldehyde and Gluteraldehyde were purchased from
Fisher Scientific (Fair Lawn, NJ, USA). BioRad Alkaline Phosphatase Substrate kit (Hercules,
CA, USA) and Invitrogen Quant-iT PicoGreen dsDNA Assay kit (Eugene, Oregon, USA) were
used in this study. Alizarin Red and Cetylpyridinium chloride was procured from Acros Organics
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(New Jersey, USA). Cell culture media was DMEM (HG) purchased from Lonza (Walkersville,
USA).
4.2.2

Preparation of microspheres

Oil in water solvent- evaporation, followed by sintering of formed microspheres using a
solvent/non-solvent mixture was used for producing microsphere of i) Cellulose acetate (CA), ii)
poly (lactic-co-glycolic acid) 85:15 (PLGA). In brief, 13 (w/v) % of CA polymer was dissolved
in a solvent mixture containing methylene chloride and acetone at a ratio of 9:1 to produce
microspheres. A 20 (w/v) % solution in methylene chloride was used in the case of PLGA
polymer to produce the microspheres. The polymer solutions were then poured in a thin stream
into an aqueous media containing 1.25(w/v) % PVA as a surfactant, with constant stirring at
250rpm to form an oil-in-water emulsion. These suspensions were stirred overnight to evaporate
the solvent to obtain hardened microspheres. Isolated microspheres were washed repeatedly with
deionized (DI) water, dried, and sieved into different microsphere sizes. Microspheres in the size
range of 600-710 and 710-800µm were mixed at a weight ratio of 1:1 and sintered into micro
porous scaffolds using either solvent-non-solvent or heat sintering based on the polymer(352,
391).
4.2.3

Preparation of micro-porous sintered microsphere scaffolds

Teflon molds of different dimensions were filled with CA microspheres to which a 200µL
volume of an optimized solvent/non-solvent composition, acetone: cyclohexane in the ratio of
3:1 (v/v), was added to cover the microspheres. Solvent was allowed to evaporate at room
temperature to obtain sintered microsphere scaffolds. Cylindrical scaffolds measuring 5mm
diameter X 10mm height were used for the characterization of hydration properties while 8mm
diameter X 2mm thick tablets were used for cell studies and animal experiments. The control
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PLGA micro porous scaffolds with identical micro-particle sizes were produced by heat sintering
at 95oC for 45 minutes using Teflon molds(352).
4.2.4

Preparation of micro-nano structured scaffolds

A modified biomimetic approach was used to functionalize micro porous scaffolds with type I
collagen. In brief, both control and test scaffolds were incubated in a 0.1 (w/v) % collagen type I
solution with a pH adjusted to 4.2 at 37°C for 7 days to promote molecular collagen selfassembly. The dried scaffolds were treated with UV light for 30 min each side to achieve
collagen nanofiber stability and washed repeatedly with DI water to remove buffer salts.
4.2.5

In Vitro human Mesenchymal Stem Cells (hMSCs) culture on scaffolds

Human bone marrow derived mesenchymal stem cells were purchased from Lonza (Lonza,
Walkersville, USA) and expanded as per the protocol provided by the supplier. Cells used for all
experiments were at passage 5. The basal media consisted of DMEM (HG) (Lonza, Walkersville,
USA) supplemented with 10% FBS and 1% antibiotics (Penicillin-Streptomycin). The
osteogenic media was composed of basal media with 0.2mM L- Ascorbic acid and 7.0mM
Glycerol 2-phosphate disodium salt and 0.1µM Dexamethasone.
Scaffolds were soaked in 70% ethanol for 20min and allowed to dry in the cell culture hood.
Each side of the scaffold was exposed to UV light for 20 minutes in the tissue culture hood.
Scaffolds were soaked in basal media overnight prior to seeding with the hMSCs. Each scaffold
was seeded with 250,000 cells in a 50µL cell suspension and incubated for 4h before additional
media was added. A total of 500µL basal media was added to the samples in a 48 well plate and
then switched to osteogenic media following 24h. The media was changed every other day and
cultures were maintained for 21 days. One set of scaffolds was also cultured in basal media up to
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21 days to evaluate hMSC proliferation using pico-green assay. All studies were done in
triplicate for each time point and each group of scaffolds.
4.2.6

Cell viability

Viability of hMSCs on the scaffolds was analyzed with a live/dead cell viability kit. In brief,
calcein AM enters live cells and reacts with intracellular esterase to produce a bright green
fluorescence, while ethidium homodimer-1 enters only dead cells with damaged membranes and
produces a bright red fluorescence upon binding to nucleic acids. Scaffolds were imaged on 3, 7,
14 and 21 days of osteoinduction using a Zeiss 780 /Laser Scanning Confocal Microscope
(LSCM) at magnifications of 10X to view cells independently and along with the scaffolds. 3D
reconstruction of the confocal stacks was done using Imaris software (Bitplane).
4.2.7

Cell proliferation

Rate of hMSCs proliferation after transferring to osteogenic media was quantified by measuring
the amount of cellular DNA content at various culture points using a Picogreen dsDNA assay. In
brief, at different culture time of 3, 7, 14 and 21 days, the cellular constructs were washed twice
with PBS, transferred to new well plates and 1ml of 1% Triton X-100 solution was added to lyse
the cells. The well plates underwent three freeze-thaw cycles, between -70oC and room
temperature, and mixed with the aid of a pipette to extract cell lysate from the 3D scaffolds prior
to analysis. 125µL of sample DNA was transferred into a new well plate to which 375µL
(component B) and 500µL (Component A) kit reagents were added. Well plates were covered
with aluminum foil to prevent light exposure and incubated for 5min. A BioTek plate reader was
used to read fluorescence (485nm/535nm). Optical readings were converted in DNA
concentration using a standard curve.
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4.2.8

Alkaline phosphatase activity

Alkaline phosphatase activity of hMSCs on the scaffolds was evaluated as a marker of osteoblast
phenotype progression using an ALP substrate kit. A 100µL of cell lysate was transferred into a
well plate to which a 400µL of P-NPP (para- nitro phenol phosphate) substrate and buffer
solution were added and incubated at 37ºC for 30min. After 30 minutes, 500µL of 0.4N of
sodium hydroxide was added to stop the reaction. The intensity of the color produced though the
reaction is proportional to ALP activity. The optical density of the solution was measured at
405nm using a BioTek plate reader. The results for ALP activity were optical density and these
were normalized to scaffold volume.
4.2.9

Mineralized matrix deposition by cells

Mineralized matrix deposition by osteoinduced hMSCs on the scaffolds were evaluated as
marker of mature osteoblast phenotype using an Alizarin Red staining method for calcium
deposition at 21 days of osteoinduction. This colorimetric analysis is based on solubilizing the
red matrix precipitate with cetylpyridinium chloride (CPC) to yield a purple solution. In brief, at
21 days of osteoinductive cell culture, cellular constructs were fixed in 70% ethanol for 1h, at
room temperature and then stained with 40mM Alizarin Red (Sigma) solution for 10 min at room
temperature. After washing 5-10 times with distilled water to remove the adsorbed/absorbed dye,
chemically bound red matrix precipitate was solubilized in 1mL of 10% CPC until color was
stable. The optical density of the solution was read at 562nm using BioTek plate reader. The
results for calcium deposition were also normalized to scaffold volume.
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4.2.10 Gene expression
The RNA from scaffolds was extracted using RNeasy Plus Universal Mini Kit (Quiagen,
Valencia, CA, USA) as per the manufacturer’s protocol. Briefly, each scaffold was washed with
sterile PBS (pH 7.4) and then RNA extraction was carried out using RNeasy Plus Universal R kit
(Quiagen, Valencia, CA, USA). Briefly, Quiazol R/ chloroform extraction yielded an aqueous
layer. This layer was loaded on to columns and washed using buffers successively to collect
RNA in a micro centrifuge tube and suspended in 30µL of RNase-free water. The RNA was
measured using a nanodrop spectrophotometer and 1.5µg RNA was used for DNAse treatment,
to eliminate any remnant genomic DNA contamination. A DNA-freeTM Kit (ambion, life
technologies, Foster City, CA, USA) was used and the manufacturer’s protocol was used to
digest the cDNA.
This DNAse treated RNA was used to reverse transcribe into cDNA using iSript advanced
reverse transcription kit (Bio-rad, Hercules, California, U.S.A.), using the manufacturer’s
protocol. To each sample, 4µL of reaction buffer and 1µL of advanced reverse transcriptase
enzyme were added. Following incubation at 42°C for 30 minutes and enzyme inactivation at
85°C for 5 minutes, the cDNA was ready for gene expression analysis.
Prime- PCR (Bio- Rad, Hercules, California, U.S.A.), gene arrays where primers of
osteochondral genes were used for the gene expression analysis. Validated SYBR green primers
of the following genes were analyzed: GAPDH, TBP, HPRT1 (internal control genes expressions
were normalized to), Coll1A1, Coll1A2, Coll3A1, Coll2A1, BGLAP, MMP-13, Coll10A1,
Sox9, RUNX-2, ALPL, IBSP, BMP-2, DMP-1, SPARC (ON), MMP-9, MMP-13, IHH. To each
of the test wells, 10µL of 2X Sos Advanced SYBR green mix, 10µl of cDNA with ultrapure
water (equivalent to 12.5ng) was added. All controls to check for purity of starting material
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including gDNA contamination, and RNA integrity were included and passed the quality control
criteria. Samples used were cells seeded and osteoinduced on PLGA, PLGAc, CA and CAc.
PLGA was kept at 1.0 and the gene expression fold changes were with reference to PLGA.
4.2.11 Osteogenic marker Immunostaining
The scaffolds seeded with hMSCs were harvested at 21 days of osteoinduction and washed with
PBS (pH 7.4) prior to fixation with 4% paraformaldehyde (PFA) in PBS (pH 7.4) at room
temperature for 10 minutes. The samples were then washed with PBS (pH 7.4) and
permeabilized using 0.1% Triton X-100 in 1X PBS (pH 7.4) for 10 minutes. Samples were
washed again with PBS (pH 7.4) and subsequently incubated in 3% bovine serum albumin
(BSA) in 1X PBS (pH 7.4) solution for 30 min to block non- specific antibody binding. Primary
antibodies at specific concentrations (Colleen Rabbit anti human (abcam, Cambridge, MA,
U.S.A.) at 1:200 dilution; and bone sialoprotein Rabbit anti human (Millipore, Billerica, MA,
U.S.A. at a dilution of 1:100)) were dissolved in 1% BSA/ PBS (pH 7.4) buffer. Scaffolds were
incubated in primary antibody solution for one hour at room temperature. This was followed by
rinsing of samples with PBS (pH 7.4). Dylight 594- Goat- anti- Rabbit secondary antibody
(Jackson immune, West Grove, PA, U.S.A.) at a dilution of 1:400 was dissolved in 1% BSA/
PBS (pH 7.4) buffer along with Alexafluor 488- Phalloidin (Invitrogen, Eugene, Oregon, USA)
at a 1:40 dilution were added to scaffold construct for one hour. This was followed by rinsing of
samples 3 times with PBS (pH 7.4). NucBlue (DAPI) at a 2 drops/ ml of PBS (pH 7.4) was used
for staining the cellular nuclei. This was followed by confocal imaging with z- stacking for each
of the scaffolds for visualization of the marker (red)/ cytoskeleton (green) and nuclei (blue).
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4.2.12 Statistical analysis
All data are reported as the mean ± standard deviation (SD) of results from at least three
independent runs. In case of experiments with two groups a student t- test was performed. In the
case of experiments with multiple groups and multiple time points a 2- way- ANOVA with
Bonferroni posttest was performed. In the case of experiments that focused on one time point and
several groups, a one- way- ANOVA with Tukey posttest was performed. 95% Confidence
interval was employed to arrive at the p values. The denotation of significances given by p
values are- *p<0.001 (extremely significant), #p<0.01 (very significant),

@

p<0.05 (significant).

Analyses were performed using GraphPad Prism Software (GraphPad Software, San Diego, CA).
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4.3
4.3.1

Results
Characterization of hMSC response

Good cell viability on PLGA, PLGAc, CA and CAc from day 3 to day 21 was evident (Figure
4.3). In the current study all structures were seeded at a high cell density to study the osteogenic
phenotype development and hence the cell proliferation rates were constant due to confluency
(Figure 4.1 a, b, c and Figure 4.4). The alkaline phosphatase activity (ALP), as a precursor of
osteoblast maturation, and mineralization determined by alizarin red staining (ALZ), as a marker
of late stages of osteoblastic maturation, were evaluated at 21 days. The ALP activity was
highest on CAc and it was significantly greater than CA. However, this was not the case with
PLGAc and PLGA, as there was no difference between the two groups in ALP activity (Figure
4.1d). Mineralization was higher on collagen-coated groups than on their uncoated counterparts.
However mineralization on CAc was significantly greater than mineralization on PLGAc
(Figure 4.1 e,f). These findings indicate that the osteoblastic phenotype progression may be
greater on CAc than the other groups including PLGAc.
To further understand if there is a difference in osteochondral progression of seeded hMSCs, the
expression of osteochongral genes and proteins were analyzed (Figure 4.5 and Figure 4.2).
Collage 1 (Coll1), an important ECM component of bone was significantly upregulated in all
groups in contrast to PLGA. The CAc group had the highest collagen expression and it was
remarkably greater than PLGAc and CA (Figure 4.2a). Osteonectin (ON), a protein associated
with the collagen ECM, also showed a similar trend with cells on CAc showing the highest
levels of expression (Figure 4.2b). Bone sialoprotein (BSP), a mature marker of osteoblasts, was
upregulated considerably on CA and CAc in contrast to PLGA and PLGAc. Interestingly CAc
performed better than CA, but cells on PLGAc and PLGA showed no significant difference in
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BSP expression (Figure 4.2c). Additionally, an important osteoblastic transcription factor Runx2
was seen to be significantly upregulated on CAc in contrast to all other groups (Figure 4.2d).
Furthermore we examined genes for osteochondral progression (Figure 4.5), such as alkaline
phosphatase (ALPL), Collagen III (Coll3A1), Matrix metalloproteinase 13 (MMP13), Sox9 and
Collagen10A1 (Coll10A1). We saw an upregulation of these genes on the natural polymers (CA
and CAc) in contrast to the synthetic polymers (PLGA and PLGAc). CAc showed the highest
expression of all the genes indicating greatest osteoinduction of seeded hMSC. To visualize
phenotype expression and cellularity within scaffolds, immunostains were performed for
osteoblastic markers such as Coll1 and BSP along with phalloidin for cytoskeletal F-actin and
Nucblue for cell nuclei. While the cells and markers were distributed evenly on the CA and CAc
groups, PLGAc showed better cellular distribution than PLGA. The cells and markers were
confined to the microspheres, with very little cellularity in the pores (Figure 4.2e,f). Thus
osteoblastic maturation was greatest on CAc followed by CA, indicating the effectiveness of
natural polymeric micro-nano structured scaffolds towards osteoinduction of stem cells. The
CAc scaffolds induced greater osteogenic progression than PLGAc as the biomimetic nature of
CAc was more conducive than PLGAc.
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Figure 4.1 Viability, proliferation and osteoblastic markers of seeded hMSCs
In vitro phenotype development by hMSCs seeded on to scaffolds under osteoinduction.
Viability of seeded cells over time on PLGA (top left), PLGAc (top right), CA (bottom left) and
CAc (bottom right) with live (green)/ dead (red) staining at a) Day 3 and b) Day 21. Scalebar =
200µm. c) DNA content by pico- green assay over 21 days in culture d) Alkaline phosphatase
activity at 21 days of osteoinduction on PLGA, PLGAc, CA and CAc. Mineralization at 21 days
of osteoinduction on scaffolds measured by e) visual micrographs of alizarin red stained
scaffolds (PLGA, PLGAc, CA and CAc- top to bottom) and f) Colorimetric quantification of
calcium deposition on PLGA, PLGAc, CA and CAc. One – way ANOVA with Tukey post test,
with 95% confidence intervals, *P<0.001, #P<0.01, @P<0.05.
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Figure 4.2 Osteoblastic gene and protein expression by hMSCs
Osteoblast markers expressed by osteoinduced hMSCs on PLGA, PLGAc, CA and CAc at 21
days. Osteogenic gene expression of a) Collagen1A1 (Coll1A1), b) Osteonectin (ON), c) Bone
Sialoprotein (BSP) and d) Runx2. Immunostaining for osteoblastic protein markers (Marker- red/
F-actin (Phalloidin)- green/ Nucleus (Nucblue DAPI)- blue) staining of PLGA (top left), PLGAc
(top right), CA (bottom left) and CAc (bottom right) e) Collagen1/ F- actin/ Nuclei staining f)
Bone sialoprotein/ F- actin/ Nuclei and g) No primary control ( Background -red/ F- actin
(Phalloidin)- green/ Nuclei (DAPI)- blue) scalebar = 200µm. One – way ANOVA with Tukey
post test, with 95% confidence intervals, *P<0.001, #P<0.01, @P<0.05.
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4.4

Discussion

Cells adhere to materials through adsorbed ligands, by binding to these ligands via their integrin
receptors(423). The classical view in material-protein interaction argues that a hydrophobic
matrix, due to its favourable surface energy, adsorbs higher quantity of proteins from the
surrounding environment. These absorbed proteins play an important function in regulating
cellular events(424-426). However, the absolute quantity of adsorbed proteins onto a material
could not be correlated to cell adhesion(427). Many reports identify the importance of matrix
hydrophilicity as an essential feature for achieving cell adhesion and long term
biocompatibility(428). Studies focused on improving the matrix hydrophilicity, without altering
its chemistry or surface roughness, led to greater cellular adhesion demonstrating that cellular
responses were optimal on slightly hydrophilic materials(377). Though experimental evidence is
minimal, it is believed that hydrophilic matrices may lead to a more native-like conformation of
the adsorbed proteins in turn producing better cellular responses(429). The differential response
of collagen self-assembly on CA and PLGA polymers could be an attributing factor for the
observed D-banding patterns on the CA matrix alone.
The chemical functional groups on a material can influence cellular responses immensely. For
instance Curran et al. cultured bone marrow derived mesenchymal stem cells (MSCs) on glass
substrates modified to contain the functional groups: like -CH3, -SH, –COOH, –OH, and –NH2,
under basal, osteogenic and chondrogenic conditions. They found that the -CH3 functional
groups helped maintain the multipotency of MSCs, while the –OH and –NH2 groups were
conducive for osteogenic differentiation, and the –COOH and –SH groups on the substrate
supported chondrogenic differentiation. These differences were observed both under basal and
stimulated conditions(413). Many other studies have used materials that varied only by the
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chemical functional groups on the biomaterial’s surface and all of them have shown that the
chemical functionalities on the material surface can have a profound influence on stem cell
behavior(37, 340). These changes can be attributed to the resulting material surface energy and
hydration characteristic that determine the conformation of adsorbed proteins and in turn cellular
adhesion(414). In the present study, polysaccharide CA provides aforementioned functionalities
and control PLGA polyester lacks these groups to study the osteochondral phenotype progression
of seeded stem cells. Apart from this, the observed micro scale roughness of CA groups over the
smooth morphology of PLGA, could also act as an inductive factor for osteogenic differentiation
of stem cells(430).
In order to understand the effect of the properties of the material towards stem cell
differentiation, hMSCs were seeded on all the polymers and differentiated into osteoblastic
lineage. The hMSCs showed good viability for the period in culture on both the polyesters and
the polysaccharides. However, the cells spread on the microspheres and the interpore spaces of
CA and CAc, and PLGAc but not in the case of PLGA. The inclusion of integrin ligand such as
collagen or the presence of a hydrophilic polymer that allows for integrin ligands from the media
to be presented in the right conformation may have lead to better cell spreading on the CA, CAc
and PLGAc matrices against the microsphere focused cellularity of PLGA (Figure 4.1 a, b, c
and Figure 4.4). PLGA is shown to have a contact angle above 90°, but CA has a much lower
contact angle of around 55°. It has been seen that several studies that a contact angle between 3565°, may be more conducive for cell adhesion than a contact angle above 90°(431, 432). Hence
the CA materials showed greater cell adhesion and spread than PLGA, owing to their hydrophilic
nature.
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The presence of collagen, which is an integrin ligand could compensate in the case of PLGAc,
leading to greater uniformity in cell distribution. However, the osteochondral progression of
seeded MSCs was higher on CA and CAc both in terms of gene and protein levels and
distribution (Figure 4.2, 4.5). The long bones of our body are formed by endochondral
ossification. In this process the MSCs undergo a transition through the formation of a condensed
chondrogenic template to facilitate the formation of bone. The material properties may have
attributed to better cell adhesion by integrin signaling on the MSCs seeded on CA and CAc.
These could translate into better cell- cell contact as well. This is likely to be more conducive for
cellular condensation and hence the greater osteochondral progression seen on CA and CAc.
Though both CAc and PLGAc possessed collage, the collagen on CAc was seen to be more
biomimetic than the collagen on PLGAc. It has been shown in literature that denaturation of
collagen leads to loss of mechanical stimuli needed for MSC’s osteoblastic differentiation(405,
406). It is also known that the Hedgehog signaling pathway, seen to play an important role in
osteochondral progression(433, 434) in the body is upregulated by type one collagen with the
native structure(435). Hence we observed that the CAc micro-nano structured biopolymer was
most osteoinductive, to an extent greater than its PLGAc counterpart.

4.5

Conclusions

We conclude that the natural polymer based micro- nano structured CAc scaffolds mediated the
greatest degree of cell spreading and distribution along with greatest levels of osetoblastic
differentiation of the seeded MSCs. While the PLGA platform showed similar viability and cell
proliferation levels, the CA scaffolds showed better cell and osteoblastic marker distribution
throughout its microspgeres and the interpore spaces. Hence these studies have shown the
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potential of CA and CAc scaffolds to be osteoinductive when used in combination with MSCs.
Since MSCs are a very clinically relevant cell population, the translational relevance of using CA
and CAc scaffolds in combnation with MSCs may be great.
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4.6

Supplemental Figures

Figure 4.3 Viability of seeded hMSCSs
Live (green)/ dead (red) staining of cells on scaffolds at a) Day 3, b) Day 7, c) Day 14, d) Day
21. PLGA (top left) PLGAc (top right), CA (bottom left) and CAc (bottom right) show good
viability of seeded hMSC throughout all culture time points.
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Figure 4.4 Proliferation of seeded hMSCs
a) hMSC proliferation measured by pico- green assay over 21 days of culture in basal and b)
osteoinduced condition. Two- way ANOVA with Bonferroni post- test, with 95% confidence
intervals, *P<0.001, #P<0.01, @P<0.05.
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Figure 4.5 Osteochondral gene expression by seeded hMSCs
Osteochondral gene expression by osteoinduced hMSCs on PLGA, PLGAc, CA and CAc. a)
ALPL- Alkaline phosphatase, b) Coll3A1- collagen 3A1, c) MMP13- Matrix metaloprotease 13,
d) Sox9, e) Coll10A1- collagen 10A1. One – way ANOVA with Tukey posttest, with 95%
confidence intervals, *P<0.001, #P<0.01, @P<0.05
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5 Chapter 5
Charecterization of the Biocompatibility of CA-Collagen, Micro-Nano Structured Scaffolds
in vivo
5.1

Introduction

Any foreign material that is placed into a host tends to elicit an immune reaction. When a
material is first implanted into the body, it comes into contact with blood. A layer of protein
from the host coats the implanted biomaterial. Various proteins like fibrin, fibrinogen,
vitronectin and a host of other proteins are found in this mix, along with immunoglobulins like
IgE and opsonins like compliment activated factor C3b(436) etc. The neutrophils home and try
to resolve the new foreign body by trying to digest it with their activity. However the biomaterial
is too large and once this acute phase resolved, the macrophages home to the implant and since
they are also incapable of destroying the foreign body, the fusion of macrophages occurs, leading
to the formation f multinucleated giant cells (MNCs), that are characteristic of a foreign body
reaction (FBR). Eventually a layer of collagen produced by fibroblasts encapsulates the implant.
This is known as fibroencapsulation of the biomaterial(437).
Biocompatibility is a complex factor that involves the immune response by the body to the
implanted foreign material. Though every material tends to elicit an immune response, it is
important to make sure that the FBR to a material is acceptable as per the norms laid out by
regulatory agencies before implantation into the body. Though cell viability in vitro can and is
used as a measure of biocompatibility, implantation into the body is necessary to understand the
tissue response to the material and establish its safety for usage an implant biomaterial for tissue
engineering. The (IOS) 10993 criteria for biomaterial biocompatibility mandates implantation
into animals and require that the implants be non- toxic on implantation(437).
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Taking these factors into consideration, implantation of CA, CAc and PLGA polymers under
subcutaneous pouches of rats were conducted. The rats were sacrificed and the immune response
in the tissue infiltrating into the scaffold matrix were determined by histological staining and
histomorphometric measurements. These studies were designed to test the safety of the new CA
and CAc polymeric scaffolds against an FDA approved (PLGA) polymer.

5.2
5.2.1

Materials and Methods
Subcutaneous implantation

Sprague Dawley rats of 250-300 grams of body weight were purchased from Charles River
(Wilmington, MA, USA). All procedures for animal use were approved by the Institutional
Animal Care and Use Committee (IACUC), at the UConn Health. Isoflurane (3%) in a gaseous
mix with oxygen was used as the anesthetic. Each rat was implanted with six scaffolds, two of
each kind (PLGA, CA and CAc). Briefly, the dorsal side of the rats were shaved and prepped
with betadine and alcohol. A 2.5 cm long incision was created to make a subcutaneous pouch
and individual scaffolds (8X2mm) were implanted into pouches. The pouches were sutured and
animals were monitored regularly. At each of the 2, 4, 8 and 12 weeks of implantation time
points, two rats were sacrificed using carbon dioxide overdose and four scaffolds (n=4) of each
type (PLGA, CA and CAc) were removed and collected for evaluation.
5.2.2

Histological staining

The scaffold samples were harvested along with the surrounding subcutaneous tissue, washed in
PBS (pH 7.4) and fixed in 4% PFA/ PBS (pH 7.4) overnight at 4°C. The scaffolds were rinsed in
PBS (pH 7.4) after fixation and transferred to a 1:1 mix of OCT and 30% Sucrose solution in
PBS (pH 7.4). The samples were incubated for 24h at 4°C. The samples were then transferred to
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OCT alone at room temperature for an hour. The samples were flash frozen and sectioned into
10µm thick sections and captured on cryo-films. The cryo films were fixed onto slides using UVcuring adhesive. The samples were hydrated in water and Hematoxylin and eosin staining and
Gomori Trichrom staining was performed.
5.2.3

Histomorphometric analysis

The hematoxylin and eosin stained samples were used for characterization of cell types
infiltrating the implants. Two independent evaluators scored the samples for multinucleated giant
cells (MNC) characteristic of foreign body response, macrophages, fibroblasts and blood vessels
based on cell morphology, in consultation with a clinical pathologist. The gomori trichrome
samples were used as guidelines for confirmation of cellular phenotype. FIJI (NIH) software was
used to count the total number of cells in each type and to measure the tissue area in the pore of
each group of scaffold. All the scores were normalized to the tissue area fraction. Tissue area
fraction was equal to Tissue area in section (i.e. tissue area in the pores of the scaffold)/ Total
area of the section. An n=3 was used for this analysis.
5.2.4

Statistical analysis

All data are reported as the mean ± standard deviation (SD) of results from at least three
independent runs. In case of experiments with two groups a student t- test was performed. In the
case of experiments with multiple groups and multiple time points a 2- way- ANOVA with
Bonferroni posttest was performed. In the case of experiments that focused on one time point and
several groups, a one- way- ANOVA with Tukey posttest was performed. 95% Confidence
interval was employed to arrive at the p values. The denotation of significances given by p
values are- *p<0.001 (extremely significant), #p<0.01 (very significant),

@

p<0.05 (significant).

Analyses were performed using GraphPad Prism Software (GraphPad Software, San Diego, CA).
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5.3
5.3.1

Results
Cellularity in the scaffolds

Subcutaneously implanted PLGA, CA and CAc scaffolds in Sprague Dawley® rats retrieved at
week 2, 4, 8 and 12 were processed for histology. At the earliest time point CA scaffolds had
very little cellularity compared to PLGA controls. However, the CAc scaffolds presented good
cellularization at the early time point (2 weeks) (Figure 5.1a). The collagen content of the tissue
was also higher in CAc than CA (Figure 5.1c). As time progressed the cellularization of CA
groups increased at 4 weeks (Figure 5.1 b,d) with the CAc scaffolds showing more
cellularization than CA. However by 8 weeks all the materials looked similar in terms of their
cellular and collagen content (Figure 5.2 a, c). At 12 weeks there was a marginal decrease in the
cellularity of PLGA, but the tissue infiltration of the CA and CAc scaffolds were greater (Figure
5.2 b, d). Quantitatively the tissue infiltration in the CA material was lower than PLGA in the
earlier time points after implantation of the material (at 2 and 4 weeks). However at 8 weeks all
the scaffolds had a comparable amount of tissue infiltration and by 12 weeks the CA material
showed greater cellular content than the other groups (Figure 5.3b).
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5.3.2

Immune response to scaffolds

The macrophages population on CA was considerably higher than CAc at the earliest (week 2)
time point (40X magnified images of Figure 5.1 a,c). However these differences were
insignificant with progress in time (40X magnified images of Figure 5.1 b,d; Figure 5.2 a, c;
b,d; Figure 5.3 c). The multinucleated giant cells (MNCs) representing the FBR of the tissue to
the biomaterial indicated a significantly higher FBR to CA than on PLGA, but not on CAc soon
after implantation at around 2 weeks (40X magnified images of Figure 5.1 a,c and Figure 5.3
a). These significances did not persist at later time points (40X magnified images of Figure 5.1
b,d;Figure 5.2 a, c) until 12 weeks (Figure 5.2 b, d) when PLGA showed considerably greater
number of MNCs than CA and CAc (Figure 5.3 a).
5.3.3

Vascularity in scaffolds

Vascularity of all the materials were pretty low to begin with at 2 weeks but increased at a
similar rate on all the materials (Figure 5.3 d).
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Figure 5.1 Staained histological sections at early time points
Histological staining of subcutaneously implanted PLGA, CA abnd CAc at early time points. (a,
c- at 2 weeks , b, d- at 4 weeks ). a), b)- Hematoxylin and eosin staining, c), d)- Gomori
trichrome staining. Scalebars on 1X magnification = 3mm, scalebar on 20X and 40X
magnifications= 300 µm.
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Figure 5.2 Stained histological sections at late time points
Histological staining of subcutaneously implanted PLGA, CA abnd CAc at late time points (a,cat 8 weeks, b,d- at 12 weeks). a), b) Hematoxylin and eosin staining, c), d) Gomori trichrome
staining. Scalebars on 1X magnification = 3mm, scalebar on 20X and 40X magnifications= 300
µm.
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Figure 5.3 Histomorphometric analysis of subcutaneous implants
Histomorphometric analysis of implanted scaffolds over time- Immune response represented by
a) multinucleated giant cells (MNCs), and, b) percentage tissue area, c) macrophages and d)
number of blood vessels. Two- way ANOVA with Bonferroni post- test, with 95% confidence
intervals, *P<0.001, #P<0.01, @P<0.05.
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5.4

Discussion

Biocompatibility is a basic criterion for using any biomaterial in the body. Though
biocompatibility was thought to be elicited by bioinert materials that did not lead to adverse
reaction, presently it is defined as a biomaterial’s ability to elicit an appropriate tissue response
when implanted in the body(437). As mentioned in the introduction of this chapter, the tissue
response to the natural polymeric CA and CAc materials were contrasted with the PLGA
scaffolds. As per the expert opinion of clinical pathologist all the materials elicited an immune
response that indicated good immune tolerance by the body. Cellulose and its derivatives are
well known to be biocompatible as implants(231). Its blood biocompatibility had led to the
formulation of hemostatic devices based on cellulose. However the CA scaffolds used by us have
tested as highly hydrophilic materials (Chapter 3). As stated in the introduction the first step in
biomaterial recognition in the body after implantation is by adsorption of several proteins and
opsonins onto the surface of the biomaterial. In this regards, the C3 fragment of the compliment
system plays an important role in eliciting the FBR response. For instance Elwin et al. showed
that C3 compliment factor adsorbed in modified surfaces that were highly hydrophobic showed
denaturation of the adsorbed protein(438). This led to exposure of the epitopes recognized by the
antigens in the body. With biomaterials used as contact lenses, the more hydrophilic ones lead to
greater biocompatibility and lesser protein buildup(439). So, in general, hydrophilic materials
have been seen to induce greater bio-acceptance in the body. It was shown by Sussman et al, that
the same material implanted as a solid piece vs as an interconnected porous scaffold can elicit
very different immune response. While the solid material showed a fibrotic response the porous
sctucture showed greater biocompatibility(440). Hydrogels that show very little protein
adsorption onto their surface have also shown great biocompatibility and tissue integration
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responses(441). Here in these studies we observed a lack of immune tolerance for the CA
scaffold at the early time points of 2 and 4 weeks in comparison to PLGA. However the collagen
coated counterparts did not suffer this lag time for cellularization of the biomaterial and they had
a lower FBR response. CA being extremely hydrophilic could have shown a lag in the adsorption
of bodily proteins stably onto its surface at the early time points of implantation in turn leading
to a lag in cellular infiltration/ adhesion. However the presence of exogenous collagen may have
helped with achieving initial tissue infiltration and biocompatibility of the CAc over the CA
scaffolds. On the other hand, at the latest time point of 12 weeks PLGA that showed good
responses in terms of cellularization and FBR started showing a reduction in tissue content and
an increase in MNCs representative of an increasing FBR with time in contrast to CA. PLGA
and synthetic polymers like PLLA may elicit an adverse immune response with time due to the
change in the environmental pH associated with the degradation of the polymer matrix(365). On
the other hand CA which showed slow cellularization showed long term biocompatibility. The
presence of collagen in CAc may have hastened the process of cellularization and immune
acceptance of the material by the body. The results of material characterization (chapter 3) and
cellular viability (chapter 4) agree well with the results of long-term biocompatibility of the
natural polymers seen in this chapter.

5.5

Conclusions

We conclude that CA 3D porous microsphere scaffolds show good long-term biocompatibility.
Inclusion of collagen nanofibers may be beneficial in achieving biocomapatibility soon after
implantation. This implies that the CA, CAc and PLGA materials can be safely implanted into
animals for examining functional bone regeneration by the scaffolds.
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6 Chapter 6
Characterization of Bone Formation by Natural Polymeric Materials in a Critical Sized
Calvarial Defect in Combination with Bone Marrow Stromal Cells
6.1

Introduction

Bone represent one of the most transplanted organ(5). About 0.5 million bone grafts are carried
out in the U.S. alone, (6-8) per annum(5). Though using bone from the patient itself
(autografting) is considered the golden standard for achieving bone healing, it is restricted by
availability and discomfort to the patient. Allografts on the other hand help overcome these
limitations, but carry the threat of low remodeling due to excessive processing and possibility of
disease transmission(9). Hence in bone tissue engineering, biomaterial scaffolds, biological
factors and cells used alone or in a combination promises better bone regeneration(9). Here, the
tissue engineered scaffolds act as a template for regeneration to occur and the properties of the
biomaterial can dictate the nature of bone regeneration achieved(33).
It is well known that the scaffold properties such as hydrophilicity(34), morphology(35),
porosity, and mechanical properties(39) can be used to direct effective bone healing. Both
synthetic and natural polymers have been used as scaffold materials for bone regeneration. The
most popular polymeric materials used commercially are PLLA and PLGA(395). Though
synthetic polymers lend themselves to be readily modified to obtain the desired molecular
weights and hence gaining control over their mechanical and degradation properties is possible,
concerns are raised due to their hydrophobic nature and acidic bulk degradation products that
could impact bone formation in the body(343, 396). Strategies such as inclusion of
hydroxyapatite have given a buffering effect under such conditions(344).
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Natural polymers such as polysaccharides and proteins on the other hand are synthesized in
biological systems like plants, animals and microbes and therefore their structure and chemistry
are similar to the ECM macromolecules seen in our body(442). Hence these natural polymers
offer greater biocompatibility in tissue healing(335, 345). Though a number of attempts have
been made to include natural polymers with synthetic polymers for bone tissue engineering(443,
444), very few materials made of bio-polymers alone have been successful in providing the
functions of mechanical competence, porosity and bioactivity(445). We were successful in
developing a natural polymeric platform that combined mechanical competence(352) with
bioactivity(391). For example, collagen(346, 347), chitosan(345), polysaccharide(348) and
protein based scaffolds are often presented in the form of porous sponges, fiber matrices or
hydrogels. These scaffolds lack the mechanical stability and require chemical crosslinking to
produce stable scaffolds. During scaffold fabrication, extensive processing and cross-linking
compromises the biological functionality of these scaffolds(349-351). We followed a twopronged approach by having a mechanically competent sintered microsphere 3D- porous base
structure made of cellulose acetate (CA), further functionalized with self-assembled nanofibrillar
collagen (CAc)(352, 391).
Often times, the inclusion of factors or stem cells is needed to achieve complete tissue
regeneration and the biomaterial scaffold acts as a delivery vehicle(330). In this context, while
the delivery of growth factors such as BMPs have had mixed outcome such as bone formation in
non-target regions(446, 447), a clinically viable alternative is the use of patient derived bone
marrow stromal cells (BMSCs)(448-450). The scaffold used to deliver the cells also acts as an
instructive temporary ECM to control and direct the survival(451), proliferation(452) and
differentiation(421) of the stem cells(453, 454) and ultimately dictated the quality of regenerated

158

bone(455). Hence the mechanical(422), pore properties(456, 457), chemical functionalities(37,
413), topographical(39) and nanoscale(39, 379) features can all influence osteogenic
differentiation of BMSCs. Most of these studies however do not examine the role of these
material characteristics towards regeneration in vivo when combined with BMSCs. It is
extremely critical to understand the behavior of materials with superior physicochemical
properties in the body to formulate scaffolds with potential use in human bone regeneration
applications.
In this study, we compare the performance of a natural polymer based CA and (CAc)
scaffolds(352, 391) along with the synthetic polymeric (PLGA) scaffold(458, 459), in terms of
their ability to heal a critical sized bone defect in a two hole (bilateral) calvarial mouse model. In
the first set of studies, cellulosic- CA, CAc and synthetic- PLGA 3 D-porous materials alone
were implanted into the bilateral calvarial defects in mice. In the second set of studies, BMSCs
from donor mice were seeded at equal numbers on to each of the matrices and implanted into the
calvaria of mice.
It was hypothesized that the natural polymers may act as a better matrix for cellular infiltration,
by offering greater biocompatibility. We also hypothesized that the natural polymers (CA, CAc)
materials may offer a more osteoinductive environment towards the seeded BMSCs and lead to
better quality of bone formation in a critical-sized defect. The bone formation was monitored at 8
weeks after implantation to determine the ability of scaffold alone in inducing bone formation
and in combination with seeded BMSCs. The BMSCs from the host mice had a green fluorescent
collagen reporter gene, as they became osteoblasts and the donor mice had BMSCs that had a
cyan fluorescent collagen reporter gene if they became osteoblasts. Hence this tool helped us
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identify the probable origin of bone formation in the materials seeded with BMSCs based on
blue/ green fluorescence.
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6.2
6.2.1

Materials and Methods
Materials

Cellulose acetate (Mw: 30K) (CA), and Polyvinyl Alcohol (30,000-70,000) (PVA) were
procured from Sigma -Aldrich (St. Louis, MO, USA). Poly (lactic-co-glycolic acid) 85:15
(PLGA) was purchased from lakeshore biomaterials (Birmingham, USA).

Acetone,

Dichloromethane, Cyclohaxane, Paraformaldehyde and Gluteraldehyde were purchased from
Fisher Scientific (Fair Lawn, NJ, USA).
6.2.2

Preparation of microspheres

Oil in water solvent- evaporation, followed by sintering of formed microspheres using a
solvent/non-solvent mixture was used for producing microsphere of i) Cellulose acetate (CA), ii)
poly (lactic-co-glycolic acid) 85:15 (PLGA). In brief, 13 (w/v) % of CA polymer was dissolved
in a solvent mixture containing methylene chloride and acetone at a ratio of 9:1 to produce
microspheres. A 20 (w/v) % solution in methylene chloride was used in the case of PLGA
polymer to produce the microspheres. The polymer solutions were then poured in a thin stream
into an aqueous media containing 1.25(w/v) % PVA as a surfactant, with constant stirring at
250rpm to form an oil-in-water emulsion. These suspensions were stirred overnight to evaporate
the solvent to obtain hardened microspheres. Isolated microspheres were washed repeatedly with
deionized (DI) water, dried, and sieved into different microsphere sizes. Microspheres in the size
range of 200- 425µm were sintered into micro porous scaffolds using either solvent-non-solvent
or heat sintering based on the polymer(352, 391).
6.2.3

Preparation of micro-porous sintered 3D microsphere scaffolds

Metal molds were filled with CA microspheres to which a 200µL volume of an optimized
solvent/non-solvent composition, acetone: cyclohexane in the ratio of 3:1 (v/v), was added to
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cover the microspheres. Solvent was allowed to evaporate at room temperature to obtain sintered
microsphere scaffolds. Cylindrical scaffolds measuring 3.5mm diameter X 1mm height were
used for implantation into mouse calvaria. The control PLGA micro porous scaffolds with
identical micro-particle sizes were produced by heat sintering at 95oC for 45 minutes using
Teflon molds(352).
6.2.4

Preparation of collagen naonfiber infused cellulose 3D microporous scaffolds

A modified biomimetic approach was used to functionalize micro porous scaffolds with type I
collagen. In brief, both control and test scaffolds were incubated in a 0.1 (w/v) % collagen type I
solution with a pH adjusted to 4.2 at 37°C for 7 days to promote molecular collagen selfassembly. The dried scaffolds were treated with UV light for 30 min each side to achieve
collagen nanofiber stability and washed repeatedly with DI water to remove buffer salts.
Microspheres in the size range of 200-425µm diameters were sintered and infused with selfassembled collagen and used in this study (391).
6.2.5

Characterization of internal structure of scaffolds by SEM

Scanning electron microscopy (SEM) was used to characterize scaffold morphology and evaluate
collagen fiber diameter and distribution. Scaffolds were sputter coated with Au/Pd using a
Polaron E5100 sputtering system (Quorum Technologies, East Sussex, UK) to achieve an
eighteen nanometer thick coating before viewing under SEM. The samples were viewed using
FEI Nova NanoSEM 450 scanning electron microscope (FEI, Hillsboro, OR, USA) operated at
an accelerating voltage of 2kV at various magnifications.
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6.2.6

Design of calvarial implantation studies

The Institutional Animal Care and Use Committee (IACUC) at The University of Connecticut
Health Center approved all procedures for animal use and all efforts were made to minimize
animal suffering. 10-12 week old CD-1 wild type female mice, weighing 26-32 g were used for
implantation of the scaffolds alone. The10-12 week old male transgenic mice, weighing 25-30 g
used as hosts for implantation had a green fluorescence in their osteoblasts as the expression of
EGFP is driven by a 3.6 kb fragment of collagen 1 promotor (Col 3.6- TPZ mice- host)(460).
These host mice were NOD SCID and gama irradiated (NSG) to facilitate the immune
acceptance of donor cells. The transgenic mice used to obtain the bone marrow stromal cells
(BMSCs) to seed the scaffolds before implantation had blue fluorescence in their osteoblasts as
the expression of CFP is driven by a 3.6 kb fragment of collagen 1 promotor (Col 3.6 –Cyan
mice- donor)(460, 461). Thus the BMSCs from donor mice becoming osteoblasts fluoresce blue,
while the BMSCs becoming osteoblasts fluoresce green. Thus the fluorescent reporters acted as a
tool to determine the quantity of active osteoblasts formed by the donor cells and the host cells.
Critical sized calvarial defects (3.5 mm diameter) were created on both the sides of the calvarium
of mice and a scaffold of 3.5mm diameter X 1mm height was implanted into each of the defects.
The studies contained 3 groups with control scaffold on the left side and test scaffold on the right
side as given by Figure 6.2 A. In the study using no cells, six samples (n=6) were used, while
twenty-four samples (n= 24) were examined in the case of studies where the scaffolds were
seeded with donor cells. Each scaffold was sterilized by soaking in 70% ethanol followed by UV
treatment on both the sides for 20-minutes per side. They were then washed with sterile PBS and
either directly implanted (study1) or implanted after seeding donor cells as described below
(study 2). Each scaffold was seeded by immersion into 1 X106 BMSCs cultured to confluence
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and spun down into a pellet prior to transplantation(462). The samples were retrieved at 8 weeks
for radiological and histological examination.
6.2.7

BMSC Culture

For experiments where the scaffolds were seeded with cells, donor mice (Col3.6- Cyan) of 6-8
weeks of age were sacrificed by carbondioxide asphyxiation and sprayed with ethanol to avoid
contamination from mouse hair/ skin. The tibia and femur of these mice were isolated and briefly
washed with sterile PBS. The bone epiphyses were removed to expose the marrow and then
flushed with media. The media was made up by adding 1% Penicillin/ Streptomycin and 10%
FBS to α-MEM. The flushed cells were filtered using a 70µm cell strainer and the filtrate was
spun down by centrifugation for ten minutes at 350Xg. The pelleted cells were suspended well
in the media and plated at a density of 3 X 106 cells/cm2. A fifty percent media removal and
replacement was completed at day 4 of plating and a hundred percent removal and replacement
of media was done after 7 days of culture. Once the cells reached confluency by day 10, they
were lifted with Trypsin EDTA (2.5%) solution and suspended in media with serum to achieve a
cellular concentration of 1X106 cells/mL of media(463).
6.2.8

Calvarial surgery

A combination of Ketamine (135 mg/kg) and Xylazine (15 mg/kg) was administered (I.P.) were
used to anesthetize the mice (CD-1 wild type mice for implantation of scaffold alone and 3.6colTPZ mice in the case of experiments with BMSC seeded scaffolds), for the surgical implantation
of the scaffolds. A clipper was used to cleanse the area and followed by topical application of
70% ethanol to removed hairs on their heads and clean the surface for the surgery. The mice
heads were dissected with a clean incision to reach the cranium. A 3.5mm critical sized defect
was made on each side of the cranium using a drill bit, making sure that the underlying dura
164

matter was not damaged. A two-hole mouse calvarial model was used and the scaffolds were
placed into theses defects as per the study design (Figure 6.2 B). In the case of the cell-seeded
scaffolds, the BMSCs were spun down for a minute at 10,000Xg and the pellet was seeded onto
the scaffolds by immersion of the scaffold until all the cells in the pellet got onto the material.
Thus each scaffold received 1X106 cells (Col3.6- Cyan), in the case of the cell seeded scaffold
implantation experiments. Hence each mouse received two implants on either side of their
calvaria(454).
6.2.9

Sample harvest

The animals were sacrificed using carbon dioxide asphyxiation followed by cervical dislocation
at 8 weeks post implantation of the scaffolds. An alizarin red injection (30mg/kg body weight,
I.P.) was administered 24hours prior to sacrifice of the animals in order to label the newly
formed bone(463). The skulls of the mice were dissected, washed in PBS at pH 7.4 and fixed
using 10% buffered formalin for 4 days. An X-ray cabinet (Faxitron LX-60) was used for digital
X-ray capture at a 43 magnification (6 s at 26 kVp). The samples were then cryosectioned for
histological and immunostaining. The fixed samples were washed in PBS at pH 7.4 and
transferred to 30% sucrose solution in PBS at pH 7.4 for a day. The tissue was embedded in
Shandon Cryomatrix-TM placed in cryo-molds by flash freezing on dry ice. The frozen sections
were stored in -20°C until sectioning. Leica CM3050S cryostat (Leica, Wetzlar) was used for
obtaining 10µm thick sections of the embedded samples by employing the tape transfer
technique (Cryofilm type IIC (10), Section-Lab Co. Ltd.)(464) The samples were imaged for
mineral content (DIC- white) and new bone formation (red) in the case of unseeded scaffolds. In
the case of cell seeded implants, the mineral content (white), Alizarin Complexone label (ACred) for new bone formation, donor cells (cyan), and host cells (green) were imaged using dark
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field and fluorescent microscope. Serial sections were used for immunostaining for bone
sialoprotein (BSP) and Collagen (Coll1). Another set of histological sections was serially stained
for alkaline phosphatase and DAPI (AP/ DAPI) to determine osteogenic activity and cellularity,
and tartrate resistant acid phosphatase (TRAP) activity to determine bone resorbing osteoclastic
activity. A Zeiss Axio Scan.Z1 (Carl Zeiss MicroImaging Inc.) was used to details from 4-100X
magnifications. The excitation (Ex) and emission (Em) filters used were as follows: AC: Ex545/25, Em-605/70; Col3.6TPZ: Ex- 500/20, Em-535/30; Col3.6ECFP: Ex-436/20, Em-480/40;
TRAP: Ex-405/440, Em-550/560; AP: Ex-640/630, Em-690/650; Col: Ex-650/590, Em738/663; BSP: Ex- 556/513, Em- 613/570.
6.2.10 Histomorphometric analysis of calvarial implants
In the case of unseeded scaffolds n=3 from each group were analyzed and in the case of cell
seeded scaffolds n=7 was used for CA, n=7 was used for CAc and n=6 for PLGA. Some samples
were eliminated due to sample slippage from defect. The image analysis was done using Fiji
(NIH software). Each individual channel was used and converted into an 8-bit image. Each of
these images was appropriately thresholded to quantify the signal and eliminate the noise.
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6.3
6.3.1

Results
Scaffold Morphology

The 3D porous scaffolds of PLGA were golden in color (Figure 6.1A), while the CA (Figure
6.1B) and CAc (Figure 6.1C) were opaque and white in color. Under higher magnification, with
scanning electron microscope (SEM), the PLGA 3D porous materials (Figure 6.1 D, G, J)
showed a smooth morphology (arrows). On the other hand the morphology presented by CAc
(Figure 6.1 E, H, K) showed many undulations on the surface (arrows). The collagen nanofibers
were present on the CA microspheres in CAc (Figure 6.1 F, I, L). The collagen fibers formed a
coating on the microsphere without accumulating at the pores of the material (arrows).
6.3.2

Radiological examination of bone formation with scaffolds alone and scaffolds along
with BMSCs

The animals were sacrificed and the whole calvaria were dissected out after 8 weeks of
implantation (Figure 6.3- A, B, C in the case of unseeded scaffolds and Figure 6.4A- 1,2,3 in
the case of scaffolds seeded with BMSCs) and examined by X-ray to evaluate the amount of
bone formation in the materials. The radioopacity of the tissue formed in the case of implants
alone was very low, and mostly represented a background signal only (Figure 6.3- D, E and F).
This did not represent a significant amount of bone formation by the materials in the absence of
cells. However, when the materials were seeded with 1X106 BMSCs from donor mice, the
scaffolds showed bone formation (Figure 6.4A- 4, 5, 6). While all the materials showed bone
formation in the presence of BMSCs, on quantifying the radioopacity in each material group, the
amount of bone formed with CA and CAc was twice as much as what was observed with PLGA
(Figure 6.4B). This difference was statistically very significant (P< 0.001).
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6.3.3

Histological analysis of implantation of scaffolds alone

The bone formation was not very high when the materials alone were implanted into calvarial
defect and examined after 8 weeks of implantation (Top row -DIC in Figure 6.5, and
supplemental Figures 6.13, 6.14). There was not much robust mineral deposition (Top row –AC
red label in Figure 6.5, and supplemental Figures 6.13, 6.14). This was indicative of low
degrees of bone mineral deposition. The materials showed presence of cells in their interior
along (Middle row –DAPI Blue stain in Figure 6.5, and supplemental figures 6.13, 6.14) with
robust alkaline phosphatase activity, indicative of osteoblastic activity (Middle row –AP Red
stain label in Figure 6.5, and supplemental figures 6.13, 6.14). However, the PLGA scaffolds
had most of the cellularity (DAPI- blue) and osteoblastic activity (AP- red) confined to the
periphery of the implant (Middle rows: Figure 6.13, Inset C; Figure 6.5, Inset C). On the other
hand the cellularity (DAPI- blue) and osteoblastic activity (AP- red) were seen well inside the
scaffold interior and were more evenly distributed in the case of CA (Middle rows: Figure 6.13,
Inset D; Figure 6.14, Inset C) and CAc (Middle rows: Figure 6.5, Inset D; Figure 6.14, Inset
D). Finally, the osteoclastic activity was also seen better distributed in CA (Final rows: Figure
6.13, Inset F; Figure 6.14, Inset F) and CAc (Final rows: Figure 6.5, Inset F; Figure 6.14, Inset
F) than in PLGA (Final rows: Figure 6.13, Inset E; Figure 6.5, Inset E). Therefore, though the
materials alone could not facilitate proper bone formation in the defects by themselves, the
cellularization, osteoblastic and osteoclastic cellular activity in the case of PLGA were confined
mostly to the periphery of the materials. In the case of CA and CAc, a well-distributed
cellularity, along with uniformly spread osteoblast and osteoclast activity was seen. There was
no significant difference between the test and the control materials in the quantity of cells or the
osteoblast and osteoclast activity. Therefore the materials alone did not lead to appreciable bone
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formation, but in the presence of BMSCs the bone formed in the test CA and CAc groups was
twice that formed in PLGA
6.3.4

ECM protein deposition by scaffolds and BMSCs

The collagen I (Coll I) and bone sialoprotein (BSP) content of scaffolds loaded with BMSCs was
evaluated by immunostaining (Coll I- yellow, BSP- red). Both Coll I and BSP were found in all
the sections. The BSP content was similar between the groups (Bottom row and top row: Figure
6.15, Figure 6.6, Figure 6.16 and Figure 6.7A). The distribution of collagen was confined to
certain areas in the case of PLGA and a continuous collagenous ECM was absent. Therefore
though collagen was present it did not bridge the defect well in the case of PLGA (Figure 6.15A, C; Figure 6.6- A, C). However, the distribution of collagen was more
uniform throughout the matrix in the case of CA (Figure 6.15- B, D; Figure 6.16- A, C) and
CAc (Figure 6.6- B, D; Figure 6.16- B, D). The intensity of the signal, when contrasted to the
host bone was weaker in the case of PLGA (Figure 6.15- A, C; Figure 6.6- A, C vs the central
insets in the rows). The intensity of collagen signal was comparable to host bone in the case of
CA (Figure 6.15- B, D; Figure 6.16- A, C vs the central inset in the rows) and CAc (Figure 6.6B, D; Figure 6.16- B, D vs the central insets in the rows). Quantitatively, the collagen content of
CA and CAc was almost twice as much as the collagen presented by the regenerated tissue in
PLGA (Figure 6.7B). The difference was very significant. All scaffolds seeded with BMSCs
showed bone formation (DIC signal in Figure 6.17, Figure 6.8, and Figure 6.18) and new
mineral deposition (AC- red signal in Figure 6.17, Figure 6.8, and Figure 6.18). Bone
formation was confined to certain regions of the material in the case PLGA (Figure 6.17- A, C,
E, G; Figure 8- A, C, E, G), with minimal closure of the defect at the interphase of calvarium
and the dura of the mice.
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On the other hand the bone formation was well distributed and a good bone bridge was formed at
the interphase of the calvarium and dura in the case of CA (Figure 6.17- B, D, F, H; Figure
6.18- A, C, E, G) and CAc (Figure 6.8- B, D, F, H). Quantitatively, the bone area on CA and
CAc was approximately twice that seen in PLGA implants (Figure 6.9A). However the quantity
of bone mineral deposition (Figure 6.9B), donor cells (Figure 6.9C) and host cells (Figure
6.9C) in all the groups was no significantly different. In all the groups, the Col3.6- Cyan (donor)
cells presented greater intensity than the Col3.6- Tpz (host cells).The donor cells also presented
better merger with the AC (red), new mineral signal (smaller insets in each of the insets of
Figure 6.17, Figure 6.8, and Figure 6.18).
6.3.5

Osteoblastic and osteoclastic activity in scaffolds seeded with BMSCs

The cellular content (DAPI- blue) of the scaffolds was similar between PLGA, CA and CAc
(Lowest panel: Figure 6.19, Figure 6.10, Figure 6.20, and Figure 6.12A). The AP (red) content
was also similar between the groups (Middle panel: Figure 6.19, Figure 6.10, Figure 6.20, and
Figure 6.12B). However, the distribution was more uniform and a continuous layer of cells with
active AP content was seen in the case of CA and CAc. The PLGA materials showed cell (DAPI)
and AP distribution more in certain pockets than in the other parts of the material. There was also
a lack of continuous tissue (Figure 6.19- E, A; Figure 6.10- E, A) and osteoblastic AP activity
at the interphase of the cranium and dura in the PLGA implants (Figure 6.19- C, A; Figure
6.10- C, A), while a good degree of tissue and ostoblastic activity was seen in analogous regions
of CA (Figure 6.19- D, B; Figure 6.20- C, A) and CAc (Figure 6.10- D, B; Figure 6.20- D, B)
Though the osteoclastic bone resorption was not different between all the groups (Figure 6.12
C), the distribution of osteoclast activity, as given by TRAP staining was more homogenous with
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CA (Figure 6.21- B, C) and CAc (Figure 6.11B, Figure 6.21D), than with PLGA (Figure
6.11A, Figure 6.21A)
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.
Figure 6.1 Morphology of scaffold
Examination of scaffold structure. Photographic images of 3D microporous scaffolds used (A)
PLGA, (B) CA, (C) CAc, scale bar= 1mm; SEM images at 100X magnification (D) PLGA, (E)
CA, (F) CAc, scale bar= 500µm; SEM images at 500X magnification (G) PLGA, (H) CA, (I)
CAc, scale bar= 100µm; SEM images at 1000X magnification (J) PLGA, (K) CA, (L) CAc, scale
bar= 50µm.
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Figure 6.2 Calvarial Surgery and scaffold groups implanted
Surgical procedure and schematic of the study groups. (A) Steps in the surgical implantation: (1)
Creation of two circular 3.5mm defects on the two sides of mouse calvaria, (2) removal of
calvarial bone, (3) Implantation of the scaffolds into the defects, (4) Closure of the implants by
suturing the skin. (B) Groups 1: left side defect was filled with PLGA and the right side defect
with CA, group 2: left side defect was filled with PLGA and the right side was filled with CAc,
group 3: left side was filled with CA and the right side was filled with CAc. In study 1, the
materials alone were used. In study 2, 1X106 Col3.6- Cyan BMSCs from donor mice were
seeded on to each scaffold before implantation into host mice with Col3.6- Tpz BMSCs.
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Figure 6.3 Calvarial impants with material only
Whole calvaria and X- ray radiograph of defects implanted with scaffolds alone. Whole calvarial
mount of (A) group 1- PLGA vs CA, (B) group 2- PLGA vs CAc, (C) group 3- CA vs CAc.; Xray radiographs of (D) group 1- PLGA vs CA, (E) group 2- PLGA vs CAc, (F) group 3- CA vs
CAc.
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Figure 6.4 Calvarial implants with materials and donor cells
Whole calvaria and X- ray radiograph of defects implanted with scaffolds and cells. (A) Top
panel: 1. Group 1- PLGA vs CA, 2. Group 2- PLGA vs CAc, 3. Group 3- CA vs CAc.; X-ray
radiographs of 4. Group 1- PLGA vs CA, 5. Group 2- PLGA vs CAc, 6. Group 3- CA vs CAc.
(B) Quantitative radio opacity of defect area normalized to radio opacity of host bone, both
measured per unit area; PLGA, n=6; CA, n=6; CAc, n=7. One way ANOVA with Tukey posttest with 95% confidence interval, *P<0.001, #P<0.01, @P<0.05.

175

Figure 6.5 Histological sections of scaffolds without cells (Group 2)
Cell infiltration and bone forming/resorbing activity with implantation of scaffolds alone into
calvarial defects. Flourescent histological cross sectional images of calvaria implanted with
material alone at 8 weeks, Group 2: PLGA vs CAc, Top row: DIC- Differential interference
channel image with AC- red labeled alizarin complexon marking new mineral deposition (PLGA
inset A, CAc inset B); Middle row: AP- Alkaline phosphatase activity for osteoblastic activity
with DAPI- cell nuclei (PLGA inset C, CAc inset D). Lowest row: TRAP- Tartrate-resistant acid
phosphatase staining as a marker of osteoclastic activity (PLGA inset E, CAc inset F).
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Figure 6.6 ECM markers immunostained on cell seeded scaffolds (Group 2)
Immunofluorescently stained (ECM proteins: Coll1-Collagen1/ Bone sialoprotein- BSP)
histological cross sectional images of calvaria implanted with material and BMSCs at 8 weeks,
Group 2: PLGA vs CAc, Top row: Coll1- yellow, BSP- red (PLGA inset A, CAc inset B);
Middle row: Coll1- yellow (PLGA inset C, CAc inset D). Lowest row: BSP- red (PLGA inset E,
CAc inset F).
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Figure 6.7 ECM protein content on seeded implants
Quantification of pixel intensity of signal normalized to the defect area (A) BSP- Bone
sialoprotein (red in Figure 6.6), (B) Coll 1- Collagen 1 (yellow in Figure 6). One way ANOVA
with Tukey posttest with 95% confidence intervals, *P<0.001, #P<0.01, @P<0.05.
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Figure 6.8 Stained histological sections of cell seeded scaffolds (Group 2)
Flourescent histological cross sectional images of calvaria implanted with material and BMSCs
at 8 weeks, Group 2: PLGA vs CAc, Top row: DIC- Differential interference channel image to
visualize bone and microspheres with AC- red labeled alizarin complexon marking new mineral
deposition, Donor cells- Col3.6- Cyan (blue), Host cells- Col3.6-Tpz (green) (PLGA inset A,
CAc inset B); Second row: DIC- Differential interference channel image to visualize bone and
microspheres with AC- red labeled alizarin complexon marking new mineral deposition (PLGA
inset C, CAc inset D). Third row: DIC- Differential interference channel image to visualize bone
and microspheres with Donor cells- Col3.6- Cyan (blue) (PLGA inset E, CAc inset F). Fourth
row: DIC- Differential interference channel image to visualize bone and microspheres with Host
cells- Col3.6-Tpz (green) (PLGA inset G, CAc inset H). Mineral deposition, host and donor cell
participation in bone formation by materials along with BMSCs
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Figure 6.9 Quantification of bone formation, host and donor cells
Quantification of pixel intensity of signal normalized to area of defect (A) Bone area fractionDIC quantification, (B) New mineral formation- AC quantification, (C) Donor cells- Col3.6Cyan quantification, (D) Host cells- Col3.6-Tpz quantification, (E) Host (Green bars) and Donor
(Blue bars) cells in each scaffold group. One way ANOVA with Tukey post-test with 95%
confidence intervals, *P<0.001, #P<0.01, @P<0.05.
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Figure 6.10 Osteoblastic activity on cell seeded scaffolds (Group 2)
Flourescent histological cross sectional images of calvaria implanted with material and BMSCs
at 8 weeks, Group 2: PLGA vs CAc, Top row: AP for osteoblastic activity - red, DAPI for cell
nuclei- blue (PLGA inset A, CAc inset B); Middle row: AP for osteoblastic activity- red (PLGA
inset C, CAc inset D). Lowest row: DAPI for cell nuclei- blue (PLGA inset E, CAc inset F).

Figure 6.11 Osteoclastic activity on cell seeded scaffolds (Group2)
Flourescent histological cross sectional images of calvaria implanted with material and BMSCs
at 8 weeks, Group 2: PLGA vs CAc, TRAP- Tartrate-resistant acid phosphatase staining as a
marker of osteoclastic activity (PLGA inset A, CAc inset B).
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Figure 6.12 Quantification of osteoblastic and osteoclastic activity on seeded implants
Quantification of pixel intensity of signal normalized to area of defect (A)DAPI- cells, (B)
AP/DAPI- osteoblastic activity, (C) TRAP- osteoclastic activity. One way ANOVA with Tukey
post-test with 95% confidence intervals, *P<0.001, #P<0.01, @P<0.05.
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6.4

Discussion

Scaffold based bone tissue engineering relies on the ability of this temporary ECM to direct
tissue healing in a desirable direction(40). Though synthetic polymers are used widely for
scaffolding applications, there is a clear need to formulate and characterize the performance of
scaffolds made of biopolymers(442), such as polysaccharides and proteins, due to their
inherently bioactive nature and greater cost effectiveness(445). Several attempts have been made
to construct completely biopolymeric scaffolds(457, 465, 466) and blend of synthetic and natural
polymers(443, 444, 459). Many of these were not very successful as the materials could not meet
the dual goals of providing a mechanically robust support and be bioactive at the same time. For
example, collagen(346, 347), chitosan(345), polysaccharide(348) and protein based scaffolds are
often presented in the form of porous sponges, fiber matrix or hydrogels. These scaffolds lack
the mechanical stability and require chemical crosslinking to produce stable scaffolds. During
scaffold fabrication, extensive processing and cross-linking compromises the biological
functionality of these scaffolds(349-351).
The system developed by us contains a cellulose derivative as the 3D sintered microsphere base,
further functionalized by self-assembled collagen nanofibers for greater bioactivity.
Additionally, employing BMSCs has become a clinically relevant practice and it is important
that the materials used as scaffolds channel progenitor cell differentiation into the tissue type
specific lineage(449, 455).
Here in the present study, we contrast the performance of two biopolymeric systems (cellulose
acetate (CA) and cellulose acetate- collagen (CAc)) with a synthetic polymer- PLGA, both
formulated similarly to present a 3D-porous scaffold structure, for their ability to facilitate
healing of a critical sized calvarial defect by (a) implantation of the material alone and by (b)
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implantation of the materials along with clinically relevant donor derived BMSCs. The
morphology of PLGA and CA were markedly different. While PLGA showed very smooth
interfaces (Figure 6.1 G, J), the CA materials showed many undulations indicative of rough
scaffold morphology (Figure 6.1 H, K). The nanofibrillar collagen coated the microspheres
without obstructing the pores of the scaffold structure (Figure 6.1 I, L). Deligianni et al., found
that rough surfaces were more conducive for attachment and osteoblastic differentiation of
BMSCs in vitro(467). Lincks et al., also found that Titanium implants with rough surfaces may
be better for orthopaedic applications(468) and allow for greater osteointegration of the implant.
Hence we hypothesized that the natural polymers due to the rough morphology may serve as
better matrices to elicit osteoblast and progenitor cell response when implanted in a critical sized
defect.
Infiltration of cells into the scaffold interior has been a challenge with tissue engineered scaffolds
and often times there is bone formation at the periphery of synthetic scaffolds(459) with limited
cellularity at the core(36), due to constrains of diffusion(458) and material degradation product
accumulation at the core of the scaffold(396). This could explain why Jiang et al., saw greater
defect bridging in the presence of natural polymeric (chitosan and heparin) blends of PLGA, but
only peripheral bone formation was observed with PLGA alone(459), when these polymeric
scaffolds were implanted in the long bone defect of rabbits.
In the present paper, our results have demonstrated that that the natural polymer based CA and
CAc 3D- porous scaffolds show greater tissue infiltration into the interior parts of the scaffold,
while most of the cellularity was confined to the periphery in the case of PLGA (Figures 6.5,
6.13and 6.14). This could be attributed to higher biocompatible nature(469) of the natural
polymeric materials in contrast to the synthetic polymers that can accumulate toxic
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products(470) at their core due to their degradation properties(471). However, the materials were
incapable of inducing complete healing of the defect by themselves (Figure 6.3). These results
are in agreement with the observation of Gohil et al.(446), and Yu et al.(454), who also did not
find considerable bone formation by collagen based materials alone, without the inclusion of
growth factors or cells. Hence the CA and CAc materials showed greater tissue infiltration than
PLGA, due to the higher biocompatibility of the natural polymeric systems over PLGA.
A simple and clinically feasible method of enhancing bone healing is by the inclusion of patient
derived BMSCs along with the biomaterial scaffold(449). Therefore, equal numbers of BMSCs
were seeded on all the scaffolds. The CA and CAc materials lead to bridging of the defect by
bone formation at the interface of dura and the calvarium. This bridging did not occur with
PLGA (DIC channel in Figures 6.8, 6.17, and 6.18). Moreover, the bone formation (DIC
channel) and new mineral deposition (AC- red channel) was confined to specific intensely
stained regions of PLGA, while it was well distributed throughout the material in CA and CAc
(DIC, and AC-red channels in Figures 6.8, 6.17, and 6.18). The fraction of scaffold area covered
by bone was significantly higher in the natural polymers (CA and CAc) than PLGA (Figure
6.9A). The bone formation as detected by the radio-opacity of the defect by X-ray revealed twice
as much bone formation on CA and CAc in comparison to PLGA (Figure 6.4). Further, the
collagen content and staining intensity were more and well distributed on the CA and CAc
materials than PLGA (Figure 6.6, 6.15 and 6.16). There was also twice as much collagen
produced on the BMSC seeded CA and CAc scaffolds than PLGA (Figure 6.7B). Thus the
collagen deposited and the bone formed was denser with the CA groups than in PLGA,
indicating that the quality of regenerated bone was greater when the natural polymers were used
in conjunction with BMSCs than with the synthetic polymer.
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PLGA scaffolds have been used in both calvarial(330) and long bone defect models(459) in
literature. Cowan et al., employed a calvarial defect model to study the effect of PLGA by itself
and after inclusion of appetite for bone formation. When stem cells (adipose derived and
BMSCs) were used on these materials, only the apatite coated PLGA led to low levels of bone
formation. The inclusion of the apatite may have led to a more conducive pH neutralized system
to aid in bone formation by progenitors. Jiang et al., saw greater defect bridging in the presence
of natural polymeric (chitosan and heparin) blends of PLGA, but only peripheral bone formation
was observed with PLGA alone(459). The highly hydrophobic and degradative nature of popular
synthetic polymeric scaffolds of materials like PLGA may not be as conducive for cell survival
in the scaffold interior and hence these scaffolds are less likely to promote as much
cellularization as naural polymers like CA. Our results agree well with these observations in
literature, indicating that the use of natural polymers like CA with BMSCs may be more
beneficial in achieving bone defect healing.
We had coated collagen onto CA (CAc) in the hope of seeing greater regenerative outcomes due
to presence of an ECM component of bone(472, 473). We had allowed type 1 collagen to selfassemble into nanofibers on the CA microspheres to include a nanofibrillar bone-ECM
component to enhance the performance of CA microsphere platform(391). We however did not
see significant differences at 8 weeks post- implantation between CA and CAc, in terms of
quantity or quality of the regenerated bone. This could be due to degradation of collagen from
the matrix at an earlier time point. Though the coating may have helped with achieving
biocompatibility at an earlier stage of implantation, on a long run there may not be much
difference between the collagen coated and uncoated CA 3D porous scaffolds (unpublished
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data). Hence a technique to improve the retainment of collagen for prolonged nanofiber
bioactivity may be to chemically cross-link the collagen nanofibers(474).
When donors BMSCs were used it was also observed that the number of donor cells far exceeded
the number of host cells in all the three materials tested (Figure 6.9 C, D, E). Though the trends
show an increase in both donor and host cell types on CA and CAc, they were not significantly
different in number in contrast to PLGA (Figure 6.9E). The donor cells (Cyan- blue signal)
showed greater degree of localization with the newly deposited mineral (AC- red signal), while a
relatively thin layer of host cells (Tpz- Green signal) can be seen in the same regions (Boxed
areas of the insets in-Figures 6.8, 6.17 and 6.18). Hence the donor BMSCs may have
contributed to bone formation directly themselves and indirectly by signaling the host cells to
home to the region of injury. The fact that no bone formation or active remodeling occurred in
the absence of BMSCs indicated that the donor cells were indispensable for proper bone
formation to occur. However the quality of bone formed even in the presence of BMSCs was
twice as good on the natural polymers (CA and CAc) than the synthetic polymer (PLGA), in
terms of ECM collagen content, area of the defect covered by bone and hence the radio-opaque
density of the regenerated bone. Additionally there was a good bone defect closure seen when
CA and CAc were used along with BMSCs. Finally the pattern of cellular content, bone
formation, osteoblastic (Figure 6.10, 6.19 and 6.20) and osteoclastic (Figure 6.11, 6.21) activity
seem to be focused to specific loci on PLGA in contrast to a more well distributed organization
on CA and CAc. Therefore this study indicates that the usage of BMSCs in combination with an
osteoconductive 3D- porous natural polymeric matrix such as CA/ CAc can lead to higher
quality of bone regeneration than the convention synthetic polymers like PLGA.
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Synthetic polymers are known to adsorb many plasma proteins non- specifically due to their
hydrophobic nature(475). On the other hand polysaccharides such as starch, and cellulose are
known for their hydrophilic nature and for lower degrees of non-specific protein
adsorption(476). Hence Alves et al. noted that plasma treatments used to make synthetic
polymeric surfaces more hydrophilic and promote cell adhesion did not lead to better cell
adhesion on a complete polysaccharide material(477). Yunfei et al., doped 1- 7% nanocrystalline cellulose onto PLGA. Inclusion of cellulose with PLGA led to increased
hydrophilicity of the resulting nanofibers and helped with greater degree of cell adhesion onto
the material than pure PLGA(478). While a degree of hydrophobicity is essential for protein
adsorption onto materials and hence the recognition of these proteins by cells to adhere onto the
material, a highly hydrophilic or a highly hydrophobic surface is not likely to support the proper
conformation of adsorbed proteins and their retainment on the biomaterial surface(34) to elicit a
healing response from the target tissue. Thus CA and CAc showed greater biocompatibility and
progenitor cell differentiation potential than synthetic polymer PLGA.
Several attempts have been made to employ cellulose based structures in tissue engineering.
Barbie et al. had conducted a 34 week implantation of cellulose into the femur of rabbits and
seen a good degree of integration and minimal inflammatory reaction with the material(479).
Cellulose and cellulose phosphate materials were also seen to support bone healing(480).
Additionally, CA fibrous matrices supported cardiac cell growth and activity(242). These studies
had however not utilized the mechanical competence of cellulose, a feature extremely essential
for a bone scaffold. In the present study we have formulated a mechanically competent, 3D
porous structure of cellulose acetate and contrasted its performance with a model synthetic
polymer for its ability to heal a critical sized defect of the bone. Our results indicate that
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cellulose based materials can perform better as scaffold for bone regeneration than conventional
synthetic polymer matrices, when designed to possess the desirable characteristics of surface
roughness, hydrophilicity, nutrient transfer and mechanical competence. This opens the
possibility for Cellulose based scaffolds to be used in BTE applications.

6.5

Conclusions

In summary, we conclude that the natural polymeric CA based 3D porous scaffolds were
superior to well- established synthetic PLGA scaffolds of similar dimensions in inducing healing
of critical sized bone defects. The natural polymeric materials (CA and CAc) allowed better
cellular infiltration than synthetic materials (PLGA) when implanted into a critical sized bone
defect, indicative of the scaffold’s osteoconductive nature when used alone. When equal
numbers of BMSCs were seeded onto these CA, CAc and PLGA materials before implantation,
we found twice as much bone and collagen formation with the biopolymeric scaffolds than
PLGA. These observations indicate the higher density and quality of regenerated bone when the
natural polymeric scaffolds were used in conjunction with stem cells. We however did not see an
increased bone formation with the inclusion of collagen nanofibers (CAc), which contradicts our
in vitro studies. This observation could be due to degradation of collagen at a faster rate than
what is seen in vitro, and hence the effects of nanofibrillar collagen were negligible after 8 weeks
of implantation. Finally, the donor BMSCs seeded were found in regions of new mineral
deposition along with fewer host BMSCs indicating that the donor BMSCs could be involved in
the formation of new bone both directly by depositing the matrix and indirectly by signaling the
host BMSCs to contribute to the process. Though there were no differences in the amount of
donor
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BMSCs retained by the materials, the distribution of these cells were uniform throughout the
scaffold on the biopolymers than on the synthetic polymer. This study proves that natural
polymeric 3D- porous structures of cellulose could be used to induce effective bone formation, in
combination with patient derived BMSCs and such matrices could be an effective alternative to
PLA and PLGA synthetic polymers based BTE scaffolds with superior utility.
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6.6

Supplemental Figures

Figure 6.13 Histological sections of scaffolds without cells (Group 1)
Histological sections of scaffolds without cells (Group 1) Flourescent histological cross sectional
images of calvaria implanted with material alone at 8 weeks, Group 1: PLGA vs CA, Top row:
DIC- Differential interference channel image with AC- red labeled alizarin complexon marking
new mineral deposition (PLGA inset A, CA inset B); Middle row: AP- Alkaline phosphatase
activity for osteoblastic activity with DAPI- cell nuclei (PLGA inset C, CA inset D). Lowest
row: TRAP- Tartrate-resistant acid phosphatase staining as a marker of osteoclastic activity
(PLGA inset E, CA inset F).
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Figure 6.14 Histological sections of scaffolds without cells (Group 3)
Flourescent histological cross sectional images of calvaria implanted with material alone at 8
weeks, Group 3: CA vs CAc, Top row: DIC- Differential interference channel image with ACred labeled alizarin complexon marking new mineral deposition (CA inset A, CAc inset B);
Middle row: AP- Alkaline phosphatase activity for osteoblastic activity with DAPI- cell nuclei
(CA inset C, CAc inset D). Lowest row: TRAP- Tartrate-resistant acid phosphatase staining as a
marker of osteoclastic activity (CA inset E, CAc inset F).
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Figure 6.15 ECM markers immunostained on cell seeded scaffolds (Group 1)
Immunoflourescent stained (ECM proteins: Coll1-Collagen1/ Bone sialoprotein- BSP)
histological cross sectional images of calvaria implanted with material and BMSCs at 8 weeks,
Group 1: PLGA vs CA, Top row: Coll1- yellow, BSP- red (PLGA inset A, CA inset B); Middle
row: Coll1- yellow (PLGA inset C, CA inset D). Lowest row: BSP- red (PLGA inset E, CA inset
F).
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Figure 6.16 ECM markers immunostained on cell seeded scaffolds (Group 3)
Immunoflourescent stained (ECM proteins: Coll1-Collagen1/ Bone sialoprotein- BSP)
histological cross sectional images of calvaria implanted with material and BMSCs at 8 weeks,
Group 3: CA vs CAc, Top row: Coll1- yellow, BSP- red (CA inset A, CAc inset B); Middle row:
Coll1- yellow (CA inset C, CAc inset D). Lowest row: BSP- red (CA inset E, CAc inset F).

194

Figure 6.17 Stained histological sections of cell seeded scaffolds (Group 1)
Flourescent histological cross sectional images of calvaria implanted with material and BMSCs
at 8 weeks, Group 1: PLGA vs CA, Top row: DIC- Differential interference channel image to
visualize bone and microspheres with AC- red labeled alizarin complexon marking new mineral
deposition, Donor cells- Col3.6- Cyan (blue), Host cells- Col3.6-Tpz (green) (PLGA inset A, CA
inset B); Second row: DIC- Differential interference channel image to visualize bone and
microspheres with AC- red labeled alizarin complexon marking new mineral deposition (PLGA
inset C, CA inset D). Third row: DIC- Differential interference channel image to visualize bone
and microspheres with Donor cells- Col3.6- Cyan (blue) (PLGA inset E, CA inset F). Fourth
row: DIC- Differential interference channel image to visualize bone and microspheres with Host
cells- Col3.6-Tpz (green) (PLGA inset G, CA inset H).
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Figure 6.18 Stained histological sections of cell seeded scaffolds (Group 3)
Flourescent histological cross sectional images of calvaria implanted with material and BMSCs
at 8 weeks, Group 3: CA vs CAc, Top row: DIC- Differential interference channel image to
visualize bone and microspheres with AC- red labeled alizarin complexon marking new mineral
deposition, Donor cells- Col3.6- Cyan (blue), Host cells- Col3.6-Tpz (green) (CA inset A, CAc
inset B); Second row: DIC- Differential interference channel image to visualize bone and
microspheres with AC- red labeled alizarin complexon marking new mineral deposition (CA
inset C, CAc inset D). Third row: DIC- Differential interference channel image to visualize bone
and microspheres with Donor cells- Col3.6- Cyan (blue) (CA inset E, CAc inset F). Fourth row:
DIC- Differential interference channel image to visualize bone and microspheres with Host cellsCol3.6-Tpz (green) (CA inset G, CAc inset H).
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Figure 6.19 Osteoblastic activity on cell seeded scaffolds (Group 1)
Flourescent histological cross sectional images of calvaria implanted with material and BMSCs
at 8 weeks, Group 1: PLGA vs CA, Top row: AP for osteoblastic activity - red, DAPI for cell
nuclei- blue (PLGA inset A, CA inset B); Middle row: AP for osteoblastic activity- red (PLGA
inset C, CA inset D). Lowest row: DAPI for cell nuclei- blue (PLGA inset E, CA inset F).
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Figure 6.20 Osteoblastic activity on cell seeded scaffolds (Group 3)
Flourescent histological cross sectional images of calvaria implanted with material and BMSCs
at 8 weeks, Group 3: PLGA vs CAc, Top row: AP for osteoblastic activity - red, DAPI for cell
nuclei- blue (CA inset A, CAc inset B); Middle row: AP for osteoblastic activity- red (CA inset
C, CAc inset D). Lowest row: DAPI for cell nuclei- blue (CA inset E, CAc inset F).
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Figure 6.21 Osteoclastic activity on cell seeded scaffolds (Group 1 and 3)
Flourescent histological cross sectional images of calvaria implanted with material and BMSCs
at 8 weeks, TRAP- Tartrate-resistant acid phosphatase staining as a marker of osteoclastic
activity, Top row: Group 3: PLGA vs CA, (PLGA inset A, CA inset B). Bottom row: Group 1:
CA vs CAc (CA inset C, CAc inset D).
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7

Chapter 7
Future Directions

7.1

Stabilizing self- assembled collagen in vivo and uncovering the mechanism of
material- protein interactions
Cellulose-collagen based matrices and related characterization for bone healing applications
clearly establish their advantages over the synthetic polymer PLGA. The observed foreign
body reaction at early stages to cellulose following its implantation may be lower due delay
in the adsorption of bodily proteins onto the scaffold due to its increased hydrophilicity as
compared to PLGA. Applying collagen coating on to the cellulose scaffold via self-assembly
process may be a viable strategy to attain greater biological activity immediately after
implantation. Hydrophilic nature and extensive inter- and intra-molecular hydrogen bonding
of cellulose allowed a biomimetic presentation of the ECM protein collagen. This translated
into greater induction of stem cell osteoblastic differentiation in vitro and bone healing in
vivo when combined with bone marrow stromal cells. Significantly higher amount of bone
was formed with cellulose-collagen scaffolds with cells as compared to PLGA control in a
critical sized bone defect.
Bone healing between CA and CAc groups at 8 weeks (late) time point was at the same
level. The erosion of collagen nanofibers from the scaffold in the body, due to the dynamic
environment presented by MMPs could be a reason for the observed lack of difference
between CA and CAc groups. It is worth investigating to crosslink collagen nanofibers to
avoid their erosion to access the contributions of collagen nanofibers in long term bone
healing. Many chemical collagen cross-linking mythologies have been reported that retain
the bioactivity and may serve as a means to achieve this goal(481-483).
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An important observation during the study was the biomimetic self-assembly of collagen
nanofibers on the cellulose surface. Few studies have looked into the absorption of protein
and their confirmation to specific material surfaces but underlying mechanisms vastly
remains unknown. One of the bottlenecks to understanding the mechanism of protein
assembly on material surfaces is the lack of techniques that do not modify the proteins by
fluorescently tagging them or subjecting it to changes that distort their native state. Using
simulation based analysis and complimenting it with real time protein folding studies
materials like CA would explain the differential nature of protein adsorption and nanofiber
assembly on these surfaces. For instance, it would be good to combine optical based
methods employing fluorescently tagged ECM protein conformational studies(484) along
with nano-sensors to detect the variation in electrostatic potential as it interacts with a
material over time(485).
Collagen self-assembly on the CA scaffold was applied under static conditions in this study
and approximately 90% of the collagen content was found on the scaffolds. Employing a
dynamic collagen coating process with agitation and solvent evaporation may lead to
presentation of the collagen with uniform nanofiber deposition throughout the scaffold
architecture. Similarly MSCs were cultured on the scaffolds in a static condition prior to
implantation. A dynamic cell culture approach in a bioreactor setup may help to increase the
scaffold cellularity prior to implantation into an osseous defect and further improve the bone
healing efficacy(316).
7.2

Mechanism of bone formation in calvarial defects in the presence of BMSCs
Previous studies have shown the important role of BMSCs in conjunction with scaffolds in
healing the critical sized bone defect in rat calvaria(486). In the present study we found host
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MSCs along with the donor BMSCs in the areas of dynamic bone formation. However,
majority of the cell population was donor BMSCs seeded on the scaffold. In this study we
did not able to quantify the contributions of each cell type towards the new bone formation.
Studies could be designed to compromise donor cells ability to form bone via viral
transfection to establish the contributions of donor BMSCs in bone healing. These studies
may contribute to our understanding of donor BMSCs contributions in forming new bone
against the trophic effect of BMSCs towards progenitor and bone cells from the host(486).
7.3

Scaffold degradation properties
Cellulose degradation is mediated by the enzyme as opposed to hydrolytic degradation that
is seen with the PLGA. The lack of body enzymes that facilitates the cellulose degradation
makes it stable at the implantation cites for the longer period of times. A detailed study
should look at the effect of long term implantation of these scaffolds in a bone defect to
study its degradation and its integration with the surrounding tissue. The lack of acidic
degradation byproducts as seen with PLA, PGA and PLGA that compromise osseous
formation and integration may benefit from the use of cellulose derived implants and
scaffolds. Suitable chemical modifications to cellulose to reduce the hydrogen bonding may
promote matrix erosion and hence control the scaffold replacement from cite of implantation
are currently under investigation. Additionally creating hydrolytically labile ester, anhydride
and amide linkages between cellulose backbone chains are also under investigation to
promote cellulose erosion and degradation. In addition encapsulation of enzymes in the bulk
of the CA scaffold or bending the material with a fast eroding natural or synthetic material
may serve as an alternative chemical modification to promote its degradation. These efforts
are focused on retaining the bulk mechanical strength of cellulose while giving the freedom
to promote its degradation much like a synthetic polymer PLGA. In all these approaches
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rigorous cell and biocompatibility studies should be conducted to establish the suitability of
these materials for load bearing bone healing applications. Similar methodologies could be
extended to other polysaccharide materials to promote their erosion and degradation in
tissue healing application.
.
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